# ESC Guidelines: Atrial Fibrillation (2024)

**Source**: `2024_Atrial_Fibrillation.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 101

---

## Table of Contents

- [2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)](#2024-esc-guidelines-for-the-management-of-atrial-f) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 6)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. What is new](#21-what-is-new) *(p. 9)*
  - [3. Definitions and clinical impact](#3-definitions-and-clinical-impact) *(p. 13)*
    - [3.1. Definition and classification of AF](#31-definition-and-classification-of-af) *(p. 13)*
    - [3.2. Diagnostic criteria for AF](#32-diagnostic-criteria-for-af) *(p. 14)*
    - [3.3. Symptoms attributable to AF](#33-symptoms-attributable-to-af) *(p. 15)*
    - [3.4. Diagnostic evaluation of new AF](#34-diagnostic-evaluation-of-new-af) *(p. 15)*
    - [3.5. Adverse events associated with AF](#35-adverse-events-associated-with-af) *(p. 16)*
    - [3.6. Atrial flutter](#36-atrial-flutter) *(p. 17)*
  - [4. Patient pathways and management of AF](#4-patient-pathways-and-management-of-af) *(p. 17)*
    - [4.1. Patient-centred, multidisciplinary AF management](#41-patient-centred,-multidisciplinary-af-managemen) *(p. 17)*
      - [4.1.1. The patient at the heart of care](#411-the-patient-at-the-heart-of-care) *(p. 17)*
      - [4.1.2. Education and shared decision-making](#412-education-and-shared-decision-making) *(p. 18)*
      - [4.1.3. Education of healthcare professionals](#413-education-of-healthcare-professionals) *(p. 19)*
      - [4.1.4. Inclusive management of AF](#414-inclusive-management-of-af) *(p. 19)*
    - [4.2. Principles of AF-CARE](#42-principles-of-af-care) *(p. 19)*
  - [5. [C] Comorbidity and risk factor management](#5-[c]-comorbidity-and-risk-factor-management) *(p. 25)*
    - [5.1. Hypertension](#51-hypertension) *(p. 26)*
    - [5.2. Heart failure](#52-heart-failure) *(p. 26)*
    - [5.3. Type 2 diabetes mellitus](#53-type-2-diabetes-mellitus) *(p. 27)*
    - [5.4. Obesity](#54-obesity) *(p. 27)*
    - [5.5. Obstructive sleep apnoea](#55-obstructive-sleep-apnoea) *(p. 27)*
    - [5.6. Physical inactivity](#56-physical-inactivity) *(p. 27)*
    - [5.7. Alcohol excess](#57-alcohol-excess) *(p. 28)*
  - [6. [A] Avoid stroke and thromboembolism](#6-[a]-avoid-stroke-and-thromboembolism) *(p. 28)*
    - [6.1. Initiating oral anticoagulation](#61-initiating-oral-anticoagulation) *(p. 28)*
      - [6.1.1. Decision support for anticoagulation in AF](#611-decision-support-for-anticoagulation-in-af) *(p. 28)*
    - [6.2. Oral anticoagulants](#62-oral-anticoagulants) *(p. 30)*
      - [6.2.1. Direct oral anticoagulants](#621-direct-oral-anticoagulants) *(p. 31)*
      - [6.2.2. Vitamin K antagonists](#622-vitamin-k-antagonists) *(p. 32)*
      - [6.2.3. Clinical vs. device-detected subclinical AF](#623-clinical-vs-device-detected-subclinical-af) *(p. 32)*
    - [6.3. Antiplatelet drugs and combinations with anticoagulants](#63-antiplatelet-drugs-and-combinations-with-antico) *(p. 33)*
    - [6.4. Residual ischaemic stroke risk despite anticoagulation](#64-residual-ischaemic-stroke-risk-despite-anticoag) *(p. 33)*
    - [6.5. Percutaneous left atrial appendage occlusion](#65-percutaneous-left-atrial-appendage-occlusion) *(p. 33)*
    - [6.6. Surgical left atrial appendage occlusion](#66-surgical-left-atrial-appendage-occlusion) *(p. 34)*
    - [6.7. Bleeding risk](#67-bleeding-risk) *(p. 35)*
      - [6.7.1. Assessment of bleeding risk](#671-assessment-of-bleeding-risk) *(p. 35)*
      - [6.7.2. Management of bleeding on anticoagulant therapy](#672-management-of-bleeding-on-anticoagulant-therap) *(p. 35)*
  - [7. [R] Reduce symptoms by rate and rhythm control](#7-[r]-reduce-symptoms-by-rate-and-rhythm-control) *(p. 38)*
    - [7.1. Management of heart rate in patients with AF](#71-management-of-heart-rate-in-patients-with-af) *(p. 38)*
      - [7.1.1. Indications and target heart rate](#711-indications-and-target-heart-rate) *(p. 39)*
      - [7.1.2. Heart rate control in the acute setting](#712-heart-rate-control-in-the-acute-setting) *(p. 39)*
      - [7.1.3. Long-term heart rate control](#713-long-term-heart-rate-control) *(p. 39)*
      - [7.1.4. Atrioventricular node ablation and pacemaker implantation](#714-atrioventricular-node-ablation-and-pacemaker-i) *(p. 40)*
    - [7.2. Rhythm control strategies in patients with AF](#72-rhythm-control-strategies-in-patients-with-af) *(p. 40)*
      - [7.2.1. General principles and anticoagulation](#721-general-principles-and-anticoagulation) *(p. 40)*
      - [7.2.2. Electrical cardioversion](#722-electrical-cardioversion) *(p. 43)*
      - [7.2.3. Pharmacological cardioversion](#723-pharmacological-cardioversion) *(p. 43)*
      - [7.2.4. Antiarrhythmic drugs](#724-antiarrhythmic-drugs) *(p. 44)*
      - [7.2.5. Catheter ablation](#725-catheter-ablation) *(p. 45)*
      - [7.2.6. Anticoagulation in patients undergoing catheter ablation](#726-anticoagulation-in-patients-undergoing-cathete) *(p. 46)*
      - [7.2.7. Endoscopic and hybrid AF ablation](#727-endoscopic-and-hybrid-af-ablation) *(p. 47)*
      - [7.2.8. AF ablation during cardiac surgery](#728-af-ablation-during-cardiac-surgery) *(p. 48)*
      - [7.2.9. Atrial tachycardia after pulmonary vein isolation](#729-atrial-tachycardia-after-pulmonary-vein-isolat) *(p. 48)*
  - [8. [E] Evaluation and dynamic reassessment](#8-[e]-evaluation-and-dynamic-reassessment) *(p. 48)*
    - [8.1. Implementation of dynamic care](#81-implementation-of-dynamic-care) *(p. 49)*
    - [8.2. Improving treatment adherence](#82-improving-treatment-adherence) *(p. 49)*
    - [8.3. Cardiac imaging](#83-cardiac-imaging) *(p. 49)*
    - [8.4. Patient-reported outcome measures](#84-patient-reported-outcome-measures) *(p. 50)*
  - [9. The AF-CARE pathway in specific clinical settings](#9-the-af-care-pathway-in-specific-clinical-setting) *(p. 51)*
    - [9.1. AF-CARE in unstable patients](#91-af-care-in-unstable-patients) *(p. 51)*
    - [9.2. AF-CARE in acute and chronic coronary syndromes](#92-af-care-in-acute-and-chronic-coronary-syndromes) *(p. 51)*
    - [9.3. AF-CARE in vascular disease](#93-af-care-in-vascular-disease) *(p. 53)*
    - [9.4. AF-CARE in acute stroke or intracranial haemorrhage](#94-af-care-in-acute-stroke-or-intracranial-haemorr) *(p. 53)*
      - [9.4.1. Management of acute ischaemic stroke](#941-management-of-acute-ischaemic-stroke) *(p. 53)*
      - [9.4.2. Introduction or re-introduction of anticoagulation after ischaemic stroke](#942-introduction-or-re-introduction-of-anticoagula) *(p. 54)*
      - [9.4.3. Introduction or re-introduction of anticoagulation after haemorrhagic stroke](#943-introduction-or-re-introduction-of-anticoagula) *(p. 54)*
    - [9.5. AF-CARE for trigger-induced AF](#95-af-care-for-trigger-induced-af) *(p. 54)*
    - [9.6. AF-CARE in post-operative patients](#96-af-care-in-post-operative-patients) *(p. 55)*
    - [9.7. AF-CARE in embolic stroke of unknown source](#97-af-care-in-embolic-stroke-of-unknown-source) *(p. 55)*
    - [9.8. AF-CARE during pregnancy](#98-af-care-during-pregnancy) *(p. 56)*
    - [9.9. AF-CARE in congenital heart disease](#99-af-care-in-congenital-heart-disease) *(p. 57)*
    - [9.10. AF-CARE in endocrine disorders](#910-af-care-in-endocrine-disorders) *(p. 57)*
    - [9.11. AF-CARE in inherited cardiomyopathies and primary arrhythmia syndromes](#911-af-care-in-inherited-cardiomyopathies-and-prim) *(p. 57)*
    - [9.12. AF-CARE in cancer](#912-af-care-in-cancer) *(p. 58)*
    - [9.13. AF-CARE in older, multimorbid, or frail patients](#913-af-care-in-older,-multimorbid,-or-frail-patien) *(p. 58)*
    - [9.14. AF-CARE in atrial flutter](#914-af-care-in-atrial-flutter) *(p. 58)*
  - [10. Screening and prevention of AF](#10-screening-and-prevention-of-af) *(p. 58)*
    - [10.1. Epidemiology of AF](#101-epidemiology-of-af) *(p. 58)*
    - [10.2. Screening tools for AF](#102-screening-tools-for-af) *(p. 59)*
    - [10.3. Screening strategies for AF](#103-screening-strategies-for-af) *(p. 60)*
      - [10.3.1. Single timepoint screening ‘snapshot’](#1031-single-timepoint-screening-‘snapshot’) *(p. 61)*
      - [10.3.2. Prolonged screening](#1032-prolonged-screening) *(p. 61)*
    - [10.4. Factors associated with incident AF](#104-factors-associated-with-incident-af) *(p. 62)*
    - [10.5. Primary prevention of AF](#105-primary-prevention-of-af) *(p. 62)*
      - [10.5.1. Hypertension](#1051-hypertension) *(p. 63)*
      - [10.5.2. Heart failure](#1052-heart-failure) *(p. 63)*
      - [10.5.3. Type 2 diabetes mellitus](#1053-type-2-diabetes-mellitus) *(p. 63)*
      - [10.5.4. Obesity](#1054-obesity) *(p. 63)*
      - [10.5.5. Sleep apnoea syndrome](#1055-sleep-apnoea-syndrome) *(p. 63)*
      - [10.5.6. Physical activity](#1056-physical-activity) *(p. 63)*
      - [10.5.7. Alcohol intake](#1057-alcohol-intake) *(p. 64)*
  - [11. Key messages](#11-key-messages) *(p. 64)*
  - [12. Gaps in evidence](#12-gaps-in-evidence) *(p. 64)*
  - [13. ‘What to do’ and ‘What not to do’ messages from the guidelines](#13-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 66)*
  - [14. Evidence tables](#14-evidence-tables) *(p. 69)*
  - [15. Data availability statement](#15-data-availability-statement) *(p. 69)*
  - [16. Author information](#16-author-information) *(p. 69)*
  - [Appendix](#appendix) *(p. 70)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2024 ESC Guidelines for the management 
of atrial fibrillation developed in collaboration 
with the European Association 
for Cardio-Thoracic Surgery (EACTS)
Developed by the task force for the management of atrial fibrillation of the 
European Society of Cardiology (ESC), with the special contribution of the 
European Heart Rhythm Association (EHRA) of the ESC.  
Endorsed by the European Stroke Organisation (ESO)
Authors/Task Force Members: Isabelle C. Van Gelder  *†, (Chairperson) 
(Netherlands), Michiel Rienstra  
±, (Task Force Co-ordinator) (Netherlands), 
Karina V. Bunting  
±, (Task Force Co-ordinator) (United Kingdom), 
Ruben Casado-Arroyo  
(Belgium), Valeria Caso  
1 (Italy), Harry J.G.M. Crijns  
(Netherlands), Tom J.R. De Potter  
(Belgium), Jeremy Dwight (United Kingdom), 
Luigina Guasti  
(Italy), Thorsten Hanke  
2 (Germany), Tiny Jaarsma  
(Sweden), 
Maddalena Lettino  
(Italy), Maja-Lisa Løchen  
(Norway), R. Thomas Lumbers  
(United Kingdom), Bart Maesen  
2 (Netherlands), Inge Mølgaard (Denmark), 
Giuseppe M.C. Rosano (United Kingdom), Prashanthan Sanders  
(Australia), 
Renate B. Schnabel  
(Germany), Piotr Suwalski  
2 (Poland), Emma Svennberg  
(Sweden), Juan Tamargo  
(Spain), Otilia Tica  
(Romania), Vassil Traykov  
(Bulgaria), Stylianos Tzeis (Greece), Dipak Kotecha  *†, (Chairperson) 
(United Kingdom), and ESC Scientific Document Group  
© The European Society of Cardiology 2024. All rights reserved. For permissions, please email: journals.permissions@oup.com.
* Corresponding authors: Isabelle C. Van Gelder, Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Tel: +31 50 361 1327. 
Email: i.c.van.gelder@umcg.nl; and Dipak Kotecha, Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom & NIHR Birmingham Biomedical Research Centre, 
University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom. Tel: +44 121 371 8124. Email: d.kotecha@bham.ac.uk
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
± The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
1 Representing European Stroke Organisation (ESO).
2 Representing European Association for Cardio-Thoracic Surgery (EACTS).
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council of Cardio-Oncology, Council on Cardiovascular Genomics, Council on Stroke.
Working Groups: Cardiac Cellular Electrophysiology, Cardiovascular Pharmacotherapy, E-Cardiology, Thrombosis.
Patient Forum
https://doi.org/10.1093/eurheartj/ehae176
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Nikolaos Dagres, (CPG Review Co-ordinator) (Germany), Bianca Rocca, (CPG Review 
Co-ordinator) (Italy), Syed Ahsan (United Kingdom)2, Pietro Ameri (Italy), Elena Arbelo (Spain), Axel Bauer 
(Austria), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), 
Ovidiu Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier (France), Bruna Gigante (Sweden), 
Michael Glikson (Israel), Ziad Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser (Germany), 
Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab (Germany), Paulus Kirchhof (Germany), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), Gregory Y.H. Lip 
(United Kingdom), John Mandrola (United States of America), Nikolaus Marx (Germany), John William Mcevoy 
(Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Denisa Muraru (Italy), 
Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio Paciaroni 
(Italy)1, Agnes A. Pasquet (Belgium), Eva Prescott (Denmark), Filip Rega2 (Belgium), Francisco Javier Rossello 
(Spain), Marcin Rucinski (Poland), Sacha P. Salzberg2 (Switzerland), Sam Schulman (Canada), Philipp Sommer 
(Germany), Jesper Hastrup Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten Cate 
(Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. Vrints (Belgium), Adam Witkowski (Poland), and 
Katja Zeppenfeld (Netherlands)
All experts involved in the development of these guidelines have submitted declarations of interest 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or 
www.escardio.org/guidelines for supplementary documents as well as evidence tables.
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and 
medical knowledge and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, 
discrepancy and/or ambiguity between the ESC Guidelines and any other official recommendations or guidelines issued by the relevant 
public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged 
to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the 
implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way 
whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do 
the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated 
recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the 
scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s 
responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription. The ESC 
warns readers that the technical language may be misinterpreted and declines any responsibility in this respect.
Permissions. The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational 
use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written 
permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher of 
the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords 
Guidelines • Atrial fibrillation • AF-CARE • Comorbidity • Risk factors • Anticoagulation • Rate control • Rhythm 
control • Cardioversion • Antiarrhythmic drugs • Catheter ablation • AF surgery • Evaluation • Stroke • 
Thromboembolism
ESC Guidelines                                                                                                                                                                                          3315


<!-- PAGE 3 -->

### Page 3

Table of contents
1. Preamble .............................................................................................................. 3319
2. Introduction ....................................................................................................... 3321
2.1. What is new .............................................................................................
3322
3. Definitions and clinical impact .................................................................... 3326
3.1. Definition and classification of AF ...................................................
3326
3.2. Diagnostic criteria for AF ...................................................................
3327
3.3. Symptoms attributable to AF ...........................................................
3328
3.4. Diagnostic evaluation of new AF .....................................................
3328
3.5. Adverse events associated with AF ................................................
3329
3.6. Atrial flutter ..............................................................................................
3330
4. Patient pathways and management of AF ............................................. 3330
4.1. Patient-centred, multidisciplinary AF management .................
3330
4.1.1. The patient at the heart of care .............................................. 3330
4.1.2. Education and shared decision-making ................................. 3331
4.1.3. Education of healthcare professionals ................................... 3332
4.1.4. Inclusive management of AF ...................................................... 3332
4.2. Principles of AF-CARE .........................................................................
3332
5. [C] Comorbidity and risk factor management ................................... 3338
5.1. Hypertension ............................................................................................
3339
5.2. Heart failure ..............................................................................................
3339
5.3. Type 2 diabetes mellitus ......................................................................
3340
5.4. Obesity .......................................................................................................
3340
5.5. Obstructive sleep apnoea ...................................................................
3340
5.6. Physical inactivity ....................................................................................
3340
5.7. Alcohol excess .........................................................................................
3341
6. [A] Avoid stroke and thromboembolism .............................................. 3341
6.1. Initiating oral anticoagulation .............................................................
3341
6.1.1. Decision support for anticoagulation in AF ........................ 3341
6.2. Oral anticoagulants ................................................................................
3343
6.2.1. Direct oral anticoagulants ........................................................... 3344
6.2.2. Vitamin K antagonists ................................................................... 3345
6.2.3. Clinical vs. device-detected subclinical AF ........................... 3345
6.3. Antiplatelet drugs and combinations with anticoagulants ....
3346
6.4. Residual ischaemic stroke risk despite anticoagulation ..........
3346
6.5. Percutaneous left atrial appendage occlusion ............................
3346
6.6. Surgical left atrial appendage occlusion ........................................
3347
6.7. Bleeding risk ..............................................................................................
3348
6.7.1. Assessment of bleeding risk ....................................................... 3348
6.7.2. Management of bleeding on anticoagulant therapy ......... 3348
7. [R] Reduce symptoms by rate and rhythm control ......................... 3351
7.1. Management of heart rate in patients with AF .........................
3351
7.1.1. Indications and target heart rate .............................................. 3352
7.1.2. Heart rate control in the acute setting ................................. 3352
7.1.3. Long-term heart rate control .................................................... 3352
7.1.4. Atrioventricular node ablation and pacemaker 
implantation ................................................................................................... 3353
7.2. Rhythm control strategies in patients with AF ..........................
3353
7.2.1. General principles and anticoagulation ................................. 3353
7.2.2. Electrical cardioversion ................................................................ 3356
7.2.3. Pharmacological cardioversion .................................................. 3356
7.2.4. Antiarrhythmic drugs .................................................................... 3357
7.2.5. Catheter ablation ............................................................................ 3358
7.2.6. Anticoagulation in patients undergoing catheter ablation
3359
7.2.7. Endoscopic and hybrid AF ablation ........................................ 3360
7.2.8. AF ablation during cardiac surgery .......................................... 3361
7.2.9. Atrial tachycardia after pulmonary vein isolation ............. 3361
8. [E] Evaluation and dynamic reassessment ............................................. 3361
8.1. Implementation of dynamic care .....................................................
3362
8.2. Improving treatment adherence ......................................................
3362
8.3. Cardiac imaging .......................................................................................
3362
8.4. Patient-reported outcome measures ............................................
3363
9. The AF-CARE pathway in specific clinical settings ............................ 3364
9.1. AF-CARE in unstable patients ..........................................................
3364
9.2. AF-CARE in acute and chronic coronary syndromes ............
3364
9.3. AF-CARE in vascular disease .............................................................
3366
9.4. AF-CARE in acute stroke or intracranial haemorrhage ........
3366
9.4.1. Management of acute ischaemic stroke ................................ 3366
9.4.2. Introduction or re-introduction of anticoagulation after 
ischaemic stroke .......................................................................................... 3367
9.4.3. Introduction or re-introduction of anticoagulation after 
haemorrhagic stroke .................................................................................. 3367
9.5. AF-CARE for trigger-induced AF ....................................................
3367
9.6. AF-CARE in post-operative patients .............................................
3368
9.7. AF-CARE in embolic stroke of unknown source .....................
3368
9.8. AF-CARE during pregnancy ...............................................................
3369
9.9. AF-CARE in congenital heart disease ............................................
3370
9.10. AF-CARE in endocrine disorders .................................................
3370
9.11. AF-CARE in inherited cardiomyopathies and primary 
arrhythmia syndromes ..................................................................................
3370
9.12. AF-CARE in cancer .............................................................................
3371
9.13. AF-CARE in older, multimorbid, or frail patients ..................
3371
9.14. AF-CARE in atrial flutter ..................................................................
3371
10. Screening and prevention of AF ............................................................. 3371
10.1. Epidemiology of AF .............................................................................
3371
10.2. Screening tools for AF .......................................................................
3372
10.3. Screening strategies for AF ..............................................................
3373
10.3.1. Single timepoint screening ‘snapshot’ .................................. 3374
10.3.2. Prolonged screening ................................................................... 3374
10.4. Factors associated with incident AF ............................................
3375
10.5. Primary prevention of AF ................................................................
3375
10.5.1. Hypertension ................................................................................. 3376
10.5.2. Heart failure ................................................................................... 3376
10.5.3. Type 2 diabetes mellitus ........................................................... 3376
10.5.4. Obesity ............................................................................................. 3376
10.5.5. Sleep apnoea syndrome ............................................................ 3376
10.5.6. Physical activity .............................................................................. 3376
10.5.7. Alcohol intake ................................................................................ 3377
11. Key messages .................................................................................................. 3377
12. Gaps in evidence ............................................................................................ 3377
13. ‘What to do’ and ‘What not to do’ messages from the 
guidelines .................................................................................................................. 3379
14. Evidence tables ............................................................................................... 3382
15. Data availability statement ......................................................................... 3382
16. Author information ...................................................................................... 3382
17. Appendix ........................................................................................................... 3383


<!-- PAGE 4 -->

### Page 4

Tables of Recommendations
Recommendation Table 1 — Recommendations for the diagnosis of 
AF (see also Evidence Table 1) ....................................................................... 3328
Recommendation Table 2 — Recommendations for symptom 
evaluation in patients with AF (see also Evidence Table 2) ................ 3328
Recommendation Table 3 — Recommendations for diagnostic 
evaluation in patients with new AF (see also Evidence Table 3) ..... 3328
Recommendation Table 4 — Recommendations for patient-centred 
care and education (see also Evidence Table 4) ...................................... 3332
Recommendation Table 5 — Recommendations for comorbidity 
and risk factor management in AF (see also Evidence Table 5) ....... 3339
Recommendation Table 6 — Recommendations to assess and 
manage thromboembolic risk in AF (see also Evidence Table 6) .... 3342
Recommendation Table 7 — Recommendations for oral 
anticoagulation in AF (see also Evidence Table 7) .................................. 3344
Recommendation Table 8 — Recommendations for combining 
antiplatelet drugs with anticoagulants for stroke prevention (see also 
Evidence Table 8) .................................................................................................. 3346
Recommendation Table 9 — Recommendations for 
thromboembolism despite anticoagulation (see also Evidence 
Table 9) ..................................................................................................................... 3346
Recommendation Table 10 — Recommendations for percutaneous 
left atrial appendage occlusion (see also Evidence Table 10) ............ 3347
Recommendation Table 11 — Recommendations for surgical left 
atrial appendage occlusion (see also Evidence Table 11) .................... 3348
Recommendation Table 12 — Recommendations for assessment of 
bleeding risk (see also Evidence Table 12) ................................................. 3348
Recommendation Table 13 — Recommendations for management 
of bleeding in anticoagulated patients (see also Evidence Table 13)
3351
Recommendation Table 14 — Recommendations for heart rate 
control in patients with AF (see also Evidence Table 14) ................... 3351
Recommendation Table 15 — Recommendations for general 
concepts in rhythm control (see also Evidence Table 15) .................. 3355
Recommendation Table 16 — Recommendations for electrical 
cardioversion of AF (see also Evidence Table 16) .................................. 3356
Recommendation Table 17 — Recommendations for 
pharmacological cardioversion of AF (see also Evidence Table 17)
3356
Recommendation Table 18 — Recommendations for 
antiarrhythmic drugs for long-term maintenance of sinus rhythm 
(see also Evidence Table 18) ............................................................................ 3358
Recommendation Table 19 — Recommendations for catheter 
ablation of AF (see also Evidence Table 19) ............................................. 3359
Recommendation Table 20 — Recommendations for 
anticoagulation in patients undergoing catheter ablation (see also 
Evidence Table 20) ............................................................................................... 3360
Recommendation Table 21 — Recommendations for endoscopic 
and hybrid AF ablation (see also Evidence Table 21) ........................... 3360
Recommendation Table 22 — Recommendations for AF ablation 
during cardiac surgery (see also Evidence Table 22) ............................. 3361
Recommendation Table 23 — Recommendations to improve 
patient experience (see also Evidence Table 23) .................................... 3364
Recommendation Table 24 — Recommendations for patients with 
acute coronary syndromes or undergoing percutaneous 
intervention (see also Evidence Table 24) ................................................. 3366
Recommendation Table 25 — Recommendations for 
trigger-induced AF (see also Evidence Table 25) .................................... 3368
Recommendation Table 26 — Recommendations for management 
of post-operative AF (see also Evidence Table 26) ............................... 3368
Recommendation Table 27 — Recommendations for patients with 
embolic stroke of unknown source (see also Evidence Table 27) .. 3369
Recommendation Table 28 — Recommendations for patients with 
AF during pregnancy (see also Evidence Table 28) ................................ 3369
Recommendation Table 29 — Recommendations for patients with 
AF and congenital heart disease (see also Evidence Table 29) ......... 3370
Recommendation Table 30 — Recommendations for prevention of 
thromboembolism in atrial flutter (see also Evidence Table 30) ..... 3371
Recommendation Table 31 — Recommendations for screening for 
AF (see also Evidence Table 31) .................................................................... 3374
Recommendation Table 32 — Recommendations for primary 
prevention of AF (see also Evidence Table 32) ....................................... 3376
List of tables
Table 1 Classes of recommendations .......................................................... 3320
Table 2 Levels of evidence ................................................................................ 3320
Table 3 New recommendations .................................................................... 3322
Table 4 Revised recommendations ............................................................... 3325
Table 5 Definitions and classifications for the temporal pattern of 
AF ................................................................................................................................. 3327
Table 6 Other clinical concepts relevant to AF ....................................... 3327
Table 7 The modified European Heart Rhythm Association 
(mEHRA) symptom classification ................................................................... 3329
Table 8 Diagnostic work-up for patients with AF .................................. 3330
Table 9 Achieving patient-centred AF management ............................. 3331
Table 10 Updated definitions for the CHA2DS2-VA score ............... 3342
Table 11 Recommended doses for direct oral anticoagulant 
therapy ....................................................................................................................... 3345
Table 12 Drugs for rate control in AF ........................................................ 3352
Table 13 Antiarrhythmic drugs for sinus rhythm restoration ........... 3357
Table 14 Non-cardiac conditions associated with trigger-induced 
AF ................................................................................................................................. 3367
Table 15 Tools for AF screening .................................................................... 3373
Table 16 Factors associated with incident AF .......................................... 3375
Table 17 ‘What to do’ and ‘what not to do’ ............................................ 3379
List of figures
Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial 
fibrillation .................................................................................................................. 3329
Figure 2 Multidisciplinary approach to AF management ...................... 3331
Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 
4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, 
persistent and permanent AF) ................................................................................
3333
Figure 4 [R] Pathway for patients with first-diagnosed AF ................. 3334
Figure 5 [R] Pathway for patients with paroxysmal AF ....................... 3335
Figure 6 [R] Pathway for patients with persistent AF .......................... 3336
Figure 7 [R] Pathway for patients with permanent AF ........................ 3337
Figure 8 Management of key comorbidities to reduce AF 
recurrence ................................................................................................................ 3338
Figure 9 Common drug interactions with oral anticoagulants .......... 3343
Figure 10 Modifying the risk of bleeding associated with OAC ....... 3349
Figure 11 Management of oral anticoagulant-related bleeding in 
patients with AF .................................................................................................... 3350
Figure 12 Approaches for cardioversion in patients with AF ............ 3354
Figure 13 Relevance of echocardiography in the AF-CARE pathway
3363
Figure 14 Antithrombotic therapy in patients with AF and acute or 
chronic coronary syndromes ........................................................................... 3365
ESC Guidelines                                                                                                                                                                                          3317


<!-- PAGE 5 -->

### Page 5

Figure 15 Non-invasive diagnostic methods for AF screening .......... 3372
Figure 16 Approaches to screening for AF ............................................... 3374
Abbreviations and acronyms
AAD
Antiarrhythmic drugs
ACE
Angiotensin-converting enzyme
ACEi
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndromes
ACTIVE W
Atrial fibrillation Clopidogrel Trial with Irbesartan 
for prevention of Vascular Events (trial)
AF
Atrial fibrillation
AF-CARE
Atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and 
thromboembolism, [R] Reduce symptoms by rate and 
rhythm control, [E] Evaluation and dynamic 
reassessment
AFEQT
Atrial Fibrillation Effect on QualiTy-of-Life 
(questionnaire)
AFFIRM
Atrial Fibrillation Follow-up Investigation of 
Rhythm Management (trial)
AFL
Atrial flutter
AFQLQ
Atrial Fibrillation Quality of Life Questionnaire
AF-QoL
Atrial Fibrillation Quality of Life (questionnaire)
AFSS
Atrial Fibrillation Severity Scale
AI
Artificial intelligence
APACHE-AF
Apixaban After Anticoagulation-associated 
Intracerebral Haemorrhage in Patients With Atrial 
Fibrillation (trial)
APAF-CRT
Ablate and Pace for Atrial Fibrillation—cardiac 
resynchronization therapy
ARB
Angiotensin receptor blocker
ARTESiA
Apixaban for the Reduction of Thromboembolism 
in Patients With Device-Detected Sub-Clinical 
Atrial Fibrillation (trial)
AT
Atrial tachycardia
ATHENA
A Placebo-Controlled, Double-Blind, Parallel Arm 
Trial to Assess the Efficacy of Dronedarone 400 mg 
twice daily for the Prevention of Cardiovascular 
Hospitalization or Death from Any Cause in 
Patients with Atrial Fibrillation/Atrial Flutter (trial)
AUGUSTUS
An open-label, 2 × 2 factorial, randomized controlled, 
clinical trial to evaluate the safety of apixaban vs. 
vitamin k antagonist and aspirin vs. aspirin placebo in 
patients with atrial fibrillation and acute coronary 
syndrome or percutaneous coronary intervention
AVERROES
Apixaban Versus Acetylsalicylic Acid to Prevent 
Stroke in Atrial Fibrillation Patients Who Have 
Failed or Are Unsuitable for Vitamin K Antagonist 
Treatment (trial)
AVN
Atrioventricular node b.p.m.
Beats per minute
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure
C2HEST
Coronary artery disease or chronic obstructive 
pulmonary disease (1 point each); hypertension 
(1 point); elderly (age ≥75 years, 2 points); systolic 
heart failure (2 points); thyroid disease 
(hyperthyroidism, 1 point)
CABANA
Catheter Ablation versus Anti-arrhythmic Drug 
Therapy for Atrial Fibrillation (trial)
CAD
Coronary artery disease
CASTLE-AF
Catheter Ablation versus Standard Conventional 
Treatment in Patients With Left Ventricle (LV) 
Dysfunction and AF (trial)
CASTLE-HTx
Catheter Ablation for Atrial Fibrillation in Patients 
With End-Stage Heart Failure and Eligibility for 
Heart Transplantation (trial)
CCS
Chronic coronary syndrome
CHADS2
Congestive heart failure, hypertension, age >75 
years, diabetes; previous stroke (2 points)
CHA2DS2-VA
Congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/transient 
ischaemic attack/arterial thromboembolism (2 
points), vascular disease, age 65–74 years (score)
CHA2DS2-VASc
Congestive heart failure, hypertension, age ≥75 
years (2 points), diabetes mellitus, prior stroke or 
TIA or thromboembolism (2 points), vascular 
disease, age 65–74 years, sex category
CKD
Chronic kidney disease
CMR
Cardiac magnetic resonance
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies (trial)
CPAP
Continuous positive airway pressure
CrCl
Creatinine clearance
CRT
Cardiac resynchronization therapy
CT
Computed tomography
CTA
Computed tomography angiography
CTI
Cavo-tricuspid isthmus
DAPT
Dual antiplatelet therapy
DOAC
Direct oral anticoagulant
EAST-AFNET 4
Early treatment of Atrial fibrillation for Stroke 
prevention Trial
ECG
Electrocardiogram
ECV
Electrical cardioversion
EHRA
European Heart Rhythm Association
ELAN
Early versus Late initiation of direct oral 
Anticoagulants in post-ischaemic stroke patients 
with atrial fibrillatioN (trial)
ESUS
Embolic stroke of undetermined source
FFP
Fresh frozen plasma
GI
Gastrointestinal
GWAS
Genome-wide association studies
HAS-BLED
Hypertension, Abnormal renal/liver function, 
Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (>65 years), 
Drugs/alcohol concomitantly (score)
HAVOC
Hypertension, age, valvular heart disease, 
peripheral vascular disease, obesity, congestive 
heart failure, and coronary artery disease
HbA1c
Haemoglobin A1c (glycated or glycosylated 
haemoglobin)
HCM
Hypertrophic cardiomyopathy
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HR
Hazard ratio i.v.
Intravenous


<!-- PAGE 6 -->

### Page 6

ICH
Intracranial haemorrhage
ICHOM
International Consortium for Health Outcomes 
Measurement
IMT
Intima-media thickness
INR
International normalized ratio (of prothrombin 
time)
LA
Left atrium
LAA
Left atrial appendage
LAAO
Left atrial appendage occlusion
LAAOS III
Left Atrial Appendage Occlusion Study
LEGACY
Long-Term Effect of Goal directed weight 
management on Atrial Fibrillation Cohort: a 5 Year 
follow-up study
LMWH
Low molecular weight heparin
LOOP
Atrial Fibrillation Detected by Continuous ECG 
Monitoring (trial)
LV
Left ventricle
LVEF
Left ventricular ejection fraction
LVH
Left ventricular hypertrophy mEHRA
Modified European Heart Rhythm Association 
score
MI
Myocardial infarction
MRI
Magnetic resonance imaging
NOAH
Non-vitamin K Antagonist Oral Anticoagulants 
in Patients With Atrial High Rate Episodes (trial)
NSAID
Non-steroidal anti-inflammatory drug
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association
OAC
Oral anticoagulant(s)
OR
Odds ratio
OSA
Obstructive sleep apnoea
PAD
Peripheral arterial disease
PCC
Prothrombin complex concentrate
PCI
Percutaneous intervention
PFO
Patent foramen ovale
POAF
Post-operative atrial fibrillation
PPG
Photoplethysmography
PROM
Patient-reported outcome measure
PVD
Peripheral vascular disease
PVI
Pulmonary vein isolation
QLAF
Quality of Life in Atrial Fibrillation (questionnaire)
QRS
Q wave, R wave, and S wave, the ‘QRS complex’ 
represents ventricular depolarization
RACE 7  
ACWAS
Rate Control versus Electrical Cardioversion  
Trial 7—Acute Cardioversion versus Wait and See 
(trial)
RACE I
RAte Control versus Electrical cardioversion study
RACE II
Rate Control Efficacy in Permanent Atrial 
Fibrillation (trial)
RACE 3
Routine versus Aggressive upstream rhythm 
Control for prevention of Early AF in heart failure 
(trial)
RACE 4
IntegRAted Chronic Care Program at Specialized 
AF Clinic Versus Usual CarE in Patients with Atrial 
Fibrillation (trial)
RATE-AF
RAte control Therapy Evaluation in permanent 
Atrial Fibrillation (trial)
RCT
Randomized controlled trial
RR
Relative risk
SAVE
Sleep Apnea cardioVascular Endpoints (trial)
SBP
Systolic blood pressure
SGLT2
Sodium-glucose cotransporter-2
SIC-AF
Successful Intravenous Cardioversion for Atrial 
Fibrillation
SORT-AF
Supervised Obesity Reduction Trial for AF 
Ablation Patients (trial)
SoSTART
Start or STop Anticoagulants Randomised Trial
SR
Sinus rhythm
STEEER-AF
Stroke prevention and rhythm control Therapy: 
Evaluation of an Educational programme of the 
European Society of Cardiology in a cluster- 
Randomised trial in patients with Atrial Fibrillation 
(trial)
STEMI
ST-segment elevation myocardial infarction
STROKESTOP
Systematic ECG Screening for Atrial Fibrillation 
Among 75 Year Old Subjects in the Region of 
Stockholm and Halland, Sweden (trial)
TE
Thromboembolism
TIA
Transient ischaemic attack
TIMING
Timing of Oral Anticoagulant Therapy in Acute 
Ischemic Stroke With Atrial Fibrillation (trial)
TOE
Transoesophageal echocardiography
TSH
Thyroid-stimulating hormone
TTE
Transthoracic echocardiogram
TTR
Time in therapeutic range
UFH
Unfractionated heparin
VKA
Vitamin K antagonist
1. Preamble
Guidelines evaluate and summarize available evidence with the aim of 
assisting health professionals in proposing the best diagnostic or thera­
peutic approach for an individual patient with a given condition. 
Guidelines are intended for use by health professionals and the 
European Society of Cardiology (ESC) makes its Guidelines freely 
available.
ESC Guidelines do not override the individual responsibility of 
health professionals to make appropriate and accurate decisions in 
consideration of each patient’s health condition and in consultation 
with that patient or the patient’s caregiver where appropriate and/ 
or necessary. It is also the health professional’s responsibility to verify 
the rules and regulations applicable in each country to drugs and de­
vices at the time of prescription and to respect the ethical rules of their 
profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated when warranted by new evidence. ESC 
Policies and Procedures for formulating and issuing ESC Guidelines can 
be found on the ESC website (https://www.escardio.org/Guidelines/ 
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC- 
Guidelines). This guideline updates and replaces the previous version 
from 2020.
The Members of this task force were selected by the ESC to include 
professionals involved with the medical care of patients with this path­
ology as well as patient representatives and methodologists. The selec­
tion procedure included an open call for authors and aimed to include 
members from across the whole of the ESC region and from relevant 
ESC Subspecialty Communities. Consideration was given to diversity 
ESC Guidelines                                                                                                                                                                                          3319


<!-- PAGE 7 -->

### Page 7

and inclusion, notably with respect to gender and country of origin. 
The task force performed a critical review and evaluation of the 
published literature on diagnostic and therapeutic approaches includ­
ing assessment of the risk–benefit ratio. The strength of every recom­
mendation and the level of evidence supporting them were weighed 
and scored according to predefined scales as outlined in Tables 1
and 2 below. Patient-reported outcome measures (PROMs) and 
patient-reported experience measures were also evaluated as the ba­
sis for recommendations and/or discussion in these guidelines. The 
task force followed ESC voting procedures and all approved recom­
mendations were subject to a vote and achieved at least 75% agree­
ment among voting members. Members of the task force with 
declared interests on specific topics were asked to abstain from voting 
on related recommendations.
Table 1 Classes of recommendations
©ESC 2024
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2024


<!-- PAGE 8 -->

### Page 8

The experts of the writing and reviewing panels provided declaration of 
interest forms for all relationships that might be perceived as real or po­
tential sources of conflicts of interest. Their declarations of interest were 
reviewed according to the ESC declaration of interest rules which can be 
found on the ESC website (http://www.escardio.org/guidelines) and have 
been compiled in a report published in a supplementary document with 
the guidelines. Funding for the development of ESC Guidelines is derived 
entirely from the ESC with no involvement of the healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. In addition to review by the CPG Committee, ESC 
Guidelines undergo multiple rounds of double-blind peer review by exter­
nal experts, including members from across the whole of the ESC region, all 
National Cardiac Societies of the ESC and from relevant ESC Subspecialty 
Communities. After appropriate revisions, the guidelines are signed off by 
all the experts in the task force. The finalized document is signed off by the 
CPG Committee for publication in the European Heart Journal.
ESC Guidelines are based on analyses of published evidence, chiefly on 
clinical trials and meta-analyses of trials, but potentially including other 
types of studies. Evidence tables summarizing key information from rele­
vant studies are generated early in the guideline development process to 
facilitate the formulation of recommendations, to enhance comprehension 
of recommendations after publication, and reinforce transparency in the 
guidelines development process. The tables are published in their 
own section of ESC Guidelines and reference specific recommenda­
tion tables.
Off-label use of medication may be presented in this guideline if a suf­
ficient level of evidence shows that it can be considered medically 
appropriate for a given condition. However, the final decisions con­
cerning an individual patient must be made by the responsible health 
professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Atrial fibrillation (AF) is one of the most commonly encountered heart 
conditions, with a broad impact on all health services across primary 
and secondary care. The prevalence of AF is expected to double in 
the next few decades as a consequence of the ageing population, an in­
creasing burden of comorbidities, improved awareness, and new tech­
nologies for detection.
The effects of AF are variable across individual patients; however, mor­
bidity from AF remains highly concerning. Patients with AF can suffer 
from a variety of symptoms and poor quality of life. Stroke and heart 
failure as consequences of AF are now well appreciated by healthcare 
professionals, but AF is also linked to a range of other thromboembolic 
outcomes. These include subclinical cerebral damage (potentially leading 
to vascular dementia), and thromboembolism to every other organ, all of 
which contribute to the higher risk of mortality associated with AF.
The typical drivers of AF onset and progression are a range of co­
morbidities and associated risk factors. To achieve optimal care for pa­
tients with AF, it is now widely accepted that these comorbidities and 
risk factors must be managed early and in a dynamic way. Failure to do 
so contributes to recurrent cycles of AF, treatment failure, poor patient 
outcomes, and a waste of healthcare resources. In this iteration of the 
European Society of Cardiology (ESC) practice guidelines on AF, the 
task force has consolidated and evolved past approaches to develop 
the AF-CARE framework (Atrial Fibrillation—[C] Comorbidity and 
risk factor management, [A] Avoid stroke and thromboembolism, [R] 
Reduce symptoms by rate and rhythm control, [E] Evaluation and dy­
namic reassessment). Comorbidities and risk factors is placed as the ini­
tial and central component of patient management. This should be 
considered first as it applies to all patients with AF, regardless of their 
thromboembolic risk factors or any symptoms that might warrant 
intervention. This is followed by considering how best to [A] avoid 
stroke and thromboembolism, and then the options available to reduce 
symptoms, and in some cases improve prognosis, through [R] rate and 
rhythm control. [E] Evaluation and reassessment should be individua­
lized for every patient, with a dynamic approach that accounts for 
how AF and its associated conditions change over time.
Patient empowerment is critical in any long-term medical problem 
to achieve better outcomes, encourage adherence, and to seek timely 
guidance on changes in clinical status. A patient-centred, shared 
decision-making approach will facilitate the choice of management 
that suits each individual patient, particularly in AF where some ther­
apies and interventions improve clinical outcomes, and others are 
focused on addressing symptoms and quality of life. Education and 
awareness are essential, not only for patients but also healthcare pro­
fessionals in order to constrain the impact of AF on patients and 
healthcare services.
With this in mind, the task force have created a range of patient 
pathways that cover the major aspects of AF-CARE. At present, these re­
main based on the time-orientated classification of AF (first-diagnosed, 
paroxysmal, persistent, and permanent), but ongoing research may allow 
for pathology-based classifications and a future of personalized medicine. 
Clinical practice guidelines can only cover common scenarios with an evi­
dence base, and so there remains a need for healthcare professionals to 
care for patients within a local multidisciplinary team. While guideline- 
adherent care has repeatedly been shown to improve patient outcomes, 
the actual implementation of guidelines is often poor in many healthcare 
settings. This has been demonstrated in the ESC’s first randomized con­
trolled trial (RCT), STEEER-AF (Stroke prevention and rhythm control 
Therapy: Evaluation of an Educational programme of the European 
Society of Cardiology in a cluster-Randomised trial in patients with Atrial 
Fibrillation), which has sought to improve guideline adherence in parallel 
to guideline production. The task force developing the 2024 AF 
Guidelines have made implementation a key goal by focusing on the under­
pinning evidence and using a consistent writing style for each recommen­
dation (the intervention proposed, the population it should be applied to, 
and the potential value to the patient, followed by any exceptions). Tables 3
and 4 below outline new recommendations and those with important re­
visions. These initiatives have been designed to make the 2024 ESC 
Guidelines for the management of AF easier to read, follow, and implement, 
with the aim of improving the lives of patients with AF. A patient version of 
these guidelines is also available at http://www.escardio.org/Guidelines/ 
guidelines-for-patients.
ESC Guidelines                                                                                                                                                                                          3321


<!-- PAGE 9 -->

### Page 9

2.1. What is new
Table 3 New recommendations
Classa
Levelb
Diagnostic evaluation of new AF—Section 3.4
A transthoracic echocardiogram is recommended in patients with an AF diagnosis where this will guide treatment decisions.
I
C
Principles of AF-CARE—Section 4.2
Education directed to patients, family members, caregivers, and healthcare professionals is recommended to optimize shared 
decision-making, facilitating open discussion of both the benefit and risk associated with each treatment option.
I
C
Access to patient-centred management according to the AF-CARE principles is recommended in all patients with AF, regardless of gender, 
ethnicity, and socioeconomic status, to ensure equality in healthcare provision and improve outcomes.
I
C
Patient-centred AF management with a multidisciplinary approach should be considered in all patients with AF to optimize management and 
improve outcomes.
IIa
B
[C] Comorbidity and risk factor management—Section 5
Diuretics are recommended in patients with AF, HF, and congestion to alleviate symptoms and facilitate better AF management.
I
C
Appropriate medical therapy for HF is recommended in AF patients with HF and impaired LVEF to reduce symptoms and/or HF 
hospitalization and prevent AF recurrence.
I
B
Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HF and AF regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and cardiovascular death.
I
A
Effective glycaemic control is recommended as part of comprehensive risk factor management in individuals with diabetes mellitus and AF, 
to reduce burden, recurrence, and progression of AF.
I
C
Bariatric surgery may be considered in conjunction with lifestyle changes and medical management in individuals with AF and body mass 
index ≥40 kg/m2 c where a rhythm control strategy is planned, to reduce recurrence and progression of AF.
IIb
C
Management of obstructive sleep apnoea may be considered as part of a comprehensive management of risk factors in individuals with AF to 
reduce recurrence and progression.
IIb
B
When screening for obstructive sleep apnoea in individuals with AF, using only symptom-based questionnaires is not recommended.
III
B
Initiating oral anticoagulation—Section 6.1
Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
A
A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
I
C
A CHA2DS2-VA score of 1 should be considered an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
IIa
C
Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of 
CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism.
I
B
Individualized reassessment of thromboembolic risk is recommended at periodic intervals in patients with AF to ensure anticoagulation is 
started in appropriate patients.
I
B
Direct oral anticoagulant therapy may be considered in patients with asymptomatic device-detected subclinical AF and elevated 
thromboembolic risk to prevent ischaemic stroke and thromboembolism, excluding patients at high risk of bleeding.
IIb
B
Oral anticoagulants—Section 6.2
A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria, to prevent underdosing and 
avoidable thromboembolic events.
III
B
Maintaining VKA treatment rather than switching to a DOAC may be considered in patients aged ≥75 years on clinically stable therapeutic 
VKA with polypharmacy to prevent excess bleeding risk.
IIb
B
Antiplatelet drugs and combinations with anticoagulants—Section 6.3
Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or 
thromboembolism.
III
B
Continued


<!-- PAGE 10 -->

### Page 10

Residual ischaemic stroke risk despite anticoagulation—Section 6.4
A thorough diagnostic work-up should be considered in patients taking an oral anticoagulant and presenting with ischaemic stroke or 
thromboembolism to prevent recurrent events, including assessment of non-cardioembolic causes, vascular risk factors, dosage, and 
adherence.
IIa
B
Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke.
III
B
Switching from one DOAC to another, or from a DOAC to a VKA, without a clear indication is not recommended in patients with AF to 
prevent recurrent embolic stroke.
III
B
Surgical left atrial appendage occlusion—Section 6.6
Surgical closure of the left atrial appendage should be considered as an adjunct to oral anticoagulation in patients with AF undergoing 
endoscopic or hybrid AF ablation to prevent ischaemic stroke and thromboembolism.
IIa
C
Stand-alone endoscopic surgical closure of the left atrial appendage may be considered in patients with AF and contraindications for 
long-term anticoagulant treatment to prevent ischaemic stroke and thromboembolism.
IIb
C
Management of bleeding on anticoagulant therapy—Section 6.7.2
Specific antidotes should be considered in AF patients on a DOAC who develop a life-threatening bleed, or bleed into a critical site, to 
reverse the antithrombotic effect.
IIa
B
Management of heart rate in patients with AF—Section 7.1
Rate control therapy is recommended in patients with AF, as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as 
a sole treatment strategy to control heart rate and reduce symptoms.
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart 
rate and reduce symptoms.
I
B
Atrioventricular node ablation combined with cardiac resynchronization therapy should be considered in severely symptomatic patients 
with permanent AF and at least one hospitalization for HF to reduce symptoms, physical limitations, recurrent HF hospitalization, and 
mortality.
IIa
B
General principles and anticoagulation—Section 7.2.1
Direct oral anticoagulants are recommended in preference to VKAs in eligible patients with AF undergoing cardioversion for 
thromboembolic risk reduction.
I
A
Cardioversion of AF (either electrical or pharmacological) should be considered in symptomatic patients with persistent AF as part of a 
rhythm control approach.
IIa
B
A wait-and-see approach for spontaneous conversion to sinus rhythm within 48 h of AF onset should be considered in patients without 
haemodynamic compromise as an alternative to immediate cardioversion.
IIa
B
Implementation of a rhythm control strategy should be considered within 12 months of diagnosis in selected patients with AF at risk of 
thromboembolic events to reduce the risk of cardiovascular death or hospitalization.
IIa
B
Early cardioversion is not recommended without appropriate anticoagulation or transoesophageal echocardiography if AF duration is 
longer than 24 h, or there is scope to wait for spontaneous cardioversion.
III
C
Electrical cardioversion—Section 7.2.2
Electrical cardioversion as a diagnostic tool should be considered in patients with persistent AF where there is uncertainty about the value of 
sinus rhythm restoration on symptoms, or to assess improvement in left ventricular function.
IIa
C
Antiarrhythmic drugs—Section 7.2.4
Antiarrhythmic drug therapy is not recommended in patients with advanced conduction disturbances unless antibradycardia pacing is 
provided.
III
C
Catheter ablation—Section 7.2.5
Sinus node disease/tachycardia–bradycardia syndrome
Atrial fibrillation catheter ablation should be considered in patients with AF-related bradycardia or sinus pauses on AF termination to 
improve symptoms and avoid pacemaker implantation.
IIa
C
Recurrence after catheter ablation
Repeat AF catheter ablation should be considered in patients with AF recurrence after initial catheter ablation, provided the patient’s 
symptoms were improved after the initial PVI or after failed initial PVI, to reduce symptoms, recurrence, and progression of AF.
IIa
B
Anticoagulation in patients undergoing catheter ablation—Section 7.2.6
Uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic 
stroke and thromboembolism.
I
A
Continued 
ESC Guidelines                                                                                                                                                                                          3323


<!-- PAGE 11 -->

### Page 11

Endoscopic and hybrid AF ablation—Section 7.2.7
Continuation of oral anticoagulation is recommended in patients with AF at elevated thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm outcome or LAA exclusion, to prevent ischaemic stroke and thromboembolism.
I
C
Endoscopic and hybrid ablation procedures should be considered in patients with symptomatic persistent AF refractory to AAD therapy to 
prevent symptoms, recurrence, and progression of AF, within a shared decision-making rhythm control team of electrophysiologists and 
surgeons.
IIa
A
AF ablation during cardiac surgery—Section 7.2.8
Intraprocedural imaging for detection of left atrial thrombus in patients undergoing surgical ablation is recommended to guide surgical 
strategy, independent of oral anticoagulant use, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Concomitant surgical ablation should be considered in patients undergoing non-mitral valve cardiac surgery and AF suitable for a rhythm 
control strategy to prevent symptoms and recurrence of AF, with shared decision-making supported by an experienced team of 
electrophysiologists and arrhythmia surgeons.
IIa
B
Patient-reported outcome measures—Section 8.4
Evaluating quality of care and identifying opportunities for improved treatment of AF should be considered by practitioners and institutions 
to improve patient experiences.
IIa
B
Acute and chronic coronary syndromes in patients with AF—Section 9.2
Recommendations for AF patients with chronic coronary or vascular disease
Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid major bleeding.
III
B
Trigger-induced AF—Section 9.5
Long-term oral anticoagulation should be considered in suitable patients with trigger-induced AF at elevated thromboembolic risk to 
prevent ischaemic stroke and systemic thromboembolism.
IIa
C
Post-operative AF—Section 9.6
Peri-operative amiodarone therapy is recommended where drug therapy is desired to prevent post-operative AF after cardiac surgery.
I
A
Concomitant posterior peri-cardiotomy should be considered in patients undergoing cardiac surgery to prevent post-operative AF.
IIa
B
Patients with embolic stroke of unknown source (ESUS)—Section 9.7
Initiation of oral anticoagulation in ESUS patients without documented AF is not recommended due to lack of efficacy in preventing 
ischaemic stroke and thromboembolism.
III
A
Atrial flutter—Section 9.14
Oral anticoagulation is recommended in patients with atrial flutter at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
B
Screening strategies for AF—Section 10.3
Review of an ECG (12-lead, single, or multiple leads) by a physician is recommended to provide a definite diagnosis of AF and commence 
appropriate management.
I
B
Population-based screening for AF using a prolonged non-invasive ECG-based approach should be considered in individuals aged ≥75 years, 
or ≥65 years with additional CHA2DS2-VA risk factors to ensure earlier detection of AF.
IIa
B
Primary prevention of AF—Section 10.5
Maintaining optimal blood pressure is recommended in the general population to prevent AF, with ACE inhibitors or ARBs as first-line 
therapy.
I
B
Appropriate medical HF therapy is recommended in individuals with HFrEF to prevent AF.
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is recommended for the general population to prevent AF.
I
B
Maintaining an active lifestyle is recommended to prevent AF, with the equivalent of 150–300 min per week of moderate intensity or 75– 
150 min per week of vigorous intensity aerobic physical activity.
I
B
Avoidance of binge drinking and alcohol excess is recommended in the general population to prevent AF.
I
B
Metformin or SGLT2 inhibitors should be considered for individuals needing pharmacological management of diabetes mellitus to prevent 
AF.
IIa
B
Weight reduction should be considered in obese individuals to prevent AF.
IIa
B
© ESC 2024
AAD, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke 
and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; ARB, angiotensin receptor blocker; BMI, body mass index; CHA2DS2-VA, 
congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 
years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; ESUS, embolic stroke of undetermined source; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LAA, left 
atrial appendage; LVEF, left ventricular ejection fraction; PVI, pulmonary vein isolation; SGLT2, sodium-glucose cotransporter-2; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cOr body mass index ≥35 kg/m2 with obesity-related complications.


<!-- PAGE 12 -->

### Page 12

Table 4 Revised recommendations
Recommendations in 2020 version
Classa
Levelb
Recommendations in 2024 version
Classa
Levelb
Section 3.2—Diagnostic criteria for AF
ECG documentation is required to establish the 
diagnosis of AF. A standard 12-lead ECG recording or a 
single-lead ECG tracing of ≥30 s showing heart rhythm 
with no discernible repeating P waves and irregular RR 
intervals (when atrioventricular conduction is not 
impaired) is diagnostic of clinical AF.
I
B
Confirmation by an electrocardiogram (12-lead, 
multiple, or single leads) is recommended to establish 
the diagnosis of clinical AF and commence risk 
stratification and treatment.
I
A
In patients with AF, it is recommended to: 
• Evaluate AF-related symptoms (including fatigue, 
tiredness, exertional shortness of breath, palpitations, 
and chest pain) and quantify the patient symptom 
status using the modified EHRA symptom scale 
before and after initiation of treatment.
• Evaluate AF-related symptoms before and after 
cardioversion of persistent AF to aid rhythm control 
treatment decisions.
I
C
Evaluating the impact of AF-related symptoms is 
recommended before and after major changes in 
treatment to inform shared decision-making and guide 
treatment choices.
I
B
Section 5—[C] Comorbidity and risk factor management
Attention to good BP control is recommended in AF 
patients with hypertension to reduce AF recurrences 
and risk of stroke and bleeding.
I
B
Blood pressure lowering treatment is recommended in 
patients with AF and hypertension to reduce 
recurrence and progression of AF and prevent adverse 
cardiovascular events.
I
B
In obese patients with AF, weight loss together with 
management of other risk factors should be considered 
to reduce AF incidence, AF progression, AF 
recurrences, and symptoms.
IIa
B
Weight loss is recommended as part of comprehensive 
risk factor management in overweight and obese 
individuals with AF to reduce symptoms and AF burden, 
with a target of 10% or more reduction in body weight.
I
B
Physical activity should be considered to help prevent 
AF incidence or recurrence, with the exception of 
excessive endurance exercise, which may promote AF.
IIa
C
A tailored exercise programme is recommended in 
individuals with paroxysmal or persistent AF to improve 
cardiorespiratory fitness and reduce AF recurrence.
I
B
Advice and management to avoid alcohol excess should 
be considered for AF prevention and in AF patients 
considered for OAC therapy.
IIa
B
Reducing alcohol consumption to ≤3 standard drinks 
(≤30 grams of alcohol) per week is recommended as 
part of comprehensive risk factor management to 
reduce AF recurrence.
I
B
Section 6.6—Surgical left atrial appendage occlusion
Surgical occlusion or exclusion of the LAA may be 
considered for stroke prevention in patients with AF 
undergoing cardiac surgery.
IIb
C
Surgical closure of the left atrial appendage is 
recommended as an adjunct to oral anticoagulation in 
patients with AF undergoing cardiac surgery to prevent 
ischaemic stroke and thromboembolism.
I
B
Section 6.7—Bleeding risk
For a formal risk-score-based assessment of bleeding 
risk, the HAS-BLED score should be considered to help 
address modifiable bleeding risk factors, and to identify 
patients at high risk of bleeding (HAS-BLED score ≥3) 
for early and more frequent clinical review and 
follow-up.
IIa
B
Assessment and management of modifiable bleeding 
risk factors is recommended in all patients eligible for 
oral anticoagulation, as part of shared decision-making 
to ensure safety and prevent bleeding.
I
B
Continued 
ESC Guidelines                                                                                                                                                                                          3325


<!-- PAGE 13 -->

### Page 13

### 3 Definitions and clinical impact

3.1. Definition and classification of AF
Atrial fibrillation is one of the most common heart rhythm disorders. 
A supraventricular arrhythmia with uncoordinated atrial activation, 
AF results in a loss of effective atrial contraction (see 
Supplementary data online for pathophysiology). AF is reflected on 
the surface electrocardiogram (ECG) by the absence of discernible 
and regular P waves, and irregular activation of the ventricles. This re­
sults in no specific pattern to RR intervals, in the absence of an atrio­
ventricular block. The definition of AF by temporal pattern is 
presented in Table 5. It should be noted that these categories reflect 
observed episodes of AF and do not suggest the underlying patho­
physiological process. Some patients may progress consecutively 
through these categories, while others may need periodic reclassifica­
tion due to their individual clinical status. Over time, some patients 
with AF develop atrial and ventricular damage, which can make at­
tempts at rhythm control futile. For this reason, or when patients 
and physicians make a joint decision for rate control, AF is classified 
as permanent (the most common ‘type’ of AF in historical registries).1
Despite many limitations, this task force have retained this temporal 
approach because most trials in patients with AF have used these de­
finitions. Classifying AF by underlying drivers could inform manage­
ment, but the evidence in support of the clinical use of such 
classification is currently lacking.
Several other classifications have been applied to patients with AF, 
many of which have limited evidence to support them. The definition 
of AF is a developing field and ongoing research may allow for 
pathology-based strategies that could facilitate personalized manage­
ment in the future. Table 6 presents some commonly used concepts 
in current clinical practice. Due to the lack of supporting evidence (par­
ticularly for the time periods stated), this task force have edited and up­
dated these definitions by consensus.
Section 7.2—Rhythm control strategies in patients with AF
AF catheter ablation for PVI should/may be considered 
as first-line rhythm control therapy to improve 
symptoms in selected patients with symptomatic: 
• Paroxysmal AF episodes.
IIa
B
Catheter ablation is recommended as a first-line option 
within a shared decision-making rhythm control 
strategy in patients with paroxysmal AF, to reduce 
symptoms, recurrence, and progression of AF.
I
A
Thoracoscopic procedures—including hybrid surgical 
ablation—should be considered in patients who have 
symptomatic paroxysmal or persistent AF refractory to 
AAD therapy and have failed percutaneous AF ablation, 
or with evident risk factors for catheter ablation failure, 
to maintain long-term sinus rhythm. The decision must 
be supported by an experienced team of 
electrophysiologists and surgeons.
IIa
B
Endoscopic and hybrid ablation procedures may be 
considered in patients with symptomatic paroxysmal 
AF refractory to AAD therapy and failed percutaneous 
catheter ablation strategy to prevent symptoms, 
recurrence, and progression of AF, within a shared 
decision-making rhythm control team of 
electrophysiologists and surgeons.
IIb
B
Thoracoscopic procedures—including hybrid surgical 
ablation—may be considered in patients with persistent 
AF with risk factors for recurrence, who remain 
symptomatic during AF despite at least one failed AAD 
and who prefer further rhythm control therapy.
IIb
C
Endoscopic and hybrid ablation procedures should be 
considered in patients with symptomatic persistent AF 
refractory to AAD therapy to prevent symptoms, 
recurrence, and progression of AF, within a shared 
decision-making rhythm control team of 
electrophysiologists and surgeons.
IIa
A
Concomitant AF ablation should be considered in 
patients undergoing cardiac surgery, balancing the 
benefits of freedom from atrial arrhythmias and the risk 
factors for recurrence (left atrial dilatation, years in AF, 
age, renal dysfunction, and other cardiovascular risk 
factors).
IIa
A
Concomitant surgical ablation is recommended in 
patients undergoing mitral valve surgery and AF suitable 
for a rhythm control strategy to prevent symptoms and 
recurrence of AF, with shared decision-making 
supported by an experienced team of 
electrophysiologists and arrhythmia surgeons.
I
A
Section 9.6—Post-operative AF
Long-term OAC therapy to prevent thromboembolic 
events may be considered in patients at risk for stroke 
with post-operative AF after cardiac surgery, 
considering the anticipated net clinical benefit of OAC 
therapy and informed patient preferences.
IIb
B
Long-term oral anticoagulation should be considered in 
patients with post-operative AF after cardiac and 
non-cardiac surgery at elevated thromboembolic risk, 
to prevent ischaemic stroke and thromboembolism.
IIa
B
© ESC 2024
AAD, antiarrhythmic drugs; AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; EHRA, European Heart Rhythm Association; HAS-BLED, Hypertension, Abnormal renal/liver 
function, Stroke, Bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol concomitantly; LAA, left atrial appendage; OAC, oral 
anticoagulant; PVI, pulmonary vein isolation; RR, relative risk. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 14 -->

### Page 14

3.2. Diagnostic criteria for AF
In many patients, the diagnosis of AF is straightforward, e.g. typical 
symptoms associated with characteristic features on a standard 
12-lead ECG that indicate the need for AF management. Diagnosis be­
comes more challenging in the context of asymptomatic episodes or AF 
detected on longer-term monitoring devices, particularly those that do 
Table 6 Other clinical concepts relevant to AF
Clinical concept
Definition
Clinical AF
Symptomatic or asymptomatic AF that is 
clearly documented by an ECG (12-lead 
ECG or other ECG devices). The 
minimum duration to establish the 
diagnosis of clinical AF for ambulatory 
ECG is not clear and depends on the 
clinical context. Periods of 30 s or more 
may indicate clinical concern, and trigger 
further monitoring or risk stratification 
for thromboembolism.
Device-detected 
subclinical AF
Device-detected subclinical AF refers to 
asymptomatic episodes of AF detected 
on continuous monitoring devices. These 
devices include implanted cardiac 
electronic devices, for which most atrial 
high-rate episodesa may be AF, as well as 
consumer-based wearable monitors. 
Confirmation is needed by a competent 
professional reviewing intracardiac 
electrograms or an ECG-recorded 
rhythm.5,6 Device-detected subclinical 
AF is a predictor of future clinical AF.7
Continued 
Table 5 Definitions and classifications for the temporal 
pattern of AF
Temporal 
classification
Definition
First-diagnosed AF
AF that has not been diagnosed before, 
regardless of symptom status, temporal pattern, 
or duration.
Paroxysmal AF
AF which terminates spontaneously within 7 
days or with the assistance of an intervention. 
Evidence suggests that most self-terminating 
paroxysms last <48 h.2
Persistent AF
AF episodes which are not self-terminating. 
Many intervention trials have used 7 days as a 
cut-off for defining persistent AF.3,4
Long-standing persistent AF is arbitrarily defined 
as continuous AF of at least 12 months’ duration 
but where rhythm control is still a treatment 
option in selected patients, distinguishing it from 
permanent AF.
Permanent AF
AF for which no further attempts at restoration 
of sinus rhythm are planned, after a shared 
decision between the patient and physician.
© ESC 2024
AF, atrial fibrillation.
AF burden
The overall time spent in AF during a 
clearly specified and reported period of 
monitoring, expressed as a percentage of 
time.
Recent-onset AF
There is accumulating data on the value 
of the term recent-onset AF in 
decision-making for acute 
pharmacological or electrical 
cardioversion of AF. The cut-off time 
interval to define this entity has not yet 
been established.8–10
Trigger-induced AF
New AF episode in close proximity to a 
precipitating and potentially reversible 
factor.11–14
Early AF
The time since diagnosis that qualifies for 
early AF is dissociated from any 
underlying atrial cardiomyopathy and is 
not well defined, broadly ranging from 3 
to 24 months.15–17 The definition of early 
AF also does not necessarily determine 
early timing of intervention.
Self-terminating AF
Paroxysmal AF which terminates 
spontaneously.2 This definition may be of 
value for decisions on acute rhythm 
control taken jointly by the patient and 
healthcare provider.
Non-self-terminating AF
Atrial fibrillation which does not 
terminate spontaneously and, if needed, 
termination can be achieved only with an 
intervention.
Atrial cardiomyopathy
A combination of structural, electrical, or 
functional changes in the atria that leads 
to clinical impact (e.g. progression/ 
recurrence of AF, limited effectiveness of 
AF therapy, and/or development of heart 
failure).18,19 Atrial cardiomyopathy 
includes inflammatory and 
prothrombotic remodelling of the atria, 
neurohormonal activation (thereby 
affecting the ventricles), and fibrosis of 
myocardial tissue.20
© ESC 2024
AF, atrial fibrillation; b.p.m., beats per minute; ECG, electrocardiogram. 
aAtrial high-rate episodes are defined as episodes generally lasting more than 5 min with an 
atrial lead rate ≥170 b.p.m.,7,21–24 detected by implanted cardiac devices that allow for 
automated continuous monitoring and storage of atrial rhythm. Atrial high-rate episodes 
need to be visually inspected because some may be electrical artefacts or false positives.
ESC Guidelines                                                                                                                                                                                          3327


<!-- PAGE 15 -->

### Page 15

not provide an ECG (see Section 10). To guard against inappropriate 
diagnosis of AF, this task force continues to recommend that ECG 
documentation is required to initiate risk stratification and AF manage­
ment. In current practice, ECG confirmation can include multiple op­
tions: not only where AF persists across a standard 12-lead ECG, but 
also single- and multiple-lead devices that provide an ECG (see 
Supplementary data online, Additional Evidence Table S1). This does 
not include non-ECG wearables and other devices that typically use 
photoplethysmography. Note that many pivotal AF trials required 
two or more ECGs documenting AF, or an established AF diagnosis be­
fore randomization.25–29 The time period of AF required for diagnosis 
on monitoring devices is not clear cut. A standard 12-lead ECG mea­
sures 10 s, while 30 s or more on single-lead or multiple-lead ECG de­
vices has generally been the consensus opinion, albeit with limited 
evidence.
3.3. Symptoms attributable to AF
Symptoms related to episodes of AF are variable and broad, and not 
just typical palpitations (Figure 1). Asymptomatic episodes of AF can 
occur,30 although 90% of patients with AF describe symptoms with 
variable severity.31 Even in symptomatic patients, some episodes of 
AF may remain asymptomatic.32,33 The presence or absence of symp­
toms is not related to incident stroke, systemic embolism, or mortal­
ity.34 However, symptoms do impact on patient quality of life.35,36
Cardiac-specific AF symptoms such as palpitations are less common 
than non-specific symptoms such as fatigue, but they significantly 
impair quality of life.36,37 Although women are often underrepresented 
in clinical trials of AF,38–40 the available literature suggests that 
women with AF appear to be more symptomatic and have poorer 
quality of life.41,42 Patients with AF report a higher burden of anxiety 
and severity of depression (odds ratio [OR], 1.08; 95% confidence 
interval [CI], 1.02–1.15; P = .009) as compared with the general 
population,43,44 with higher prevalence of these symptoms in women 
with AF.45
Assessment of AF-related symptoms should be recorded initially, 
after a change in treatment, or before and after intervention. The 
modified European Heart Rhythm Association score (mEHRA) 
symptom classification (Table 7) is similar to the New York 
Heart Association (NYHA) functional class for heart failure. It cor­
relates with quality of life scores in clinical trials, is associated with 
clinical progress and events, and may be a valuable starting point 
in routine practice to assess the burden and impact of symptoms to­
gether with the patient.46–48 Note that symptoms may also relate to 
associated comorbidities and not just the AF component. The 
patient-related effects of symptoms from AF over time can alterna­
tively be evaluated using patient-reported outcome measures (see 
Section 8.4).
3.4. Diagnostic evaluation of new AF
All patients with AF should be offered a comprehensive diagnostic as­
sessment and review of medical history to identify risk factors and/or 
comorbidities needing active treatment. Table 8 displays the essential 
diagnostic work-up for a patient with AF.
A 12-lead ECG is warranted in all AF patients to confirm rhythm, de­
termine ventricular rate, and look for signs of structural heart disease, 
conduction defects, or ischaemia.56 Blood tests should be carried out 
(kidney function, serum electrolytes, liver function, full blood count, glu­
cose/glycated haemoglobin [HbA1c], and thyroid tests) to detect any 
concomitant conditions that may exacerbate AF or increase the risk 
of bleeding and/or thromboembolism.57,58
Other investigations will depend on individualized assessment and 
the planned treatment strategy.59–65 A transthoracic echocardiogram 
(TTE) should be carried out in the initial work-up, where this will guide 
management decisions, or in patients where there is a change in cardio­
vascular signs or symptoms. The task force recognizes that accessibility 
to TTE might be limited or delayed in the primary care setting, but this 
should not delay initiation of oral anticoagulation (OAC) or other com­
ponents of AF-CARE where indicated.66 Further details on TTE and re­
assessment (e.g. if elevated heart rate limits diagnostic imaging, or 
where there is a change in clinical status) are presented in Section 8.3. 
Additional imaging using different modalities may be required to assist 
with comorbidity and AF-related management (see Supplementary 
data online, Figure S1).
Recommendation Table 1 — Recommendations for the 
diagnosis of AF (see also Evidence Table 1)
Recommendations
Classa
Levelb
Confirmation by an electrocardiogram (12-lead, 
multiple, or single leads) is recommended to establish 
the diagnosis of clinical AF and commence risk 
stratification and treatment.25–29
I
A
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 2 — Recommendations for 
symptom evaluation in patients with AF (see also 
Evidence Table 2)
Recommendations
Classa
Levelb
Evaluating the impact of AF-related symptoms is 
recommended before and after major changes in 
treatment to inform shared decision-making and 
guide treatment choices.17,36,46–55
I
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 3 — Recommendations for 
diagnostic evaluation in patients with new AF (see also 
Evidence Table 3)
Recommendations
Classa
Levelb
A transthoracic echocardiogram is recommended in 
patients with an AF diagnosis where this will guide 
treatment decisions.59,65,67
I
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 16 -->

### Page 16

3.5. Adverse events associated with AF
Atrial fibrillation is associated with a range of serious adverse events 
(Figure 1) (see Supplementary data online, Additional Evidence 
Table S2). Patients with AF also have high rates of hospitalization 
and complications from coexisting medical conditions. The most com­
mon non-fatal outcome in those with AF is heart failure, occurring in 
around half of patients over time. Patients with AF have a four- to five- 
fold increase in the relative risk (RR) of heart failure compared with 
those without AF, as demonstrated in two meta-analyses (RR, 4.62; 
95% CI, 3.13–6.83 and RR, 4.99; 95% CI, 3.0–8.22).68,69 The next 
most common adverse impacts from AF are ischaemic stroke (RR, 
2.3; 95% CI, 1.84–2.94), ischaemic heart disease (RR, 1.61; 95% CI, 
1.38–1.87), and other thromboembolic events.69–71 The latter typic­
ally include arterial thromboembolic events (preferred to the term 
systemic), although venous thromboembolism is also associated 
Patient symptoms
Adverse outcomes
Healthcare and society
A
t r
i a
l
 
fi b
r il l
a t
i o
n
I
m p
a c
t
 
a n
d
 
o u
t c
o m
e s
Palpitations
Shortness of breath
Fatigue
Chest pain
Dizziness
Poor exercise capacity
Fainting (syncope)
Anxiety
Depressed mood
Disordered sleep
Recurrent hospitalization
Heart failure
Ischaemic stroke
Thromboembolism
Cognitive decline and vascular dementia
Depression
Impaired quality of life
Death
Increasing prevalence
High economic cost
Impact on individuals,
families and communities
Doubling of AF
2010 
  2060
Lifetime risk
1 in 5   1 in 3
1–2% of healthcare expenditure
Figure 1 Impacts and outcomes associated with clinical AF. AF, atrial fibrillation.
Table 7 The modified European Heart Rhythm 
Association (mEHRA) symptom classification
Score
Symptoms
Description
1
None
AF does not cause any symptoms
2a
Mild
Normal daily activity not affected by symptoms 
related to AF
2b
Moderate
Normal daily activity not affected by symptoms 
related to AF, but patient troubled by 
symptoms
3
Severe
Normal daily activity affected by symptoms 
related to AF
4
Disabling
Normal daily activity discontinued
© ESC 2024
AF, atrial fibrillation.
ESC Guidelines                                                                                                                                                                                          3329


<!-- PAGE 17 -->

### Page 17

with AF.72,73 Patients with AF also have an increased risk of cognitive 
impairment (adjusted hazard ratio [HR], 1.39; 95% CI, 1.25–1.53)74
and dementia (OR, 1.6; 95% CI, 1.3–2.0).75–77 It should be noted 
that most of the observational studies on adverse events have a mix 
of patients taking and not taking OAC. When carefully controlling 
for the confounding effects of stroke, comorbidities, and OAC, AF ex­
posure was still significantly associated with vascular dementia (HR, 
1.68; 95% CI, 1.33–2.12; P < .001), but not Alzheimer’s disease (HR, 
0.85; 95% CI, 0.70–1.03; P = .09).78
Hospital admission rates due to AF vary widely depending on the 
population studied, and may be skewed by selection bias. In a Dutch 
RCT including first-diagnosed AF patients (mean age 64 years), car­
diovascular hospitalization rates were 7.0% to 9.4% per year.79 An 
Australian study identified 473 501 hospitalizations for AF during 
15 years of follow-up (300 million person-years), with a relative in­
crease in AF hospitalizations of 203% over the study period, in con­
trast to an increase for all hospitalizations of 71%. The age-specific 
incidence of hospital admission increased particularly in the older 
age groups.80
Atrial fibrillation is also associated with increased mortality. In 
2017, AF contributed to over 250 000 deaths globally, with an 
age-standardized mortality rate of 4.0 per 100 000 people (95% un­
certainty interval 3.9–4.2).81 The most frequent cause of death in pa­
tients with AF is heart failure related,70 with complex relationships to 
cardiovascular and non-cardiovascular disease.82 There is up to a 
two-fold increased risk of all-cause mortality (RR, 1.95; 95% CI, 
1.50–2.54),68 and cardiovascular mortality (RR, 2.03; 95% CI, 1.79– 
2.30)69 in AF compared with sinus rhythm. Even in the absence of 
major thromboembolic risk factors, the incidence of death is 15.5 
per 1000 person-years in those with AF exposure, compared 
with 9.4 per 1000 person-years without (adjusted HR, 1.44; 95% CI, 
1.38–1.50; P < .001).78 Patients with OAC-related bleeding have 
higher mortality, including both minor and major bleeding (as 
defined by the International Society on Thrombosis and 
Haemostasis scale).83 Despite OAC, patients with AF remain at high 
residual risk of death, highlighting the importance of attention to con­
comitant disease.84
3.6. Atrial flutter
Atrial flutter (AFL) is the among the most common atrial tachyarrhyth­
mias, with an overall incidence rate of 88 per 100 000 person-years, ris­
ing to 317 per 100 000 person-years in people over 50 years of age.85
Risk factors for AFL and AF are similar, and more than half of all patients 
with AFL will develop AF.85 Observational studies suggest that 
thromboembolic risk is elevated in AFL.86 In direct comparison of 
AFL with AF, some studies suggest a similar risk of stroke and others 
a lower risk in AFL,87–90 possibly due to different comorbidity burdens 
and the impact of confounders such as AFL/AF ablation and anticoagu­
lation (more frequently stopped in AFL).91
4. Patient pathways and 
management of AF
4.1. Patient-centred, multidisciplinary AF 
management
4.1.1. The patient at the heart of care
A patient-centred and integrated approach to AF management means 
working with a model of care that respects the patient’s experience, 
values, needs, and preferences for planning, co-ordination, and delivery 
of care. A central component of this model is the therapeutic relationship 
between the patient and the multidisciplinary team of healthcare profes­
sionals (Figure 2). In patient-centred AF management, patients are seen 
not as passive recipients of health services, but as active participants 
who work as partners alongside healthcare professionals. Patient- 
centred AF management requires integration of all aspects of AF man­
agement. This includes symptom control, lifestyle recommendations, 
psychosocial support, and management of comorbidities, alongside op­
timal medical treatment consisting of pharmacotherapy, cardioversion, 
and interventional or surgical ablation (Table 9). Services should be de­
signed to ensure that all patients have access to an organized model of 
AF management, including tertiary care specialist services when indi­
cated (see Supplementary data online, Table S1, Evidence Table 4 and 
Additional Evidence Table S3). It is equally important to maintain path­
ways for patients to promptly re-engage with specialist services when 
their condition alters.
Table 8 Diagnostic work-up for patients with AF
All patients
Selected patients
• Medical history to determine AF 
pattern, relevant family history, 
and comorbidities, and to assess 
risk factors for thromboembolism 
and bleeding
• Ambulatory ECG monitoring for 
assessing AF burden and 
ventricular rate control
• Exercise ECG to evaluate rate 
control or effects of class IC 
antiarrhythmic drugs
• 12-lead ECG
• Further blood tests for 
investigation of cardiovascular 
disease and refinement of stroke/ 
bleeding risk (e.g. NT-proBNP, 
troponin)
• Assess symptoms and functional 
impairment
• Transoesophageal 
echocardiography for left atrial 
thrombus and valvular disease 
assessment
• Collect generic or AF-specific 
patient-reported outcome 
measures
• Coronary CT, angiography, or 
ischaemia imaging for suspected 
CAD
• Blood tests (full blood count, 
kidney function, serum 
electrolytes, liver function, 
glucose/HbA1c, and thyroid 
function)
• CMR for evaluation of atrial and 
ventricular cardiomyopathies, 
and to plan interventional 
procedures
• Transthoracic echocardiography 
where this will guide AF-CARE 
management decisions
• Brain imaging and cognitive 
function assessment for 
cerebrovascular disease and 
dementia risk
© ESC 2024
AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment; CAD, coronary artery 
disease; CMR, cardiac magnetic resonance; CT, computed tomography; CTA, computed 
tomography angiography; ECG, electrocardiogram; HbA1c, glycated haemoglobin; 
NT-proBNP, N-terminal pro-B-type natriuretic peptide.


<!-- PAGE 18 -->

### Page 18

4.1.2. Education and shared decision-making
Clear advice about the rationale for treatments, the possibility of 
treatment modification, and shared decision-making can help patients 
live with AF (see Supplementary data online, Table S2).92 An open and 
effective relationship between the patient and the healthcare profes­
sional is critical, with shared decision-making found to improve 
outcomes for OAC and arrhythmia management.93,94 In using a 
shared approach, both the clinician and patient are involved in the 
decision-making process (to the extent that the patient prefers). 
Information is shared in both directions. Furthermore, both the 
clinician and the patient express their preferences and discuss the 
options. Of the potential treatment decisions, no treatment is 
also a possibility.95 There are several toolkits available to facilitate 
this, although most are focused on anticoagulation decisions. For ex­
ample, the Shared Decision-Making Toolkit (http://afibguide.com, 
http://afibguide.com/clinician) 
and 
the 
Successful 
Intravenous 
Cardioversion for Atrial Fibrillation (SIC-AF) score have been shown 
to reduce decisional conflict compared with usual care in patients 
with AF.93,94 Patient-support organizations can also make an import­
ant contribution to providing understandable and actionable knowl­
edge about AF and its treatments (e.g. local support groups and 
international charities, such as http://afa-international.org). As AF is a 
chronic or recurrent disease in most patients, education is central 
to empower patients, their families, and caregivers.
Atrial fibrillation
P
a t
i e
n t
-
c e
n t
r e
d
C
A
R
E
Comorbidity and risk factor management
Lifestyle help
Primary care
Cardiology
Internal medicine
Nursing care
Other
Avoid stroke and thromboembolism
Primary care
Cardiology
Neurology
Nursing care
Anticoagulation services e-Health
Reduce symptoms by rate and rhythm control
Evaluation and dynamic reassessment
Primary care
Cardiology
Pharmacy
Nursing
Family/carers e-Health
Primary care
Cardiology
Electrophysiology
Cardiac surgeons e-Health i
n t
e g
r a
t e
d
 
A
F
-
C
A
R
E
Figure 2 Multidisciplinary approach to AF management. Principal caregivers are involved in the community and hospital settings to provide optimal, 
patient-centred care for patients living with AF. AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke and 
thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment.
Table 9 Achieving patient-centred AF management
Components of patient-centred AF management:
• Optimal treatment according to the AF-CARE pathway, which includes:
∘ [C] Comorbidity and risk factor management
∘ [A] Avoid stroke and thromboembolism
∘ [R] Reduce symptoms by rate and rhythm control
∘ [E] Evaluation and dynamic reassessment
• Lifestyle recommendations
• Psychosocial support
• Education and awareness for patients, family members, and caregivers
• Seamless co-ordination between primary care and specialized AF care
How to implement patient-centred AF management:
• Shared decision-making
• Multidisciplinary team approach
• Patient education and empowerment, with emphasis on self-care
• Structured educational programmes for healthcare professionals
• Technology support (e-Health, m-Health, telemedicine)a
© ESC 2024
AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment. 
ae-Health refers to healthcare services provided using electronic methods; m-Health, 
refers to healthcare services supported by mobile devices; and telemedicine refers to 
remote diagnosis or treatment supported by telecommunications technology.
ESC Guidelines                                                                                                                                                                                          3331


<!-- PAGE 19 -->

### Page 19

4.1.3. Education of healthcare professionals
Gaps in knowledge and skills across all domains of AF care are consist­
ently described among cardiologists, neurologists, internal medicine 
specialists, emergency physicians, general practitioners, nurses, and al­
lied health practitioners.96–98 Healthcare professionals involved in 
multidisciplinary AF management should have a knowledge of all avail­
able options for diagnosis and treatment.99–101 In the STEEER-AF 
trial,99 real-world adherence to clinical practice guidelines for AF 
across six ESC countries was poor. These findings highlight the critical 
need for appropriate training and education of healthcare 
professionals.102
Specifically targeted education for healthcare professionals can in­
crease knowledge and lead to more appropriate use of OAC for 
prevention of thromboembolism.103 However, educational interventions 
for healthcare providers are often not enough to sustainably impact be­
haviour.104 Other tools may be needed, such as active feedback,103
clinical decision support tools,105 expert consultation,106 or e-Health 
learning.107
4.1.4. Inclusive management of AF
Evidence is growing on differences in AF incidence, prevalence, risk fac­
tors, comorbidities, and outcomes according to gender.108 Women di­
agnosed with AF are generally older, have more hypertension and heart 
failure with preserved ejection fraction (HFpEF), and have less diag­
nosed coronary artery disease (CAD).109 Registry studies have re­
ported differences in outcomes, with higher morbidity and mortality 
in women, although these may be confounded by age and comorbidity 
burden.110–112 Women with AF may be more symptomatic, and report 
a lower quality of life.41,113 It is unclear whether this is related to de­
layed medical assessment in women, or whether there are genuine 
sex differences. Despite a higher symptom load, women are less likely 
to undergo AF ablation than men, even though antiarrhythmic drug 
therapy seems to be associated with more proarrhythmic events in 
women.109 These observations call for more research on gender 
differences in order to prevent disparities and inequality in care. 
Other diversity aspects such as age, race, ethnicity, and transgender 
issues, as well as social determinants (including socioeconomic status, 
disability, education level, health literacy, and rural/urban location) are 
important contributors to inequality that should be actively considered 
to improve patient outcomes.114
4.2. Principles of AF-CARE
The 2024 ESC Guidelines for the management of AF have compiled and 
evolved past approaches to create principles of management to aid im­
plementation of these guidelines, and hence improve patient care and 
outcomes. There is growing evidence that clinical support tools115–118
can aid best-practice management, with the caveat that any tool is a 
guide only, and that all patients require personalized attention. The 
AF-CARE approach covers many established principles in the manage­
ment of AF, but does so in a systematic, time-orientated format with 
four essential treatment pillars (Figure 3; central illustration). Joint man­
agement with each patient forms the starting point of the AF-CARE ap­
proach. Notably, it takes account of the growing evidence base that 
therapies for AF are most effective when associated health conditions 
are addressed. A careful search for these comorbidities and risk factors 
[C] is critical and should be applied in all patients with a diagnosis of AF. 
Avoidance of stroke and thromboembolism [A] in patients with risk 
factors is considered next, focused on appropriate use of anticoagu­
lant therapy. Reducing AF-related symptoms and morbidity by effect­
ive use of heart rate and rhythm control [R] is then applied, which in 
selected patients may also reduce hospitalization or improve progno­
sis. The potential benefit of rhythm control, accompanied by consid­
eration of all risks involved, should be considered in all patients at each 
contact point with healthcare professionals. As AF, and its related co­
morbidities, changes over time, different levels of evaluation [E] and 
re-evaluation are required in each patient, and these approaches 
should be dynamic. Due to the wide variability in response to therapy, 
and the changing pathophysiology of AF as age and comorbidities ad­
vance, reassessment should be built into the standard care pathway to 
prevent adverse outcomes for patients and improve population 
health.
AF-CARE builds upon prior ESC Guidelines, e.g. the five-step 
outcome-focused integrated approach in the 2016 ESC Guidelines for 
the management of AF,119 and the AF Better Care (ABC) pathway in 
the 2020 ESC Guidelines for the diagnosis and management of AF.120
The reorganization into AF-CARE was based on the parallel develop­
ments in new approaches and technologies (in particular for rhythm 
control), with new evidence consistently suggesting that all aspects of 
AF management are more effective when comorbidities and risk factors 
have been considered. This includes management relating to symptom 
benefit, improving prognosis, prevention of thromboembolism, and the 
response to rate and rhythm control strategies. AF-CARE makes expli­
cit the need for individualized evaluation and follow-up in every patient, 
with an active approach that accounts for how patients, their AF, and 
associated comorbidities change over time. The AF-CARE principles 
have been applied to different patient pathways for ease of implemen­
tation into routine clinical care. This includes the management of first- 
diagnosed AF (Figure 4), paroxysmal AF (Figure 5), persistent AF 
(Figure 6), and permanent AF (Figure 7).
Recommendation Table 4 — Recommendations for 
patient-centred care and education (see also Evidence 
Table 4)
Recommendation
Classa
Levelb
Education directed to patients, family members, 
caregivers, and healthcare professionals is 
recommended to optimize shared decision-making, 
facilitating open discussion of both the benefit and 
risk associated with each treatment option.94,103
I
C
Access to patient-centred management according to 
the AF-CARE principles is recommended in all 
patients with AF, regardless of gender, ethnicity, and 
socioeconomic status, to ensure equality in 
healthcare provision and improve outcomes.
I
C
Patient-centred AF management with a 
multidisciplinary approach should be considered in all 
patients with AF to optimize management and 
improve outcomes.79,121–124
IIa
B
© ESC 2024
AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor 
management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate 
and rhythm control, [E] Evaluation and dynamic reassessment. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 20 -->

### Page 20

C
Comorbidity and risk factor management
Hypertension
Diabetes mellitus
Blood pressure lowering treatment
(Class I)
Patient-centred AF management with a multidisciplinary approach (Class IIa)
Education for patients, families and healthcare professionals (Class I)
Equality in healthcare provision (gender, ethnicity, socioeconomic) (Class I)
Heart failure
Diuretics for congestion
(Class I)
Overweight or obese
Weight loss
(target 10%)a
(Class I)
Obstructive sleep apnoea
Management of OSAa
(Class IIb)
Appropriate HFrEF
medical therapy
(Class I)
Bariatric surgery if rhythm controla
(Class IIb)
SGLT2 inhibitors
(Class 1)
Alcohol
Reduce to 3
drinks per week
(Class I)
 Effective glycaemic controla
(Class I)
Exercise capacity
Tailored exercise programme
(Class I)
Other risk factors/
comorbidities
Identify and manage aggressivelya
(Class I)
A
Avoid stroke and thromboembolism
Risk of thromboembolism
Start oral anticoagulation
(Class I)
Use locally-validated risk score or CHA2DS2-VA
OAC if CHA2DS2-VA
 score = 2 or more
(Class I)
Choice of anticoagulant
Assess 
bleeding risk
OAC if CHA2DS2-VA
score = 1
(Class IIa)
Use DOAC, except mechanical valve or mitral stenosis
(Class I)
Target INR 2.0–3.0;
(Class I)
>70% INR range;
(Class IIa)
or switch to DOAC
(Class I)
Assess and manage all modifiable risk factors for bleeding
(Class I)
Do not use risk scores to withhold anticoagulation
(Class III)
Do not combine antiplatelets and OAC
for stroke prevention
(Class III)
Avoid antiplatelets beyond 12 months in OAC treated
CCS/PVD
(Class III)
Temporal pattern of AF not relevant
(Class III)
Antiplatelet therapy not an alternative
(Class III)
Prevent bleeding
R
Reduce symptoms by rate and rhythm control
E
Evaluation and dynamic reassessment
See patient pathways for:
First-diagnosed AF
Paroxysmal AF
Persistent AF
Permanent AF
Consider:
AF
C A R
E
If  VKA:
Rate control drugs
Ablate and pace
Cardioversion
Catheter ablation
Endoscopic/hybrid ablation Surgical ablation
Antiarrhythmic drugs
Re-evaluate when AF episodes or non-AF admissions
ECG, blood tests,
cardiac imaging,
ambulatory ECG,
other imaging as needed
Assess new and existing risk factors 
and comorbidities
(Class I)
Stratify risk for stroke and thromboembolism
(Class I)
Check impact of AF
symptoms before and after treatment
(Class I)
Assess and manage modifiable bleeding risk factors
(Class I)
Continue OAC
despite rhythm control if risk of thromboembolism
(Class I)
Regular re-evaluation: 6 months after presentation, and then at least annually or based on clinical need
Figure 3 Central illustration. Patient pathway for AF-CARE (see Figures 4, 5, 6, and 7 for the [R] pathways for first-diagnosed, paroxysmal, persistent and 
permanent AF). AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid stroke and thromboembolism, 
[R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; CCS, chronic coronary syndrome; CHA2DS2-VA, congest­
ive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), 
vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; HFrEF, heart failure with reduced ejection fraction; INR, 
international normalized ratio of prothrombin time; OAC, oral anticoagulant; OSA, obstructive sleep apnoea; PVD, peripheral vascular disease; SGLT2, 
sodium-glucose cotransporter-2; VKA, vitamin K antagonist. aAs part of a comprehensive management of cardiometabolic risk factors.
ESC Guidelines                                                                                                                                                                                          3333


<!-- PAGE 21 -->

### Page 21

N
Patient with first-diagnosed AF
Y
Y
N
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Haemodynamically stable
Initial rate control
 (Class I)
Electrical cardioversion
(Class I)
LVEF ≤40%
Beta-blocker, digoxin,
diltiazem or verapamil
 (Class I)
Beta-blocker 
or digoxin
 (Class I)
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Cardioversion of symptomatic 
persistent AF
(Class I)
Wait-and-see if sinus rhythm restores spontaneously <48 h
 (Class IIa)
Figure 4 [R] Pathway for patients with first-diagnosed AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor man­
agement, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; LVEF, 
left ventricular ejection fraction. After following the pathway for first-diagnosed AF, patients with recurrent AF should enter the AF-CARE [R] pathway 
for paroxysmal, persistent, or permanent AF, depending on the type of their AF.


<!-- PAGE 22 -->

### Page 22

Rate control target = resting heart rate <110 b.p.m. (lenient control), 
with stricter control with continuing symptoms
(Class IIa)
Beta-blocker 
or digoxin
(Class I)
Patient with paroxysmal AF
LVEF ≤40%
Beta-blocker, digoxin,
diltiazem or verapamil
 (Class I)
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Amiodarone
(Class I)
Dronedarone, flecainide 
or propafenone
(Class I)
Catheter ablation
 (Class I)
Amiodarone or dronedarone 
(Class I)
Sotalol 
(Class IIb)
HFrEF
(LVEF ≤40%)
Stable HFmrEF
(LVEF 41–49%), 
coronary heart disease, 
valvular heart disease
Absence or minimal heart disease
Sotalol 
(Class IIb)
Recurrence of AF symptoms
Antiarrhythmic drug therapy
Y
N
Shared decision-making on rhythm control
(Class I)
If failed antiarrhythmic drug therapy
If failed catheter ablation
Re-do catheter ablation
(Class IIa)
Surgical/hybrid ablation
(Class IIb)
Antiarrhythmic drug therapy (see above)
Catheter ablationa
 (Class I)
Shared decision-making
(Class I)
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Figure 5 [R] Pathway for patients with paroxysmal AF. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor manage­
ment, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., 
beats per minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, Heart failure with reduced ejection fraction; LVEF, left ventricular 
ejection fraction. aIn patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve 
prognosis.
ESC Guidelines                                                                                                                                                                                          3335


<!-- PAGE 23 -->

### Page 23

Electrical cardioversion
Rate control target = resting heart rate <110 b.p.m. (lenient control), 
with stricter control with continuing symptoms
(Class IIa)
Beta-blocker or digoxin
(Class I)
Patient with persistent AF
LVEF ≤40%
Combination
 rate control therapy
(Class IIa)
Combination
 rate control therapy
(Class IIa)
Amiodarone
(Class I)
Dronedarone, flecainide 
or propafenone
(Class I)
Amiodarone or dronedarone 
(Class I)
Sotalol 
(Class IIb)
HFrEF
(LVEF ≤40%)
Stable HFmrEF
(LVEF 41–49%), 
coronary heart disease, 
valvular heart disease
Absence
 or minimal heart disease
Sotalol 
(Class IIb)
Recurrence of AF symptoms
Antiarrhythmic drug therapy
Y
N
Shared decision-making on rhythm control
(Class I)
If failed antiarrhythmic drug therapy
If failed catheter ablation
Catheter ablationa
 (Class IIb)
Shared decision-making, considering all rhythm control options
(Class I)
Beta-blocker, digoxin,
diltiazem or verapamil
(Class I)
Catheter ablation
(Class I)
Re-do catheter ablation
Endoscopic hybrid or surgical ablation
Antiarrhythmic drug therapy 
(see above)
Consider rate control 
strategy 
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Haemodynamic instability (Class I)
Part of rhythm control strategy (Class IIa)
Clarify benefit from sinus rhythm (Class IIa)
Endoscopic/
hybrid ablation
(Class IIa)
Figure 6 [R] Pathway for patients with persistent AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor management, 
[A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., beats per 
minute; HFmrEF, heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection 
fraction. aIn patients with HFrEF: Class I if high probability of tachycardia-induced cardiomyopathy; and Class IIa in selected patients to improve prognosis.


<!-- PAGE 24 -->

### Page 24

LVEF >40%
Patient with permanent AF
Y
Evaluation and dynamic reassessment
Initiate beta-blocker, 
digoxin, diltiazem or verapamil
 (Class I)
Continue beta-blocker,
digoxin, diltiazem 
or verapamil
 (Class I)
Combination beta-blocker with digoxin, or diltiazem/
verapamil with digoxin;
 avoiding bradycardia
(Class IIa)a
N
Rate control target = resting heart rate <110 b.p.m. (lenient control), with stricter control with continuing symptoms
(Class IIa)
Continue review and follow-up as per
AF-CARE approach
LVEF ≤40%
Continue beta-blocker or digoxin
 (Class I)
Combination beta-blocker with digoxin,
avoiding bradycardia
(Class IIa)
Y
Evaluation and dynamic reassessment
Initiate beta-blocker or digoxin
 (Class I)
Rate control target = resting heart rate  <110 b.p.m.
(lenient control), 
with stricter control 
with continuing symptoms
(Class IIa)
N
Severely symptomatic and
HF hospitalization
Atrioventricular node ablation and CRT
(Class IIa)
Y
Intensify rate control therapy under observation
Evaluation for atrioventricular node ablation in combination with pacemaker
(Class IIa)
N
Follow AF-CARE for [C] comorbidity and risk factor management & [A] avoid stroke and thromboembolism
Rate control target = resting heart rate  <110 b.p.m.
(lenient control), 
with stricter control 
with continuing symptoms
(Class IIa)
Figure 7 [R] Pathway for patients with permanent AF. AF, atrial fibrillation; AF-CARE, Atrial fibrillation—[C] Comorbidity and risk factor manage­
ment, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; b.p.m., 
beats per minute; CRT, cardiac resynchronization therapy; HF, heart failure; LVEF, left ventricular ejection fraction. Permanent AF is a shared decision 
made between the patient and physician that no further attempts at restoration of sinus rhythm are planned. aNote that the combination of beta- 
blockers with diltiazem or verapamil should only be used under specialist advice, and monitored with an ambulatory ECG to check for bradycardia.
ESC Guidelines                                                                                                                                                                                          3337


<!-- PAGE 25 -->

### Page 25

5. [C] Comorbidity and risk factor 
management
A broad array of comorbidities are associated with the recurrence 
and progression of AF. Managing comorbidities is also central to the 
success of other aspects of care for patients with AF, with evidence 
available for hypertension, heart failure, diabetes mellitus, obesity, 
and sleep apnoea, along with lifestyle changes that improve physical 
activity and reduce alcohol intake (see Supplementary data online, 
Additional Evidence Table S4). Identification and treatment of these 
comorbidities and clusters of risk factors form an important part 
of effective AF-CARE (Figure 8), with the evidence outlined in the 
rest of this section highlighting where management can improve 
patient outcomes or prevent AF recurrence. Many of these 
factors (and more) are also associated with incident AF (see 
Section 10).
Focus on key risk factors
Provide information 
without overloading
Suggested approach and targets
Setting individual targets for comorbidities and risk factors
Key targets
Behavioural change
Achievable targets
Identify and actively manage all risk factors and comorbidities
(Class I) 
Blood pressure treatment with target 120–129 mmHg /
70–79 mmHg in most adults (or as low as reasonably achievable)
(Class I) 
Effective glycaemic control with diet/medication(s)
(Class I)
Weight loss programme if overweight /obese, 
with 10% or more weight loss
(Class I) 
Management of obstructive sleep apnoea to minimize apnoeic episodes
(Class IIb)
Tailored exercise programme aiming for regular moderate/vigorous activity
(Class I)
Reduce alcohol consumption to 3 or less standard drinks per week
(Class I) 
Shared decision-making
Hypertension
Sleep apnoea
Heart failure
Diabetes
Obesity
Integrated management
Physical activity
Alcohol intake 
Optimize with diuretics to alleviate congestion appropriate,
medical therapy for reduced LVEF, and SGLT2 inhibitors for all LVEF
(Class I)
Figure 8 Management of key comorbidities to reduce AF recurrence. LVEF, left ventricular ejection fraction; SGLT2, sodium-glucose 
cotransporter-2.


<!-- PAGE 26 -->

### Page 26

5.1. Hypertension
Hypertension in patients with AF is associated with an increased risk of 
stroke, heart failure, major bleeding, and cardiovascular mortality.158–161
The target for treated systolic blood pressure (BP) in most adults is 
120–129 mmHg. Where BP-lowering treatment is poorly tolerated, 
clinically significant frailty exists or the patient’s age is 85 years or 
older, a more lenient target of <140 mmHg is acceptable or ‘as low 
as reasonably achievable’. On-treatment diastolic BP should ideally 
be 70–79 mmHg.162 In an individual participant data meta-analysis of 
22 randomized trials reporting baseline AF, a 5 mmHg reduction in 
systolic BP reduced the risk of major cardiovascular events by 9% 
(HR, 0.91; 95% CI, 0.83–1.00), with identical effect in patients with 
AF or sinus rhythm.129
In individuals with AF, hypertension often coexists with other 
modifiable and non-modifiable risk factors that all contribute to re­
currence of AF, readmission to hospital, and ongoing symptoms after 
rhythm control.163–171 Optimal control of blood pressure should be 
considered an essential component of treating AF and undertaken 
within a strategy of comprehensive risk factor management.126–128
Although the majority of research has focused on clinical outcomes, 
limited comparative data on hypertension medication suggests that 
use of angiotensin-converting enzyme (ACE) inhibitors or angioten­
sin receptor blockers (ARB) may be superior for prevention of recur­
rent AF.172–175
5.2. Heart failure
Heart failure is a key determinant of prognosis in patients with AF, as 
well as an important factor associated with recurrence and progression 
of AF.176,177 During 30 years of follow-up in the Framingham cohort, 
57% of those with new heart failure had concomitant AF, and 37% of 
those with new AF had heart failure.178 Numerous cardiovascular 
and non-cardiovascular conditions impact the development of both 
AF and heart failure, leading to the common pathway of atrial cardio­
myopathy.18 In patients with acute heart failure attending the emer­
gency department, AF is one of the most prevalent triggering factors 
of the episode.179 The development of heart failure in patients with 
AF is associated with a two-fold increase in stroke and thrombo­
embolism,180 even after anticoagulation,181 and 25% higher all-cause 
mortality.178 Prognosis may be affected by left ventricular ejection 
fraction (LVEF), with the rate of death highest with the combination 
of AF and heart failure with reduced ejection fraction (HFrEF) 
(LVEF ≤ 40%), as compared with AF and HFpEF (LVEF ≥ 50%). 
However, rates of stroke and incident heart failure hospitalization 
are similar regardless of LVEF.182 Due to how common concomitant 
AF and heart failure are in clinical practice, strategies to improve out­
comes in these patients are detailed within each component of the 
AF-CARE pathway. However, it is also critical that heart failure itself 
is managed appropriately in patients with AF to prevent avoidable ad­
verse events.
Optimization of heart failure management should follow current 
ESC Guidelines: 2023 Focused Update183 of the 2021 ESC Guidelines 
for the diagnosis and treatment of acute and chronic heart failure.137
Achieving euvolaemia with diuretics is an important first step that not 
only manages the heart failure component, but can also facilitate better 
control of heart rate in AF. For HFrEF, it should be highlighted that 
many older guideline-recommended therapies lack specific evidence 
for benefit in patients with coexisting AF. No trial data are available 
in this context for ACE inhibitors, there are conflicting data on 
ARBs,132,184 and an individual patient-level analysis of RCTs found no 
Recommendation Table 5 — Recommendations for 
comorbidity and risk factor management in AF (see 
also Evidence Table 5)
Recommendation
Classa
Levelb
Identification and management of risk factors and 
comorbidities is recommended as an integral part of 
AF care.39,125–127
I
B
Blood pressure lowering treatment is recommended 
in patients with AF and hypertension to reduce 
recurrence and progression of AF and prevent 
adverse cardiovascular events.126–130
I
B
Diuretics are recommended in patients with AF, HF, 
and congestion to alleviate symptoms and facilitate 
better AF management.
I
C
Appropriate medical therapy for HF is 
recommended in AF patients with HF and impaired 
LVEF to reduce symptoms and/or HF hospitalization 
and prevent AF recurrence.131–137
I
B
Sodium-glucose cotransporter-2 inhibitors are 
recommended for patients with HF and AF 
regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and 
cardiovascular death.136,138–140
I
A
Effective glycaemic control is recommended as part 
of comprehensive risk factor management in 
individuals with diabetes mellitus and AF, to reduce 
burden, recurrence, and progression of AF.
I
C
Weight loss is recommended as part of 
comprehensive risk factor management in 
overweight and obese individuals with AF to reduce 
symptoms and AF burden, with a target of 10% or 
more reduction in body weight.125–128
I
B
A tailored exercise programme is recommended in 
individuals with paroxysmal or persistent AF to 
improve cardiorespiratory fitness and reduce AF 
recurrence.141–146
I
B
Reducing alcohol consumption to ≤3 standard drinks 
(≤30 grams of alcohol) per week is recommended as 
part of comprehensive risk factor management to 
reduce AF recurrence.126,127,147
I
B
Bariatric surgery may be considered in conjunction 
with lifestyle changes and medical management in 
individuals with AF and body mass index ≥40 kg/m2 c 
where a rhythm control strategy is planned, to 
reduce recurrence and progression of AF.
IIb
C
Management of obstructive sleep apnoea may be 
considered as part of a comprehensive management 
of risk factors in individuals with AF to reduce 
recurrence and progression.126–128,148–154
IIb
B
When screening for obstructive sleep apnoea in 
individuals with AF, using only symptom-based 
questionnaires is not recommended.155–157
III
B
© ESC 2024
AF, atrial fibrillation; HF, heart failure; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence. 
cOr body mass index ≥35 kg/m2 with obesity-related complications.
ESC Guidelines                                                                                                                                                                                          3339


<!-- PAGE 27 -->

### Page 27

difference between beta-blockers and placebo for all-cause mortality in 
HFrEF with AF.133 However, these drugs have clear proof of safety and 
there may be other indications for these therapies beyond prognosis, 
including comorbidity management and symptom improvement. 
These and other therapies may also have dual functions, for example, 
beta-blockers or digoxin for rate control of AF, in addition to improving 
heart failure metrics and reducing hospitalization.48,185,186 More recent 
additions to HFrEF management, such as eplerenone, sacubitril- 
valsartan, and sodium-glucose cotransporter-2 (SGLT2) inhibitors, 
had substantial numbers of patients with AF enrolled in RCTs, with 
no evidence that AF status affected their ability to reduce cardiovascu­
lar mortality/heart failure hospitalization.134–136 Cardiac resynchroniza­
tion therapy (CRT) in the context of HFrEF and AF is discussed in detail 
in the 2021 ESC Guidelines on cardiac pacing and cardiac resynchroni­
zation therapy, with an important focus on ensuring effective biventri­
cular pacing (with a low threshold for considering atrioventricular node 
ablation).187 Patients who have heart failure with mildly reduced ejec­
tion fraction (HFmrEF) (LVEF 41%–49%) and AF should generally be 
treated according to guidance for HFrEF,137 albeit with limited evidence 
to date in AF.188–190 For treatment of HFpEF and AF,191 pre-specified 
subgroup data on AF from multiple large trials show that the SGLT2 
inhibitors dapagliflozin, empaglifozin, and sotagliflozin are effective in 
improving prognosis.138–140
Appropriate management of heart failure has the potential to reduce 
recurrence of AF, e.g. by reducing adverse atrial and ventricular myo­
cardial remodelling, but there are limited data for specific therapies. 
In the Routine versus Aggressive upstream rhythm Control for preven­
tion of Early AF in heart failure (RACE 3) trial, combined management 
of mild-to-moderate heart failure with ACE inhibitors/ARBs, mineralo­
corticoid receptor antagonists, statins, and cardiac rehabilitation in­
creased the maintenance of sinus rhythm on ambulatory monitoring 
at 12 months.39 This benefit was not preserved at the 5 year follow-up, 
although this may have been confounded by the lack of ongoing inter­
vention beyond the initial 12 months.192
5.3. Type 2 diabetes mellitus
Diabetes mellitus is present in around 25% of patients with AF.193–195
Patients with both diabetes and AF have a worse prognosis,196 with in­
creased healthcare utilization and excess mortality and cardiovascular 
events. The prevalence and incidence of AF and type 2 diabetes are 
widely increasing, thus making the association of these two conditions 
a public health challenge.195,197 Moreover, diabetes is a major factor in­
fluencing thromboembolic risk.198,199 Following catheter ablation of AF, 
diabetes and higher HbA1c are associated with increased length of stay 
and a greater recurrence of AF.200–203
In cohort studies, the management of diabetes mellitus as part of 
comprehensive risk factor management has been associated with re­
duced AF symptoms, burden, reversal of the type of AF (from persist­
ent to paroxysmal or no AF), and improved maintenance of sinus 
rhythm.126–128 However, robust evidence is limited, and individual 
glucose-lowering medications have had variable effects on AF.204–206
There are emerging data of the use of SGLT2 and glucagon-like 
peptide-1 antagonists in patients with diabetes and AF that may impact 
on treatment choice in the near future. Importantly, diabetes frequently 
coexists with multiple risk factors in patients with AF, and a compre­
hensive approach to management is required. Further details are 
provided in the 2023 ESC Guidelines for the management of cardiovas­
cular disease in patients with diabetes.207
5.4. Obesity
Obesity frequently coexists with other risk factors that have been inde­
pendently associated with the development of AF.208,209 Obesity (body 
mass index [BMI] ≥30 kg/m2) and being overweight (BMI >25 kg/m2) 
are associated with a greater risk of recurrent atrial arrhythmias after 
AF ablation (13% increase for every 5 kg/m2 higher BMI).210–212 In 
the setting of comprehensive risk factor management, weight loss of 
≥10% in overweight and obese individuals with AF has been associated 
with reduced AF symptoms and AF burden in an RCT (aiming for BMI 
<27 kg/m2).125 Cohort studies have also shown a graded response to 
maintenance of sinus rhythm,126 improved ablation outcomes,128 and 
reversal of the type of AF127 commensurate with the degree of weight 
loss and risk factor management. However, in the Supervised Obesity 
Reduction Trial for AF Ablation Patients (SORT-AF) randomized trial 
in AF ablation patients, a sole weight loss intervention that achieved 
4% loss in weight over 12 months did not impact ablation outcomes.213
This is consistent with the findings in LEGACY (Long-Term Effect of 
Goal directed weight management on Atrial Fibrillation Cohort: a 5 
Year follow-up study) that showed that weight loss of ≤3% had no im­
pact on AF recurrence.126 Observational studies have raised the possi­
bility of a point of no return in terms of the benefit of weight loss,214 but 
also the possibility that bariatric surgery can improve symptoms and re­
duce AF recurrence.215–217
5.5. Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is a highly prevalent condition, particu­
larly in patients with AF.157,218 Optimal screening tools in the AF popu­
lation are still under evaluation, although it may be reasonable to screen 
for OSA in patients where a rhythm control strategy is being pursued. 
Polysomnography or home sleep apnoea testing are suggested in pref­
erence to screening questionnaires.155–157,219 Questionnaires assessing 
daytime sleepiness are poor predictors of moderate-to-severe OSA.155
Which parameter should be used to focus on risk of AF in patients with 
OSA, and to guide OSA treatment in patients with AF, is still 
unclear.220,221
Observational studies have suggested that individuals with OSA not 
treated with continuous positive airway pressure (CPAP) respond 
poorly to treatments for AF, with an increased risk of recurrence 
after cardioversion or ablation.222 Conversely, OSA patients treated 
with CPAP seem to mitigate their propensity toward developing 
AF.148–153,222–224 A small randomized trial of CPAP vs. no therapy de­
monstrated reversal of atrial remodelling in individuals with moderate 
OSA.154 However, other small RCTs have failed to show a benefit of 
CPAP therapy on ablation outcomes225 or post-cardioversion.226
Data on the cardiovascular mortality benefit of CPAP therapy in 
OSA are inconclusive.227–230
5.6. Physical inactivity
Reduced cardiorespiratory fitness frequently coexists with other modi­
fiable risk factors and has been associated with a greater recurrence of 
AF after catheter ablation.141 Better cardiorespiratory fitness has a de­
monstrated inverse relationship to AF burden in both middle-aged and 
elderly people.141 Small RCTs, meta-analyses, and observational


<!-- PAGE 28 -->

### Page 28

cohorts have shown that regular aerobic exercise may also improve 
AF-related symptoms, quality of life, and exercise capacity.142,143
Better cardiorespiratory fitness and a gain in cardiorespiratory fitness 
over time are associated with a greater reduction in AF burden and im­
proved maintenance of sinus rhythm.141–145
5.7. Alcohol excess
Alcohol consumption can increase the risk of adverse events in patients 
with AF, such as thromboembolism, death, or AF-related hospitaliza­
tion.231,232 Alcohol is associated with an increased risk of ischaemic 
stroke in patients with newly diagnosed AF, and alcohol abstinence after 
AF diagnosis can reduce the risk of ischaemic stroke.233 In patients re­
ceiving OAC, alcohol excess is associated with a greater risk of bleed­
ing,234 mediated by poor adherence, alcohol–drug interactions, liver 
disease, and variceal bleeding.
Alcohol consumption is associated with a dose-dependent increase 
in the recurrence of AF after catheter ablation.147,235 In an RCT among 
regular non-binge drinkers with AF, the goal of abstinence led to a sig­
nificant reduction in AF recurrence and burden; alcohol intake was re­
duced from 16.8 to 2.1 standard drinks per week (≤30 grams or 3 
standard drinks of alcohol) in the intervention arm, with 61% attaining 
abstinence.147 In observational data of patients undergoing catheter ab­
lation, reduction of consumption to ≤7 standard drinks (≤70 grams of 
alcohol) per week was associated with improved maintenance of sinus 
rhythm.128,235
6. [A] Avoid stroke and 
thromboembolism
6.1. Initiating oral anticoagulation
Atrial fibrillation is a major risk factor for thromboembolism, irre­
spective of whether it is paroxysmal, persistent, or permanent.236,237
Left untreated, and dependent on other patient-specific factors, the 
risk of ischaemic stroke in AF is increased five-fold, and one in every 
five strokes is associated with AF.238 The default approach should 
therefore be to provide OAC to all eligible patients, except those 
at low risk of incident stroke or thromboembolism. The effectiveness 
of OAC to prevent ischaemic stroke in patients with AF is well estab­
lished.239,240 Antiplatelet drugs alone (aspirin, or aspirin in combin­
ation with clopidogrel) are not recommended for stroke prevention 
in AF.241,242
6.1.1. Decision support for anticoagulation in AF
Tools have been developed to enable easier implementation of OAC 
in patients with clinical AF. The majority of OAC clinical trials have 
used variations of the CHADS2 score to indicate those at risk (with 
points for chronic heart failure, hypertension, age, diabetes, and 2 
points for prior stroke/transient ischaemic attack [TIA]). Although 
most available stroke risk scores are simple and practical, the predict­
ive value of scores is generally modest (see Supplementary data 
online, Table S3).243–245 Classification and discrimination of adverse 
events is relatively poor for all scores and hence the benefit of using 
them to select patients for OAC is unclear. There is also considerable 
variation in the definition of risk factors across countries,246 and a lack 
of evidence from clinical trials on the ability of stroke risk scoring to 
enhance clinical practice.243 This guideline continues to provide a 
Class IA recommendation for the use of OAC in patients at risk of 
thromboembolism. However, in the absence of strong evidence for 
how to apply risk scores in real-world patients, this has been sepa­
rated from the use of any particular risk score. This is also in line 
with regulatory approvals for direct oral anticoagulants (DOACs), 
which do not stipulate risk scores or numerical thresholds.25–28,245
Substantive changes have occurred in the decades since these risk 
scores were developed in regards to population-level risk factor pro­
files, therapies, and targets.198 Historical scores do not take into ac­
count parameters that have been associated with thromboembolism 
in contemporary cohorts, such as cancer, chronic kidney disease 
(CKD), ethnicity, and a range of circulating biomarkers (including tropo­
nin and B-type natriuretic peptide [BNP]). As an example, for CKD 
there is a correlation between decreasing glomerular filtration rate 
and proteinuria with stroke risk,247–250 and cohort data suggest a two- 
fold increased risk of ischaemic stroke and mortality in AF patients with 
CKD vs. without.251 Other factors, such as atrial enlargement, hyperlip­
idaemia, smoking, and obesity, have been identified in specific cohort 
studies as additional risk factors for ischaemic stroke in AF.70,252,253
Biomarkers, such as troponin, natriuretic peptides, growth differenti­
ation factor-15, cystatin C, and interleukin-6, can also indicate residual 
stroke risk among anticoagulated AF patients.254,255 Biomarker-guided 
stroke prevention is currently being evaluated in an ongoing RCT 
(NCT03753490). Until further validation within RCTs is available, this 
task force continues to support using simple clinical classification for im­
plementation of OAC. Clinicians should use tools that have been vali­
dated in their local population and take an individualized approach to 
thromboembolic risk stratification that considers the full range of 
each patient’s specific risk factors. The absolute risk level at which to 
start OAC in individual patients cannot be estimated from population- 
level studies. It will vary depending on how those factors interact with 
other medical issues, and the degree of risk acceptable or tolerated by 
that person. In general, most of the available risk scores have a thresh­
old of 0.6%–1.0% per annum of thromboembolic events for clinical AF 
to warrant OAC prescription.
Across Europe, the most popular risk score is CHA2DS2–VASc, giv­
ing points for congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/TIA/thromboembolism 
(2 points), vascular disease, age 65–74 years and female sex. 
However, implementation has varied in terms of gender. Female sex 
is an age-dependent stroke risk modifier rather than a risk factor per 
se.112,256,257 The inclusion of gender complicates clinical practice both 
for healthcare professionals and patients.258 It also omits individuals 
who identify as non-binary, transgender, or are undergoing sex hor­
mone therapy. Previous guidelines from the ESC (and globally) have 
not actually used CHA2DS2-VASc; instead providing different score le­
vels for women and men with AF to qualify for OAC. Hence, 
CHA2DS2-VA (excluding gender) has effectively been in place 
(Table 10).78 This task force proposes, in the absence of other locally 
validated alternatives, that clinicians and patients should use the 
CHA2DS2-VA score to assist in decisions on OAC therapy (i.e. without 
a criterion for birth sex or gender). Pending further trials in lower risk 
patients (NCT04700826,259 NCT02387229260), OAC are recom­
mended in those with a CHA2DS2-VA score of 2 or more and should 
be considered in those with a CHA2DS2-VA score of 1, following a 
patient-centred and shared care approach. Healthcare professionals 
should take care to assess for other thromboembolic risk factors 
that may also indicate the need for OAC prescription.
ESC Guidelines                                                                                                                                                                                          3341


<!-- PAGE 29 -->

### Page 29

Recommendation Table 6 — Recommendations to 
assess and manage thromboembolic risk in AF (see also 
Evidence Table 6)
Recommendations
Classa
Levelb
Oral anticoagulation is recommended in patients 
with clinical AF at elevated thromboembolic risk to 
prevent ischaemic stroke and 
thromboembolism.239,240
I
A
A CHA2DS2-VA score of 2 or more is recommended 
as an indicator of elevated thromboembolic risk for 
decisions on initiating oral anticoagulation.
I
C
Oral anticoagulation is recommended in all patients 
with AF and hypertrophic cardiomyopathy or 
cardiac amyloidosis, regardless of CHA2DS2-VA 
score, to prevent ischaemic stroke and 
thromboembolism.270–276
I
B
Individualized reassessment of thromboembolic risk 
is recommended at periodic intervals in patients with 
AF to ensure anticoagulation is started in appropriate 
patients.277–280
I
B
Continued 
A CHA2DS2-VA score of 1 should be considered an 
indicator of elevated thromboembolic risk for 
decisions on initiating oral anticoagulation.
IIa
C
Direct oral anticoagulant therapy may be considered 
in patients with asymptomatic device-detected 
subclinical AF and elevated thromboembolic risk to 
prevent ischaemic stroke and thromboembolism, 
excluding patients at high risk of bleeding.281,282
IIb
B
Antiplatelet therapy is not recommended as an 
alternative to anticoagulation in patients with AF to 
prevent ischaemic stroke and 
thromboembolism.242,283
III
A
Using the temporal pattern of clinical AF 
(paroxysmal, persistent, or permanent) is not 
recommended to determine the need for oral 
anticoagulation.284,285
III
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral 
anticoagulant. 
aClass of recommendation. 
bLevel of evidence.
Table 10 Updated definitions for the CHA2DS2-VA score
CHA2DS2-VA component
Definition and comments
Points 
awardeda
C
Chronic heart failure
Symptoms and signs of heart failure (irrespective of LVEF, thus including HFpEF, HFmrEF, and 
HFrEF), or the presence of asymptomatic LVEF ≤40%.261–263
1
H
Hypertension
Resting blood pressure >140/90 mmHg on at least two occasions, or current antihypertensive 
treatment. The optimal BP target associated with lowest risk of major cardiovascular events is 
120–129/70–79 mmHg (or keep as low as reasonably achievable).162,264
1
A
Age 75 years or above
Age is an independent determinant of ischaemic stroke risk.265 Age-related risk is a continuum, 
but for reasons of practicality, two points are given for age ≥75 years.
2
D
Diabetes mellitus
Diabetes mellitus (type 1 or type 2), as defined by currently accepted criteria,266 or treatment 
with glucose lowering therapy.
1
S
Prior stroke, TIA, or arterial 
thromboembolism
Previous thromboembolism is associated with highly elevated risk of recurrence and therefore 
weighted 2 points.
2
V
Vascular disease
Coronary artery disease, including prior myocardial infarction, angina, history of coronary 
revascularization (surgical or percutaneous), and significant CAD on angiography or cardiac 
imaging.267
OR 
Peripheral vascular disease, including: intermittent claudication, previous revascularization for PVD, 
percutaneous or surgical intervention on the abdominal aorta, and complex aortic plaque on 
imaging (defined as features of mobility, ulceration, pedunculation, or thickness ≥4 mm).268,269
1
A
Age 65–74 years
1 point is given for age between 65 and 74 years.
1
© ESC 2024
BP, blood pressure; CAD, coronary artery disease; CHA2DS2-VA, chronic heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/ 
arterial thromboembolism (2 points), vascular disease, age 65–74 years; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection 
fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; PVD, peripheral vascular disease. 
aIn addition to these factors, other markers that modify an individual’s risk for stroke and thromboembolism should be considered, including cancer, chronic kidney disease, ethnicity (black, 
Hispanic, Asian), biomarkers (troponin and BNP), and in specific groups, atrial enlargement, hyperlipidaemia, smoking, and obesity.


<!-- PAGE 30 -->

### Page 30

6.2. Oral anticoagulants
Vitamin K antagonists (VKA), predominantly warfarin but also other 
coumarin and indandione derivatives, have been the principal drugs to 
prevent thromboembolic events in the context of AF. As with any 
anticoagulant, a balance must be reached between preventing thrombo­
embolism and preserving physiological haemostasis, with VKA-associated 
intracranial and other major haemorrhage the most critical limitation for 
acceptance of OAC. The global switch to DOACs as first-line therapy 
has changed this risk–benefit balance, allowing more widespread pre­
scription with no need for routine monitoring (see Supplementary 
data online, Additional Evidence Tables S5–S7). This component of AF 
management may see substantive changes in the coming years, with a 
number of factor XI inhibitors in various stages of clinical evaluation. A 
phase 2 trial of abelacimab in patients with AF has shown lower rates 
of bleeding compared with rivaroxaban286; however, a phase 3 trial of 
asundexian was terminated early due to lack of efficacy against apixaban 
(NCT05643573), despite favourable phase 2 results.287 Regardless of the 
type of OAC prescribed, healthcare teams should be aware of the poten­
tial for interactions with other drugs, foods, and supplements, and in­
corporate this information into the education provided to patients and 
their carers. The list of potential interactions with VKA is broad,288,289
but there are also some common cardiovascular and non-cardiovascular 
drugs that interact with DOACs.290,291 Figure 9 highlights common and 
major interactions to consider for VKAs and DOACs.
Caution if renal function impaired
Vitamin K antagonist oral anticoagulants
Avoid where possible
NSAIDs
Fluconazole
Voriconazole
Fluoxetine
Avoid where possible
Carbamazepine
Phenytoin
Phenobarbital
Rifampicin
Ritonavir
Itraconazole
Ketoconazole  
Avoid where possible
Dronedarone
Carbamazepine
Phenytoin
Rifampicin
Ritonavir
Itraconazole
Ketoconazole
Cyclosporin
Glecaprevir/pibrentasvir
Tacrolimus
Avoid where possible
Carbamazepine
Phenytoin
Phenobarbital
Rifampicin
Ritonavir
Avoid where possible
Dronedarone
Carbamazepine
Phenytoin
Phenobarbital
Itraconazole
Ketoconazole
Posaconazole
Voriconazole
Rifampicin
Ritonavir
Limit consumption
Avoid or reduce apixaban dose if another interacting drug therapy
Avoid if another interacting drug therapy
Avoid or reduce edoxaban dose if another interacting drug therapy
Avoid or reduce edoxaban dose
Reduce warfarin dose
Apixaban
Dabigatran
Edoxaban
Delay timing of drugs and/or adjust dose
Amiodarone
Metronidazole
Sulphonamides
Allopurinol
Fluvastatin
Gemfibrozil
Fluorouracil
Increase warfarin dose
Carbamazepine
Monitor INR carefully
Dronedarone
Statins
Penicillin antibiotics
Macrolide antibiotics
Quinolone antibiotics
Rifampicin
Methotrexate
Ritonavir
Phenytoin
Sodium valproate
Tamoxifen
Chemotherapies
Posaconazole
Voriconazole
Protease inhibitors
Apalutamide
Enzalutamide
Tyrosine kinase inhibitors
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Limit consumption
Grapefruit juice
St John’s wort
Amiodarone
Ticagrelor
Verapamil
Quinidine
Clarithromycin
Posaconazole
Dronedarone
Protease inhibitors
Tyrosine kinase inhibitors
Verapamil
Cyclosporin
Clarithromycin
Erythromycin
Fluconazole
Cyclosporin
Itraconazole
Ketoconazole
Erythromycin
Alcohol
Grapefruit/cranberry juice
St John’s wort
Rivaroxaban
Direct oral anticoagulants
Figure 9 Common drug interactions with oral anticoagulants. INR, international normalized ratio of prothrombin time; NSAID, non-steroidal anti- 
inflammatory drug. This figure depicts only common or major interactions and is not an exhaustive list of all potential interactions. Please see the 
European Medicines Agency website or your local formulary for more information.
ESC Guidelines                                                                                                                                                                                          3343


<!-- PAGE 31 -->

### Page 31

6.2.1. Direct oral anticoagulants
The DOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) have all 
demonstrated at least non-inferior efficacy compared with warfarin for 
the prevention of thromboembolism, but with the added benefit of a 
50% reduction in intracranial haemorrhage (ICH).25–28 Meta-analyses of 
individual data from 71 683 RCT patients showed that standard, full-dose 
DOAC treatment compared with warfarin reduces the risk of stroke or 
systemic embolism (HR, 0.81; 95% CI, 0.73–0.91), all-cause mortality (HR, 
0.90; 95% CI, 0.85–0.95), and intracranial bleeding (HR, 0.48; 95% CI, 
0.39–0.59), with no significant difference in other major bleeding (HR, 
0.86; 95% CI, 0.73–1.00) and little or no between-trial heterogeneity.292
Post-marketing observational data on the effectiveness and safety of 
dabigatran,313,314 rivaroxaban,315,316 apixaban,317 and edoxaban318 vs. 
warfarin show general consistency with the respective phase 3 RCTs.
For patients undergoing cardioversion, three underpowered trials 
showed non-significantly lower rates of cardiovascular events with 
DOACs compared with warfarin.319–321 In meta-analysis of these 
5203 patients predominantly undergoing electrical cardioversion, the 
composite of stroke, systemic embolism, myocardial infarction (MI), 
and cardiovascular death was significantly lower at 0.42% in 
patients randomized to a DOAC vs. 0.98% in those allocated VKA 
(risk ratio, 0.42; 95% CI, 0.21–0.86; P = .017), with no heterogeneity be­
tween trials and no significant difference in major bleeding.293
Specific patient subgroups show consistent benefit with DOACs vs. 
VKAs. For heart failure, major thromboembolic events were lower in 
DOAC-treated patients vs. warfarin in subgroup analysis of landmark 
RCTs,322 confirmed in large-scale real-world data.323 In a retrospective 
cohort of patients aged over 80 years, DOAC use was associated with a 
lower risk of ischaemic stroke, dementia, mortality, and major bleeding 
than warfarin,324 but this may be confounded by prescription bias.
Direct oral anticoagulants retain their efficacy and safety over VKAs 
in patients with mild-to-moderate CKD (creatinine clearance 
[CrCl] >30 mL/min),325
although specific dosing adjustments 
apply.25–28,326 In Europe, reduced doses of rivaroxaban, apixaban, and 
edoxaban are approved in patients with severe CKD (CrCl 15–29 mL/ 
min), although limited numbers of patients were included in the major 
RCTs against VKA.327 Dabigatran is more dependent on renal elimination 
and so is contraindicated with an estimated glomerular filtration rate 
<30 mL/min/1.73 m2. Small trials have been performed in patients on 
haemodialysis, with two finding no difference between apixaban 2.5 mg 
twice daily and VKA for efficacy or safety outcomes,328,329 and one trial 
showing that rivaroxaban 10 mg led to significantly lower rates of cardiovas­
cular events and major bleeding compared with VKA.330 Careful institution 
and regular follow-up are advised when instituting anticoagulants in any pa­
tient with impaired renal function (See Supplementary data online, 
Additional Evidence Table 8).326
Direct oral anticoagulants as a class should be avoided in specific pa­
tient groups, such as those with mechanical heart valves or 
moderate-to-severe mitral stenosis. In patients with mechanical heart 
valves, an excess of thromboembolic and major bleeding events among 
patients on dabigatran therapy vs. VKA was observed, with an RCT ter­
minated prematurely.331 A trial of apixaban vs. VKA after implantation 
of a mechanical aortic valve was also stopped due to excess thrombo­
embolic events in the apixaban group.332 The restriction on DOAC use 
does not apply to bioprosthetic heart valves (including mitral) or after 
transcatheter aortic valve implantation, where DOACs can be used and 
trial data show non-inferiority for clinical events compared with 
VKAs.304,333,334 With regards to mitral stenosis, the DOAC vs. VKA 
trials excluded patients with moderate-to-severe disease. In 4531 ran­
domized patients with rheumatic heart disease and AF, VKAs led to a 
lower rate of composite cardiovascular events and death than rivarox­
aban, without a higher rate of bleeding.294 Eighty-two per cent of the 
patients included had a mitral valve area ≤2 cm, supporting the restric­
tion of DOAC use in patients with moderate-to-severe mitral stenosis. 
Note that patients with other types of valve disease (mitral regurgita­
tion and others) should preferentially be prescribed a DOAC, and 
the term ‘valvular’ AF is obsolete and should be avoided.
Inappropriate dose reductions for DOACs are frequent in clinical 
practice,311 but need to be avoided as they increase the risk of stroke with­
out decreasing bleeding risk.310 Hence, DOAC therapy should be instituted 
according to the standard full dose as tested in phase 3 RCTs and approved 
by regulators (Table 11). The prescribed dosage should consider the individ­
ual patient’s profile.335 Drug interactions need to be considered in all pa­
tients taking or planned for DOACs (see Figure 9 for common drug 
interactions).336There is insufficient evidence currently to advise on routine 
laboratory testing for DOAC levels. However, in certain situations, meas­
urement of DOAC levels (where available) may be helpful, such as severe 
bleeding, the need for urgent surgery, or thromboembolic events despite 
apparent DOAC compliance.337,338 Patients should always be involved in 
decision-making on anticoagulation,339leading to better alignment with per­
sonal preferences that can help to increase understanding and adherence.
Recommendation Table 7 — Recommendations for 
oral anticoagulation in AF (see also Evidence Table 7)
Recommendations
Classa
Levelb
Direct oral anticoagulants are recommended in 
preference to VKAs to prevent ischaemic stroke and 
thromboembolism, except in patients with 
mechanical heart valves or moderate-to-severe 
mitral stenosis.25–28,292–294
I
A
A target INR of 2.0–3.0 is recommended for patients 
with AF prescribed a VKA for stroke prevention to 
ensure safety and effectiveness.295–298
I
B
Switching to a DOAC is recommended for eligible 
patients that have failed to maintain an adequate time 
in therapeutic range on a VKA (TTR <70%) to 
prevent thromboembolism and intracranial 
haemorrhage.299–303
I
B
Keeping the time in therapeutic range above 70% 
should be considered in patients taking a VKA to 
ensure safety and effectiveness, with INR checks at 
appropriate frequency and patient-directed 
education and counselling.304–308
IIa
A
Maintaining VKA treatment rather than switching to 
a DOAC may be considered in patients aged ≥75 
years on clinically stable therapeutic VKA with 
polypharmacy to prevent excess bleeding risk.309
IIb
B
A reduced dose of DOAC therapy is not 
recommended, unless patients meet DOAC-specific 
criteria,c to prevent underdosing and avoidable 
thromboembolic events.310–312
III
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; INR, international normalized ratio 
of prothrombin time; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cSee Table 11.


<!-- PAGE 32 -->

### Page 32

6.2.2. Vitamin K antagonists
Vitamin K antagonist therapy reduces stroke risk by 64% and mortality 
by 26% in patients with AF at elevated thromboembolic risk (mostly 
warfarin in trials, compared with placebo or no treatment).239
Vitamin K antagonists are still used in many patients worldwide, but 
prescriptions have declined sharply since the introduction of 
DOACs.340,341 Vitamin K antagonists are currently the only treatment 
option in AF patients with mechanical heart valves or moderate-to- 
severe mitral valve stenosis.294,331 The use of VKAs is not only limited 
by numerous drug and food interactions (Figure 9), but also a narrow 
therapeutic range. This requires frequent monitoring and dose adjust­
ment according to the prothrombin time expressed as the international 
normalized ratio (INR).342 If the time in therapeutic range (TTR) is 
maintained for long periods (e.g. >70% with INR 2.0–3.0), then VKA 
can be effective for thromboembolic protection with an acceptable 
safety profile.295–297,343 However, VKAs are associated with higher 
rates of intracranial bleeding,299,300 and also higher rates of other types 
of bleeding compared with DOACs.83
In view of the potential safety benefits, switching from VKAs to a 
DOAC is justified where there are concerns about intracranial bleeding 
or for patient-choice reasons, and a switch is recommended where pa­
tients have failed to maintain an adequate TTR (<70%). This depends 
on patients fulfilling eligibility criteria for DOACs and should take into ac­
count other correctable reasons for poor INR control. There is limited 
data on switching OAC in older patients (≥75 years) with polypharmacy 
or other markers of frailty. A recent trial in this patient group premature­
ly stopped for futility showed that switching from VKAs to DOACs led 
to a higher primary outcome rate of major or clinically relevant non- 
major bleeding events compared with continuing with INR-guided 
VKA (17.8 vs. 10.5 per 100 patient-years, driven by non-major bleeds).309
Hence, in such patients who are clinically stable with good TTR, VKAs 
may be continued rather than switching to a DOAC after an open discus­
sion with the patient and shared decision-making.
6.2.3. Clinical vs. device-detected subclinical AF
The known benefit of anticoagulation applies to clinical AF. Two RCTs 
have been published assessing the value of DOAC therapy in device- 
detected subclinical AF. The ARTESiA trial (Apixaban for the 
Reduction of Thromboembolism in Patients With Device-Detected 
Sub-Clinical Atrial Fibrillation) was completed with 4012 patients 
with device-detected subclinical AF and a mean follow-up of 3.5 
years.282 The primary efficacy outcome of stroke or systemic embolism 
was significantly less in those randomized to apixaban compared with 
aspirin (HR, 0.63; 95% CI, 0.45–0.88; P = .007). In the intention-to-treat 
analysis, the primary safety outcome of major bleeding was higher with 
apixaban (HR, 1.36; 95% CI, 1.01–1.82; P = .04). The NOAH trial (Non- 
vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High 
Rate Episodes) was stopped prematurely due to safety concerns and 
futility for the efficacy of edoxaban, and hence provides limited informa­
tion.281 The analysis of 2536 patients with device-detected atrial high- 
rate episodes and a median follow-up of 21 months identified no differ­
ence in a composite of cardiovascular death, stroke, or embolism com­
paring edoxaban and placebo (HR, 0.81; 95% CI, 0.60–1.08; 
P = .15). Those randomized to edoxaban had a higher rate of the 
composite of death or major bleeding than placebo (HR, 1.31; 
95% CI, 1.02–1.67; P = .03). Patients had a low burden of device- 
detected subclinical AF in both trials (median duration 1.5 h and 
Table 11 Recommended doses for direct oral anticoagulant therapy
DOAC
Standard full dose
Criteria for dose reduction
Reduced dose only  
if criteria met
Apixaban
5 mg twice daily
Two out of three needed for dose reduction: 
(i) age ≥80 years 
(ii) body weight ≤60 kg 
(iii) serum creatinine ≥133 mmol/L.
2.5 mg twice daily
Dabigatran
150 mg twice daily
Dose reduction recommended if any apply: 
(i) age ≥80 years 
(ii) receiving concomitant verapamil. 
Dose reduction considered on an individual basis if any apply: 
(i) age 75–80 
(ii) moderate renal impairment (creatinine clearance 30–50 mL/min) 
(iii) patients with gastritis, oesophagitis, or gastro-oesophageal reflux 
(iv) others at increased risk of bleeding.
110 mg twice daily
Edoxaban
60 mg once daily
Dose reduction if any apply: 
(i) moderate or severe renal impairment (creatinine clearance 15–50 mL/min) 
(ii) body weight ≤60 kg 
(iii) concomitant use of ciclosporin, dronedarone, erythromycin, or ketoconazole.
30 mg once daily
Rivaroxaban
20 mg once daily
Creatinine clearance 15–49 mL/min.
15 mg once daily
© ESC 2024
DOAC, direct oral anticoagulant. 
Dose and dose adjustments are taken from the European Medicines Association Summary of Product Characteristics for each DOAC. There may be other patient-specific reasons 
for providing a reduced dose, but, in general, the standard full dose should be used to provide optimal prevention of thromboembolism related to AF. Note that antiplatelet agents 
should be stopped in most patients when commencing a DOAC (see Section 6.3). A number of drug interactions exist with each DOAC and should be taken into consideration 
(see Figure 9).
ESC Guidelines                                                                                                                                                                                          3345


<!-- PAGE 33 -->

### Page 33

2.8 h, respectively), with lower rates of thromboembolism (around 1% 
per patient-year) than would be expected for an equivalent cohort of 
patients with clinical AF and a CHA2DS2-VASc score of 4.
Considering the trade-off between potential benefit and the risk of 
major bleeding, this task force concludes that DOAC therapy may be 
considered in subgroups of patients with asymptomatic device- 
detected subclinical AF who have high estimated stroke risk and an ab­
sence of major bleeding risk factors (see Section 6.7). The duration and 
burden of subclinical AF that could indicate potential benefit from OAC 
remains uncertain.344 Regardless of the initial decision on OAC, pa­
tients with subclinical AF should receive management and follow-up 
for all aspects of AF-CARE as the risk of developing clinical AF is high 
(6%–9% per year).
6.3. Antiplatelet drugs and combinations 
with anticoagulants
Antiplatelet drugs, such as aspirin and clopidogrel, are not an alternative 
to OAC. They should not be used for stroke prevention, and can lead 
to potential harm (especially among elderly patients with AF).345–347 In 
ACTIVE W (Atrial fibrillation Clopidogrel Trial with Irbesartan for 
prevention of Vascular Events), dual antiplatelet therapy (DAPT) with 
aspirin and clopidogrel was less effective than warfarin for the preven­
tion of stroke, systemic embolism, MI, or vascular death (annual risk of 
events 5.6% vs. 3.9%, respectively; P = .0003), with similar rates of 
major bleeding.348 The AVERROES (Apixaban Versus Acetylsalicylic 
Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed 
or Are Unsuitable for Vitamin K Antagonist Treatment) trial demon­
strated a lower rate of stroke or systemic embolism with apixaban 
compared with aspirin (HR, 0.45; 95% CI, 0.32–0.62; P < .001), with 
no significant difference in major bleeding (there were 11 cases of intra­
cranial bleeding with apixaban and 13 with aspirin).242
The combination of OAC with antiplatelet agents (especially aspirin) 
without an adequate indication occurs frequently in clinical practice 
(see Supplementary data online, Additional Evidence Table S9).349,350
Bleeding events are more common when antithrombotic agents are 
combined, and no clear benefit has been observed in terms of preven­
tion of stroke or death.349 In general, combining antiplatelet drugs with 
anticoagulants (DOACs or VKAs) should only occur in selected pa­
tients with acute vascular disease (e.g. acute coronary syndromes; see 
Section 9.2). The combination of low-dose rivaroxaban (2.5 mg) with 
aspirin reduced the risk of stroke in patients with chronic vascular dis­
ease in a subanalysis of the COMPASS (Cardiovascular Outcomes for 
People Using Anticoagulation Strategies) trial,351,352 but this cannot 
be generalized to AF patients because those with an indication for full- 
dose anticoagulants were excluded.
6.4. Residual ischaemic stroke risk despite 
anticoagulation
Although OAC significantly reduces the risk of ischaemic stroke in pa­
tients with AF, there remains a residual risk.252,354 One-third of patients 
with AF presenting with an ischaemic stroke are already on anticoagu­
lation,355 with heterogeneous aetiology.356 This may include non-AF- 
related competing stroke mechanisms (such as large artery and small 
vessel diseases), non-adherence to therapy, an inappropriately low 
dose of anticoagulant, or thromboembolism despite sufficient anticoa­
gulation.357 Laboratory measurement of INR or DOAC levels may con­
tribute to revealing an amenable cause of the stroke. Regardless of 
anticoagulation status, patients with ischaemic stroke are more likely 
to have cardiovascular risk factors.358 Many clinicians managing patients 
with an incident stroke despite taking anticoagulation will be tempted 
to switch their anticoagulant regimen. While there may be some advan­
tage in switching from VKAs to DOACs for protection against future 
recurrent ischaemic or haemorrhagic stroke, this task force does not 
recommend routinely switching from one DOAC to another, or 
from a DOAC to a VKA, since this has no proven efficacy.252,356,359
There may be individual reasons for switching, including potential inter­
actions with new drugs; however, there is no consistent data across 
countries that adherence or efficacy differs between once- and twice- 
daily approaches.360,361 Emerging, but observational evidence suggests 
that switching provides limited reduction in the risk of recurrent ischae­
mic stroke.252,356,359 The alternative strategy of adding antiplatelet 
therapy to OAC may lead to an increased risk of bleeding.356,359
Aside from thorough attention to underlying risk factors and co­
morbidities, the approach to management of patients with a stroke des­
pite OAC remains a distinct challenge.
6.5. Percutaneous left atrial appendage 
occlusion
Percutaneous left atrial appendage occlusion (LAAO) is a device-based 
therapy that aims to prevent ischaemic stroke in patients with AF.362,363
In the VKA era, two RCTs compared warfarin with LAAO using the 
Recommendation Table 9 — Recommendations for 
thromboembolism despite anticoagulation (see also 
Evidence Table 9)
Recommendation
Classa
Levelb
A thorough diagnostic work-up should be 
considered in patients taking an oral anticoagulant 
and presenting with ischaemic stroke or 
thromboembolism to prevent recurrent events, 
including assessment of non-cardioembolic causes, 
vascular risk factors, dosage, and adherence.356,357
IIa
B
Adding antiplatelet treatment to anticoagulation is 
not recommended in patients with AF to prevent 
recurrent embolic stroke.356,359
III
B
Switching from one DOAC to another, or from a 
DOAC to a VKA, without a clear indication is not 
recommended in patients with AF to prevent 
recurrent embolic stroke.252,356,359
III
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 8 — Recommendations for 
combining antiplatelet drugs with anticoagulants for 
stroke prevention (see also Evidence Table 8)
Recommendation
Classa
Levelb
Adding antiplatelet treatment to oral anticoagulation 
is not recommended in AF patients for the goal of 
preventing ischaemic stroke or 
thromboembolism.345,347,353
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 34 -->

### Page 34

Watchman device. The 5-year pooled outcomes demonstrated a simi­
lar rate of the composite endpoint (cardiovascular or unexplained 
death, systemic embolism, and stroke) between the LAAO and war­
farin arms. Those randomized to LAAO had significantly lower rates 
of haemorrhagic stroke and all-cause death, but also a 71% non- 
significant increase in ischaemic stroke and systemic embolism.364
With DOACs demonstrating similar rates of major bleeding to as­
pirin,242 warfarin in the control arms in these trials is no longer standard 
of care and hence the place of LAAO in current practice is unclear. The 
Amulet occluder is an alternative LAAO device which was non-inferior 
in an RCT to the Watchman device for safety events 
(procedure-related complications, death, or major bleeding) and 
thromboembolism.365 In the PRAGUE-17 trial, 402 AF patients were 
randomized to DOAC or LAAO (Watchman or Amulet), with non- 
inferiority reported for a broad composite primary endpoint of stroke, 
TIA, systemic embolism, cardiovascular death, major or non-major clin­
ically relevant bleeding, and procedure/device-related complica­
tions.366,367 Larger trials368,369 are expected to provide more 
comprehensive data that can add to the current evidence base (see 
Supplementary data online, Additional Evidence Table S10).
Pending further RCTs (see Supplementary data online, Table S4), pa­
tients with a contraindication to all of the OAC options (the four 
DOACs and VKAs) have the most appropriate rationale for LAAO im­
plantation, despite the paradox that the need for post-procedure 
antithrombotic treatment exposes the patient to a bleeding risk that 
may be equivalent to that of DOACs. Regulatory approvals based on 
RCT protocols suggest the need for 45 days of VKA plus aspirin after 
implantation, followed by 6 months of DAPT in patients with no major 
peri-device leaks, and then ongoing aspirin (see Supplementary data 
online, Figure S2).370–372 However, real-world practice is markedly dif­
ferent and also varied. Direct oral anticoagulant administration at full 
or reduced dose has been proposed as a treatment alternative to 
warfarin.373 Observational studies have also supported the use of anti­
platelet therapy without associated increases in device-related throm­
bosis or stroke.374–376 In a propensity-matched comparison of patients 
receiving limited early OAC vs. antiplatelet treatment post-Watchman 
implantation, thromboembolic event rates and bleeding complications 
were similar.377 While waiting for solid RCT data (NCT03445949, 
NCT03568890),378 pertinent decisions on antithrombotic treatment 
are usually made on an individualized basis.379–381 Prevention of recur­
rent stroke, in addition to OAC, is another potential indication for 
LAAO. Only limited data are so far available from registries,382 with on­
going trials expected to provide more insight (NCT03642509, 
NCT05963698).
Left atrial appendage occlusion device implantation is associated 
with procedural risk including stroke, major bleeding, device- 
related thrombus, pericardial effusion, vascular complications, and 
death.362,383–385 Voluntary registries enrolling patients considered 
ineligible 
for 
OAC 
have 
reported 
low 
peri-procedural 
risk,372,376,386,387 although national registries report in-hospital ma­
jor adverse event rates of 9.5% in centres performing 5–15 LAAO 
cases per year, and 5.6% performing 32–211 cases per year 
(P < .001).388 Registries with new-generation devices report a low­
er complication rate compared with RCT data.389,390 Device- 
related thrombi occur with an incidence of 1.7%–7.2% and are 
associated with a higher risk of ischaemic stroke.386,391–397 Their 
detection can be documented as late as 1 year post-implantation 
in one-fifth of patients, thus mandating a late ‘rule-out’ imaging ap­
proach.391 Likewise, follow-up screening for peri-device leaks is 
relevant, as small leaks (0–5 mm) are present in ∼25% and have 
been associated with higher thromboembolic and bleeding events 
during 1 year follow-up in a large observational registry of one par­
ticular device.398
6.6. Surgical left atrial appendage occlusion
Surgical occlusion or exclusion of the left atrial appendage (LAA) can 
contribute to stroke prevention in patients with AF undergoing 
cardiac surgery.399,400 The Left Atrial Appendage Occlusion Study 
(LAAOS III) randomized 4811 patients with AF to undergo or not 
undergo LAAO at the time of cardiac surgery for another indication. 
During a mean of 3.8 years follow-up, ischaemic stroke or systemic em­
bolism occurred in 114 patients (4.8%) in the occlusion group and 168 
(7.0%) in the control arm (HR, 0.67; 95% CI, 0.53–0.85; P = .001).401
The LAAOS III trial did not compare appendage occlusion with anticoa­
gulation (77% of participants continued to receive OAC), and there­
fore, surgical LAA closure should be considered as an adjunct 
therapy to prevent thromboembolism in addition to anticoagulation 
in patients with AF.
There are no RCT data showing a beneficial effect on ischaemic 
stroke or systemic embolism in patients with AF undergoing LAAO 
during endoscopic or hybrid AF ablation. A meta-analysis of RCT and 
observational data showed no differences in stroke prevention or all- 
cause mortality when comparing LAA clipping during thoracoscopic 
AF ablation with percutaneous LAAO and catheter ablation.402
While the percutaneous LAAO/catheter ablation group showed a high­
er acute success rate, it was also associated with a higher risk of haem­
orrhage during the peri-operative period. In an observational study 
evaluating 222 AF patients undergoing LAA closure using a clipping de­
vice as a part of endoscopic or hybrid AF ablation, complete closure 
was achieved in 95% of patients.403 There were no intra-operative 
complications, and freedom from a combined endpoint of ischaemic 
stroke, haemorrhagic stroke, or TIA was 99.1% over 369 patient-years 
of follow-up. Trials evaluating the beneficial effect of surgical LAA clos­
ure in patients undergoing cardiac surgery but without a known history 
of AF are ongoing (NCT03724318, NCT02701062).404
There is a potential advantage for stand-alone epicardial over 
percutaneous LAA closure in patients with a contraindication for 
OAC, as there is no need for post-procedure anticoagulation after epi­
cardial closure. Observational data show that stand-alone LAA closure 
using an epicardial clip is feasible and safe.405 A multidisciplinary team 
approach can facilitate the choice between epicardial or percutaneous 
LAA closure in such patients.406 The majority of safety data and experi­
ence in epicardial LAA closure originate from a single clipping device 
(AtriClip)403,407,408
(see Supplementary data online, Additional 
Evidence Table S11).
Recommendation Table 10 — Recommendations for 
percutaneous left atrial appendage occlusion (see also 
Evidence Table 10)
Recommendation
Classa
Levelb
Percutaneous LAA occlusion may be considered in 
patients with AF and contraindications for long-term 
anticoagulant treatment to prevent ischaemic stroke 
and thromboembolism.372,376,386,387
IIb
C
© ESC 2024
AF, atrial fibrillation; LAA, left atrial appendage. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3347


<!-- PAGE 35 -->

### Page 35

6.7. Bleeding risk
6.7.1. Assessment of bleeding risk
When initiating antithrombotic therapy, modifiable bleeding risk factors 
should be managed to improve safety (Figure 10).414–418 This includes 
strict control of hypertension, advice to reduce excess alcohol intake, 
avoidance of unnecessary antiplatelet or anti-inflammatory agents, 
and attention to OAC therapy (adherence, control of TTR if on 
VKAs, and review of interacting medications). Clinicians should con­
sider the balance between stroke and bleeding risk—as factors for 
both are dynamic and overlapping, they should be re-assessed at 
each review depending on the individual patient.419–421 Bleeding risk 
factors are rarely a reason to withdraw or withhold OAC in eligible 
patients, as the risk of stroke without anticoagulation often outweighs 
the risk of major bleeding.422,423 Patients with non-modifiable risk 
factors should be reviewed more often, and where appropriate, 
a multidisciplinary team approach should be instituted to guide 
management.
Several bleeding risk scores have been developed to account for a 
wide range of clinical factors (see Supplementary data online, 
Table S5 and Additional Evidence Tables S12 and S13).424 Systematic re­
views and validation studies in external cohorts have shown contrasting 
results and only modest predictive ability.244,425–434 This task force 
does not recommend a specific bleeding risk score given the uncer­
tainty in accuracy and potential adverse implications of not providing 
appropriate OAC to those at thromboembolic risk. There are very 
few absolute contraindications to OAC (especially DOAC therapy). 
Whereas primary intracranial tumours435 or an intracerebral bleed re­
lated to cerebral amyloid angiopathy436 are examples where OAC 
should be avoided, many other contraindications are relative or tem­
porary. For example, a DOAC can often be safely initiated or re- 
initiated after acute bleeding has stopped, as long as the source has 
been fully investigated and managed. Co-prescription of proton 
pump inhibitors is common in clinical practice for patients receiving 
OAC that are at high risk of gastrointestinal bleeding. However, the evi­
dence base is limited and not specifically in patients with AF. Whereas 
observational studies have shown potential benefit from proton pump 
inhibitors,437 a large RCT in patients receiving low-dose anticoagulation 
and/or aspirin for stable cardiovascular disease found that pantoprazole 
had no significant impact on upper gastrointestinal bleeding events 
compared with placebo (HR, 0.88; 95% CI, 0.67–1.15).438 Hence, the 
use of gastric protection should be individualized for each patient 
according to the totality of their perceived bleeding risk.
6.7.2. Management of bleeding on anticoagulant 
therapy
General management of bleeding in patients receiving OAC is outlined 
in Figure 11. Cause-specific management is beyond the scope of these 
guidelines, and will depend on the individual circumstances of the pa­
tient and the healthcare environment.447 Assessment of patients with 
active bleeding should include confirmation of the bleeding site, 
bleeding severity, type/dose/timepoint of last anticoagulant intake, 
concomitant use of other antithrombotic agents, and other factors in­
fluencing bleeding risk (renal function, platelet count, and medications 
such as non-steroidal anti-inflammatories). INR testing and information 
on recent results are invaluable for patients taking VKAs. Specific 
coagulation tests for DOACs include diluted thrombin time, ecarin 
clotting time, ecarin chromogenic assay for dabigatran, and chro­
mogenic anti-factor Xa assay for rivaroxaban, apixaban, and edoxa­
ban.447–449 Diagnostic and treatment interventions to identify and 
manage the cause of bleeding (e.g. gastroscopy) should be performed 
promptly.
In cases of minor bleeding, temporary withdrawal of OAC while the 
cause is managed is usually sufficient, noting that the reduction in anti­
coagulant effect is dependent on the INR level for VKAs or the half-life 
of the particular DOAC.
For major bleeding events in patients taking VKAs, administration 
of fresh frozen plasma restores coagulation more rapidly than 
vitamin K, but prothrombin complex concentrates achieve even 
faster blood coagulation with fewer complications, and so are 
preferrable to achieve haemostasis.450 In DOAC-treated patients 
where the last DOAC dose was taken within 2–4 h, charcoal 
administration and/or gastric lavage may reduce further exposure. 
If the patient is taking dabigatran, idarucizumab can fully reverse its anti­
coagulant effect and help to achieve haemostasis within 2–4 h in 
Recommendation Table 12 — Recommendations for 
assessment of bleeding risk (see also Evidence Table 12)
Recommendations
Classa
Levelb
Assessment and management of modifiable bleeding 
risk factors is recommended in all patients eligible for 
oral anticoagulation, as part of shared 
decision-making to ensure safety and prevent 
bleeding.439–444
I
B
Use of bleeding risk scores to decide on starting or 
withdrawing oral anticoagulation is not 
recommended in patients with AF to avoid 
under-use of anticoagulation.431,445,446
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 11 — Recommendations for 
surgical left atrial appendage occlusion (see also 
Evidence Table 11)
Recommendations
Classa
Levelb
Surgical closure of the left atrial appendage is 
recommended as an adjunct to oral anticoagulation 
in patients with AF undergoing cardiac surgery to 
prevent ischaemic stroke and 
thromboembolism.400,401,408–412
I
B
Surgical closure of the left atrial appendage should be 
considered as an adjunct to oral anticoagulation in 
patients with AF undergoing endoscopic or hybrid 
AF ablation to prevent ischaemic stroke and 
thromboembolism.402,403
IIa
C
Stand-alone endoscopic surgical closure of the left 
atrial appendage may be considered in patients with 
AF and contraindications for long-term anticoagulant 
treatment to prevent ischaemic stroke and 
thromboembolism.399,405,406,413
IIb
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 36 -->

### Page 36

Hypertension
NSAIDs
Other factors
Optimize blood pressure lowering treatment
(Class I)
Do not use antiplatelet therapy beyond 12 months in stable OAC-treated patients with chronic coronary/vascular disease 
(Class III)
Do not add antiplatelet therapy to OAC to prevent thromboembolic events
(Class III)
or recurrent stroke
(Class III)
Reduce alcohol to <3
standard drinks per week
(Class I)
DOAC instead of  VKA
when antiplatelet treatment is needed
(Class I)
Keep INR 2.0–3.0
(Class I) 
and TTR >70% 
(Class IIa)
Switch to DOAC if eligible and failed to maintain
TTR on VKA
(Class I)
Minimize duration of heparin-bridging therapy
Manage all modifiable bleeding risk factors with shared decision-making
(Class I)
Do not use bleeding risk scores to decide starting or withdrawing OAC
(Class III)
Comprehensive medical history to determine all bleeding risk factors at OAC initiation/follow-up
(Class I)
Review patient more regularly
Work with multidisciplinary team to monitor risk factors
If clear contraindications for OACa, consider left atrial appendage occlusion 
(Class IIb)
Work with multidisciplinary team on each element
Ensure correct OAC dose and monitoring
Manage heart failure and achieve euvolaemia
(Class I)
Effective glycaemic control for patients with diabetes
(Class I)
Antiplatelet drugs
Alcohol intake
Unstable/variable INR
 Offer alternative analgesia or disease-modifying therapy
Re-assess at next interaction with patient
Renal impairment 
Risk of falls
Diabetes mellitus
Congestive heart failure
Reduced platelet count or function
Anaemia
Severe renal impairment, dialysis or renal transplant
Severe hepatic dysfunction or cirrhosis 
Malignancy 
Previous major bleeding
Age
Genetic factors (e.g. CYP2C9 polymorphisms)
Previous stroke
Intracerebral pathology
Cognitive impairment or dementia
Consider drug interactions
Reduce corticosteroid use 
if possible
Offer proton pump inhibitors if high GI bleeding risk
Advise restricting hazardous hobbies/occupations
Address all potentially modifiable bleeding risk factors with shared decision-making
Consider the impact of non-modifiable bleeding risk factors with shared decision-making
Figure 10 Modifying the risk of bleeding associated with OAC. DOAC, direct oral anticoagulant; GI, gastrointestinal; INR, international normalized 
ratio of prothrombin time; NSAID, non-steroidal anti-inflammatory drug; OAC, oral anticoagulant; TTR, time in therapeutic range; VKA, vitamin K 
antagonist. aAbsolute contraindications for OAC therapy are rare, and include primary intracranial tumours and intracerebral bleeds related to amyloid 
angiopathy. In most cases, contraindications may be relative or temporary. Left atrial appendage occlusion can be performed through a percutaneous or 
endoscopic approach.
ESC Guidelines                                                                                                                                                                                          3349


<!-- PAGE 37 -->

### Page 37

Assess haemodynamic status, basic coagulation parameters, blood count and kidney function
Determine dose and time of last OAC and all co-medications
Compress bleeding sites mechanically, if accessible
Patient with active bleeding
DOAC
VKA
Interrupt anticoagulation and perform diagnostic or treatment interventions
(Class I)
Aim to re-initiate anticoagulation in the absence of contraindications or if source of bleeding has been addressed
Assess risk of repeat bleeding
Intensify efforts to modify bleeding risk factors
Discuss benefits and risk of restarting OAC (shared decision-making approach)
Review choice and dose of OAC
Institute close and ongoing monitoring
Management after the bleeding episode
Minor bleeding
Non-lifethreatening major bleeding
Life-threatening or bleeding into a critical site
Delay VKA
until INR <2
Delay DOAC 
for 1–2 doses
(or more depending on recovery)
Interrupt anticoagulation and perform diagnostic or treatment interventions
(Class I)
Minor bleeding
Non-lifethreatening major bleeding
Life-threatening or bleeding into a critical site
Fluid replacement
Blood transfusion
Consider need for vitamin K,
FFP, PCC
Fluid replacement
Blood transfusion
PCC
(Class IIa)
FFP if PCC not available
Replacement of platelets where appropriate
Fluid replacement
Blood transfusion
Consider oral charcoal or gastric lavage if DOAC taken within 2–4
hours
Consider need for PCC
Fluid replacement
Blood transfusion
Specific antidotes
(Class IIa)
PCC if no antidotes available
Replacement of platelets where appropriate
Monitoring of
DOAC levels
Multidisciplinary team approach
Multidisciplinary team approach
Figure 11 Management of oral anticoagulant-related bleeding in patients with AF. DOAC, direct oral anticoagulant; FFP, fresh frozen plasma; INR, 
international normalized ratio of prothrombin time; OAC, oral anticoagulant; PCC, prothrombin complex concentrate; VKA, vitamin K antagonist.


<!-- PAGE 38 -->

### Page 38

uncontrolled bleeding.451 Dialysis can also be effective in reducing dabiga­
tran concentration. Andexanet alfa rapidly reverses the activity of factor 
Xa inhibitors (apixaban, edoxaban, rivaroxaban) (see Supplementary data 
online, Additional evidence Table S14). An open-label RCT comparing 
andexanet alfa to usual care in patients presenting with acute ICH within 
6 h of symptom onset was stopped early due to improved control of 
bleeding after 450 patients had been randomized.452 As DOAC-specific 
antidotes are not yet available in all institutions, prothrombin complex 
concentrates are often used in cases of serious bleeding on factor Xa in­
hibitors, with evidence limited to observational studies.453
Due to the complexities of managing bleeding in patients taking 
OAC, it is advisable that each institution develop specific policies involv­
ing a multidisciplinary team that includes cardiologists, haematologists, 
emergency physicians/intensive care specialists, surgeons, and others. 
It is also important to educate patients taking anticoagulants on the 
signs and symptoms of bleeding events and to alert their healthcare 
provider when such events occur.335
The decision to reinstate OAC will be determined by the severity, 
cause, and subsequent management of bleeding, preferably by a multidis­
ciplinary team and with close monitoring. Failure to reinstitute OAC after 
a bleed significantly increases the risk of MI, stroke, and death.454
However, if the cause of severe or life-threatening bleeds cannot be trea­
ted or reversed, the risk of ongoing bleeding may outweigh the benefit of 
thromboembolic protection.335
7. [R] Reduce symptoms by rate 
and rhythm control
Most patients diagnosed with AF will need therapies and/or interven­
tions to control heart rate, revert to sinus rhythm, or maintain sinus 
rhythm to limit symptoms or improve outcomes. While the concept 
of choosing between rate and rhythm control is often discussed, in real­
ity most patients require a combination approach which should be con­
sciously re-evaluated during follow-up. Within a patient-centred and 
shared-management approach, rhythm control should be a consider­
ation in all suitable AF patients, with explicit discussion of benefits 
and risks.
7.1. Management of heart rate in patients 
with AF
Limiting tachycardia is an integral part of AF management and is often 
sufficient to improve AF-related symptoms. Rate control is indicated as 
initial therapy in the acute setting, in combination with rhythm control 
therapies, or as the sole treatment strategy to control heart rate and 
reduce symptoms. Limited evidence exists to inform the best type 
and intensity of rate control treatment.457 The approach to heart 
rate control presented in Figure 7 can be used for all types of AF, includ­
ing paroxysmal, persistent, and permanent AF.
Recommendation Table 14 — Recommendations for 
heart rate control in patients with AF (see also 
Evidence Table 14)
Recommendations
Classa
Levelb
Rate control therapy is recommended in patients 
with AF, as initial therapy in the acute setting, an 
adjunct to rhythm control therapies, or as a sole 
treatment strategy to control heart rate and reduce 
symptoms.458–460
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are 
recommended as first-choice drugs in patients with 
AF and LVEF >40% to control heart rate and reduce 
symptoms.48,461,462
I
B
Beta-blockers and/or digoxin are recommended in 
patients with AF and LVEF ≤40% to control heart 
rate and reduce symptoms.40,185,463–465
I
B
Combination rate control therapy should be 
considered if a single drug does not control 
symptoms or heart rate in patients with AF, 
providing that bradycardia can be avoided, to control 
heart rate and reduce symptoms.
IIa
C
Lenient rate control with a resting heart rate of 
< 110 b.p.m. should be considered as the initial 
target for patients with AF, with stricter control 
reserved for those with continuing AF-related 
symptoms.459,460,466
IIa
B
Atrioventricular node ablation in combination with 
pacemaker implantation should be considered in 
patients unresponsive to, or ineligible for, intensive 
rate and rhythm control therapy to control heart 
rate and reduce symptoms.467–469
IIa
B
Atrioventricular node ablation combined with 
cardiac resynchronization therapy should be 
considered in severely symptomatic patients with 
permanent AF and at least one hospitalization for HF 
to reduce symptoms, physical limitations, recurrent 
HF hospitalization, and mortality.470,471
IIa
B
Intravenous amiodarone, digoxin, esmolol, or 
landiolol may be considered in patients with AF who 
have haemodynamic instability or severely depressed 
LVEF to achieve acute control of heart rate.472,473
IIb
B
© ESC 2024
AF, atrial fibrillation; b.p.m., beats per minute; HF, heart failure; LVEF, left ventricular 
ejection fraction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 13 — Recommendations for 
management of bleeding in anticoagulated patients 
(see also Evidence Table 13)
Recommendations
Classa
Levelb
Interrupting anticoagulation and performing 
diagnostic or treatment interventions is 
recommended in AF patients with active bleeding 
until the cause of bleeding is identified and resolved.
I
C
Prothrombin complex concentrates should be 
considered in AF patients on VKAs who develop a 
life-threatening bleed, or bleed into a critical site, to 
reverse the antithrombotic effect.450
IIa
C
Specific antidotes should be considered in AF 
patients on a DOAC who develop a life-threatening 
bleed, or bleed into a critical site, to reverse the 
antithrombotic effect.451,455,456
IIa
B
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3351


<!-- PAGE 39 -->

### Page 39

7.1.1. Indications and target heart rate
The optimal heart rate target in AF patients depends on the setting, 
symptom burden, presence of heart failure, and whether rate control 
is combined with a rhythm control strategy. In the RACE II (Rate 
Control Efficacy in Permanent Atrial Fibrillation) RCT of patients 
with permanent AF, lenient rate control (target heart rate <110  [beats 
per minute] b.p.m.) was non-inferior to a strict approach (<80 b.p.m. at 
rest; <110 b.p.m. during exercise; Holter for safety) for a composite of 
clinical events, NYHA class, or hospitalization.186,459 Similar results 
were found in a post-hoc combined analysis from the AFFIRM (Atrial 
Fibrillation Follow-up Investigation of Rhythm Management) and the 
RACE (Rate Control versus Electrical cardioversion) studies.474
Therefore, lenient rate control is an acceptable initial approach, unless 
there are ongoing symptoms or suspicion of tachycardia-induced car­
diomyopathy, where stricter targets may be indicated.
7.1.2. Heart rate control in the acute setting
In acute settings, physicians should always evaluate and manage under­
lying causes for the initiation of AF prior to, or in parallel to, instituting 
acute rate and/or rhythm control. These include treating sepsis, addres­
sing fluid overload, or managing cardiogenic shock. The choice of drug 
(Table 12) will depend on the patient’s characteristics, presence of heart 
failure and LVEF, and haemodynamic profile (Figure 7). In general for 
acute rate control, beta-blockers (for all LVEF) and diltiazem/verapamil 
(for LVEF >40%) are preferred over digoxin because of their more 
rapid onset of action and dose-dependent effects.462,475,476 More se­
lective beta-1 receptor blockers have a better efficacy and safety profile 
than unselective beta-blockers.477 Combination therapy with digoxin 
may be required in acute settings (combination of beta-blockers with 
diltiazem/verapamil should be avoided except in closely monitored 
situations).177,478 In selected patients who are haemodynamically 
unstable or with severely impaired LVEF, intravenous amiodarone, 
landiolol, or digoxin can be used.472,473,479
7.1.3. Long-term heart rate control
Pharmacological rate control can be achieved with beta-blockers, 
diltiazem, verapamil, digoxin, or combination therapy (Table 12) (see 
Supplementary data online, Additional Evidence Table S15).480
The choice of rate control drugs depends on symptoms, comorbid­
ities, and the potential for side effects and interactions. Combination 
therapy of different rate-controlling drugs should be considered only 
when needed to achieve the target heart rate, and careful follow-up 
to avoid bradycardia is advised. Combining beta-blockers with verap­
amil or diltiazem should only be performed in secondary care 
with regular monitoring of heart rate by 24 h ECG to check for 
bradycardia.459 Some antiarrhythmic drugs (AADs) also have rate- 
limiting properties (e.g. amiodarone, sotalol), but they should generally 
be used only for rhythm control. Dronedarone should not be instituted 
for rate control since it increases rates of heart failure, stroke, and 
cardiovascular death in permanent AF.481
Beta-blockers, specifically beta-1 selective adrenoreceptor an­
tagonists, are often first-line rate-controlling agents largely based on 
their acute effect on heart rate and the beneficial effects demonstrated 
in patients with chronic HFrEF. However, the prognostic benefit of 
beta-blockers seen in HFrEF patients with sinus rhythm may not be pre­
sent in patients with AF.133,482
Verapamil and diltiazem are non-dihydropyridine calcium channel 
blockers. They provide rate control461 and have a different adverse effect 
profile, making verapamil or diltiazem useful for those experiencing side 
effects from beta-blockers.483 In a 60 patient crossover RCT, verapamil 
and diltiazem did not lead to the same reduction in exercise capacity as 
seen with beta-blockers, and had a beneficial impact on BNP.480
Digoxin and digitoxin are cardiac glycosides that inhibit the 
sodium–potassium adenosine triphosphatase and augment parasympa­
thetic tone. In RCTs, there is no association between the use of digoxin 
and any increase in all-cause mortality.185,484 Lower doses of digoxin 
may be associated with better prognosis.185 Serum digoxin concentra­
tions can be monitored to avoid toxicity,485 especially in patients at 
higher risk due to older age, renal dysfunction, or use of interacting 
medications. In RATE-AF (RAte control Therapy Evaluation in perman­
ent Atrial Fibrillation), a trial in patients with symptomatic permanent 
AF, there was no difference between low-dose digoxin and bisoprolol 
for patient-reported quality of life outcomes at 6 months. However, 
those randomized to digoxin demonstrated fewer adverse effects, a 
greater improvement in mEHRA and NYHA scores, and a reduction 
in BNP.48 Two ongoing RCTs are addressing digoxin and digitoxin 
use in patients with HFrEF with and without AF (EudraCT- 
2013-005326-38, NCT03783429).486
Table 12 Drugs for rate control in AF
Agenta
Intravenous administration
Usual range for oral maintenance 
dose
Contraindicated
Beta-blockersb
Metoprolol 
tartrate
2.5–5 mg bolus over 2 mins; up to 15 mg 
maximal cumulative dose
25–100 mg twice daily
In case of asthma, non-selective 
beta-blockers should be avoided. 
Contraindicated in acute HF and history of 
severe bronchospasm.
Metoprolol XL 
(succinate)
N/A
50–200 mg once daily
Bisoprolol
N/A
1.25–20 mg once daily
Atenololc
N/A
25–100 mg once daily
Esmolol
500 µg/kg i.v. bolus over 1 min; followed by 
50–300 µg/kg/min
N/A
Landiolol
100 µg/kg i.v. bolus over 1 min; followed by 
10–40 µg/kg/min
N/A
Nebivolol
N/A
2.5–10 mg once daily
Carvedilol
N/A
3.125–50 mg twice daily
Continued


<!-- PAGE 40 -->

### Page 40

Due to its broad extracardiac adverse effect profile, amiodarone is 
reserved as a last option when heart rate cannot be controlled even 
with maximal tolerated combination therapy, or in patients who do not 
qualify for atrioventricular node ablation and pacing. Many of the adverse 
effects from amiodarone have a direct relationship with cumulative dose, 
restricting the long-term value of amiodarone for rate control.487
7.1.4. Atrioventricular node ablation and pacemaker 
implantation
Ablation of the atrioventricular node and pacemaker implantation (‘ablate 
and pace’) can lower and regularize heart rate in patients with AF (see 
Supplementary data online, Additional Evidence Table S16). The procedure 
has a low complication rate and a low long-term mortality risk.468,488 The 
pacemaker should be implanted a few weeks before the atrioventricular 
node ablation, with the initial pacing rate after ablation set at 70– 
90 b.p.m.489,490 This strategy does not worsen LV function,491 and may 
even improve LVEF in selected patients.492,493 The evidence base has typ­
ically included older patients. For younger patients, ablate and pace should 
only be considered if heart rate remains uncontrolled despite consideration 
of other pharmacological and non-pharmacological treatment options. The 
choice of pacing therapy (right ventricular or biventricular pacing) depends 
on patient characteristics, presence of heart failure, and LVEF.187,494
In severely symptomatic patients with permanent AF and at least one 
hospitalization for heart failure, atrioventricular node ablation combined 
with CRT should be considered. In the APAF-CRT (Ablate and Pace for 
Atrial Fibrillation-cardiac resynchronization therapy) trial in a population 
with narrow QRS complexes, atrioventricular node ablation combined 
with CRT was superior to rate control drugs for the primary outcomes 
(all-cause mortality, and death or hospitalization for heart failure), and sec­
ondary outcomes (symptom burden and physical limitation).470,471
Conduction system pacing may become a potentially useful alternate pa­
cing mode when implementing a pace and ablate strategy, once safety and 
efficacy have been confirmed in larger RCTs.495,496 In CRT recipients, the 
presence (or occurrence) of AF is one of the main reasons for suboptimal 
biventricular pacing.187 Improvement of biventricular pacing is indicated 
and can be reached by intensification of rate control drug regimens, atrio­
ventricular node ablation, or rhythm control, depending on patient and AF 
characteristics.187
7.2. Rhythm control strategies in patients 
with AF
7.2.1. General principles and anticoagulation
Rhythm control refers to therapies dedicated to restoring and main­
taining sinus rhythm. These treatments include cardioversion, AADs, 
percutaneous catheter ablation, endoscopic and hybrid ablation, and 
open surgical approaches (see Supplementary data online, Additional 
Evidence Table S17). Rhythm control is never a strategy on its own; in­
stead, it should always be part of the AF-CARE approach.
In patients with acute or worsening haemodynamic instability thought to 
be caused by AF, rapid electrical cardioversion is recommended. For other 
patients, a wait-and-see approach should be considered as an alternative to 
immediate cardioversion (Figure 12). The Rate Control versus Electrical 
Cardioversion Trial 7–Acute Cardioversion versus Wait and See (RACE 
7 ACWAS) trial in patients with recent-onset symptomatic AF without 
haemodynamic compromise showed a wait-and-see approach for spon­
taneous conversion until 48 h after the onset of AF symptoms was non- 
inferior as compared with immediate cardioversion at 4 weeks follow-up.10
Since the publication of landmark trials more than 20 years ago, the 
main reason to consider longer-term rhythm control therapy has been 
the reduction in symptoms from AF.497–500 Older studies have shown 
that the institution of a rhythm control strategy using AADs does not re­
duce mortality and morbidity when compared with a rate control-only 
strategy,497–500 and may increase hospitalization.457 In contrast, multiple 
studies have shown that rhythm control strategies have a positive effect 
on quality of life once sinus rhythm is maintained.501,502 Therefore, in the 
case of uncertainty of the presence of symptoms associated with AF, an 
attempt to restore sinus rhythm is a rational first step. In patients with 
symptoms, patient factors that favour an attempt at rhythm control 
should be considered, including suspected tachycardiomyopathy, a brief 
AF history, non-dilated left atrium, or patient preference.
Rhythm control strategies have significantly evolved due to an increas­
ing experience in the safe use of antiarrhythmic drugs,17 consistent use of 
OAC, improvements in ablation technology,503–509 and identification and 
management of risk factors and comorbidities.39,510,511 In the ATHENA 
trial (A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess 
the Efficacy of Dronedarone 400 mg twice daily for the Prevention of 
Non-dihydropyridine calcium channel antagonists
Verapamil
2.5–10 mg i.v. bolus over 5 min
40 mg twice daily to 480 mg (extended 
release) once daily
Contraindicated if LVEF ≤40%.  
Adapt doses in hepatic and renal 
impairment.
Diltiazem
0.25 mg/kg i.v. bolus over 5 min, then 
5–15 mg/h
60 mg three times daily to 360 mg 
(extended release) once daily
Digitalis glycosides
Digoxin
0.5 mg i.v. bolus (0.75–1.5 mg over 24 h in 
divided doses)
0.0625–0.25 mg once daily
High plasma levels associated with adverse 
events. 
Check renal function before starting 
digoxin and adapt dose in CKD patients.
Digitoxin
0.4–0.6 mg
0.05–0.1 mg once daily
Other
Amiodaroned
300 mg i.v. diluted in 250 mL 5% dextrose over 
30–60 min (preferably via central venous 
cannula), followed by 900–1200 mg i.v. over 24 
h diluted in 500–1000 mL via a central venous 
cannula
200 mg once daily after loading 
Loading: 200 mg three times daily for 4 
weeks, then 200 mg daily or less as 
appropriate (reduce other rate control 
drugs according to heart rate)
Contraindicated in iodine sensitivity. 
Serious potential adverse effects (including 
pulmonary, ophthalmic, hepatic, and 
thyroid). Consider numerous drug 
interactions.
© ESC 2024
AF, atrial fibrillation; CKD, chronic kidney disease; HF, heart failure; i.v., intravenous; min, minutes; N/A, not available or not widely available. Maximum doses have been defined based on the 
summary of product characteristic of each drug. 
aAll rate control drugs are contraindicated in Wolff–Parkinson–White syndrome; also intravenous amiodarone. 
bOther beta-blockers are available but not recommended as specific rate control therapy in AF and therefore not mentioned here (e.g. propranolol and labetalol). 
cNo data on atenolol; should not be used in heart failure with reduced ejection fraction or in pregnancy. 
dLoading regimen may vary; i.v. dosage should be considered when calculating total load.
ESC Guidelines                                                                                                                                                                                          3353


<!-- PAGE 41 -->

### Page 41

N
Cardioversion for atrial fibrillation
Y
Check OAC status as soon as 
possible and proceed to last step 
Pharmacological or electrical cardioversion
(Class IIa)
Decide on continued OAC post-cardioversion
Short-term OAC after cardioversion (4 weeks) for all patients, even if CHA2DS2-VA = 0
(optional if AF onset definitely <24 h and low thromboembolic risk)
Long-term OAC for all patients according to thromboembolic risk assessment
Already on therapeutic OAC
for minimum 3 weeks
Not already on OAC
Wait-and-see approach for spontaneous conversion
(Class IIa)
Initiation of DOAC
(or VKA, LMWH, 
or UFH) for 
unscheduled 
cardioversion as 
soon as possible
(Class IIa)
Therapeutic OAC
for at least 3 weeks before scheduled cardioversion 
(adherence to 
DOACs or 
INR ≥2.0 for VKAs) 
(Class I)
Suitable for wait-and-see approach
(Class IIa)
Cardioversion cannot wait
Haemodynamically stable
Emergency electrical cardioversion
(Class I)
AF onset ≥24 h or unknown
AF onset <24 h
Elective electrical cardioversion,
if needed
Check OAC status
Check current AF
episode duration
Pharmacological or electrical cardioversion
TOE guided cardioversion
(Class I)
Figure 12 Approaches for cardioversion in patients with AF. AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years 
(2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; h, hour; 
LMWH, low molecular weight heparin; DOAC, direct oral anticoagulant; OAC, oral anticoagulant; TOE, transoesophageal echocardiography; UFH, 
unfractionated heparin; VKA, vitamin K antagonist. Flowchart for decision-making on cardioversion of AF depending on clinical presentation, AF onset, 
oral anticoagulation intake, and risk factors for stroke. aSee Section 6.


<!-- PAGE 42 -->

### Page 42

Cardiovascular Hospitalization or Death from Any Cause in Patients with 
Atrial Fibrillation/Atrial Flutter), dronedarone significantly reduced the 
risk of hospitalization due to cardiovascular events or death as compared 
with placebo in patients with paroxysmal or persistent AF.512 The 
CASTLE-AF trial (Catheter Ablation versus Standard Conventional 
Treatment in Patients With Left Ventricle Dysfunction and AF) demon­
strated that a rhythm control strategy with catheter ablation can improve 
mortality and morbidity in selected patients with HFrEF and an implanted 
cardiac device.4 In end-stage HFrEF, the CASTLE-HTx trial (Catheter 
Ablation for Atrial Fibrillation in Patients With End-Stage Heart Failure 
and Eligibility for Heart Transplantation) found, in a single centre, that 
catheter ablation combined with guideline-directed medical therapy sig­
nificantly reduced the composite of death from any cause, implantation 
of left ventricular assist device, or urgent heart transplantation compared 
with medical treatment.513 At the same time, however, the CABANA 
trial (Catheter Ablation versus Anti-arrhythmic Drug Therapy for 
Atrial Fibrillation) could not demonstrate a significant difference in mor­
tality and morbidity between catheter ablation and standard rhythm and/ 
or rate control drugs in symptomatic AF patients older than 64 years, or 
younger than 65 years with risk factors for stroke.3 EAST-AFNET 4 
(Early treatment of Atrial fibrillation for Stroke prevention Trial) re­
ported that implementation of a rhythm control strategy within 1 year 
compared with usual care significantly reduced the risk of cardiovascular 
death, stroke, or hospitalization for heart failure or acute coronary syn­
drome in patients older than 75 years or with cardiovascular condi­
tions.17 Of note, rhythm control was predominantly pursued with 
antiarrhythmic drugs (80% of patients in the intervention arm). Usual 
care consisted of rate control therapy; only when uncontrolled 
AF-related symptoms occurred was rhythm control considered. 
Patients in the EAST-AFNET 4 trial all had cardiovascular risk factors 
but were at an early stage of AF, with more than 50% being in sinus 
rhythm and 30% being asymptomatic at the start of the study.
Based on all of these studies, this task force concludes that implementa­
tion of a rhythm control strategy can be safely instituted and confers ameli­
oration of AF-related symptoms. Beyond control of symptoms, sinus 
rhythm maintenance should also be pursued to reduce morbidity and mor­
tality in selected groups of patients.4,17,502,513,514
Any rhythm control procedure has an inherent risk of thrombo­
embolism. Patients undergoing cardioversion require at least 3 weeks 
of therapeutic anticoagulation (adherence to DOACs or INR >2 if 
VKA) prior to the electrical or pharmacological procedure. In acute set­
tings or when early cardioversion is needed, transoesophageal echocar­
diography (TOE) can be performed to exclude cardiac thrombus prior 
to cardioversion. These approaches have been tested in multiple 
RCTs.319–321 In the case of thrombus detection, therapeutic anticoagu­
lation should be instituted for a minimum of 4 weeks followed by repeat 
TOE to ensure thrombus resolution. When the definite duration of AF 
is less than 48 hours, cardioversion has typically been considered with­
out the need for pre-procedure OAC or TOE for thrombus exclusion. 
However, the ‘definite’ onset of AF is often not known, and observa­
tional data suggest that stroke/thromboembolism risk is lowest within 
a much shorter time period.515–519 This task force reached consensus 
that safety should come first. Cardioversion is not recommended if AF 
duration is longer than 24 hours, unless the patient has already received 
at least 3 weeks of therapeutic anticoagulation or a TOE is performed 
to exclude intracardiac thrombus. Most patients should continue OAC 
for at least 4 weeks post-cardioversion. Only for those without 
thromboembolic risk factors and sinus rhythm restoration within 24 
h of AF onset is post-cardioversion OAC optional. In the presence of 
any thromboembolic risk factors, long-term OAC should be instituted 
irrespective of the rhythm outcome.
Recommendation Table 15 — Recommendations for 
general concepts in rhythm control (see also Evidence 
Table 15)
Recommendations
Classa
Levelb
Electrical cardioversion is recommended in AF patients 
with acute or worsening haemodynamic instability to 
improve immediate patient outcomes.520
I
C
Direct oral anticoagulants are recommended in 
preference to VKAs in eligible patients with AF 
undergoing cardioversion for thromboembolic risk 
reduction.293,319–321,521
I
A
Therapeutic oral anticoagulation for at least 3 weeks 
(adherence to DOACs or INR ≥2.0 for VKAs) is 
recommended before scheduled cardioversion of AF 
and atrial flutter to prevent procedure-related 
thromboembolism.319–321
I
B
Transoesophageal echocardiography is recommended 
if 3 weeks of therapeutic oral anticoagulation has not 
been provided, for exclusion of cardiac thrombus to 
enable early cardioversion.319–321,522
I
B
Oral anticoagulation is recommended to continue 
for at least 4 weeks in all patients after cardioversion 
and long-term in patients with thromboembolic risk 
factor(s) irrespective of whether sinus rhythm is 
achieved, to prevent thromboembolism.239,319,320,523,524
I
B
Cardioversion of AF (either electrical or 
pharmacological) should be considered in 
symptomatic patients with persistent AF as part of a 
rhythm control approach.52,525,526
IIa
B
A wait-and-see approach for spontaneous 
conversion to sinus rhythm within 48 h of AF onset 
should be considered in patients without 
haemodynamic compromise as an alternative to 
immediate cardioversion.10,525
IIa
B
Implementation of a rhythm control strategy should 
be considered within 12 months of diagnosis in 
selected patients with AF at risk of thromboembolic 
events to reduce the risk of cardiovascular death or 
hospitalization.17,527
IIa
B
Initiation of therapeutic anticoagulation should 
be considered as soon as possible in the setting 
of unscheduled cardioversion for AF or atrial 
flutter to prevent procedure-related 
thromboembolism.319–321,528
IIa
B
Repeat transoesophageal echocardiography should be 
considered before cardioversion if thrombus has been 
identified on initial imaging to ensure thrombus 
resolution and prevent peri-procedural 
thromboembolism.529
IIa
C
Early cardioversion is not recommended without 
appropriate anticoagulation or transoesophageal 
echocardiography if AF duration is longer than 24 h, or 
there is scope to wait for spontaneous cardioversion.522
III
C
© ESC 2024
AF, atrial fibrillation; DOAC, direct oral anticoagulant; INR, international normalized ratio 
of prothrombin time; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3355


<!-- PAGE 43 -->

### Page 43

7.2.2. Electrical cardioversion
Electrical cardioversion (ECV) can be safely applied in the elective and 
acute setting (see Supplementary data online, Additional Evidence 
Table S18) with sedation by intravenous midazolam, propofol, or 
etomidate.530 Structured and integrated care for patients with acute- 
onset AF at the emergency department is associated with better out­
comes without compromising safety.531 Rates of major adverse clinical 
events after cardioversion are significantly lower with DOACs com­
pared with warfarin.293
Blood pressure monitoring and oximetry should be used routinely. 
Intravenous atropine or isoproterenol, or temporary transcutaneous 
pacing, should be available in case of post-cardioversion bradycardia. 
Biphasic defibrillators are standard because of their superior efficacy 
compared with monophasic defibrillators.532–534 There is no single op­
timal position for electrodes, with a meta-analysis of 10 RCTs showing 
no difference in sinus rhythm restoration comparing anterior-posterior 
with antero-lateral electrode positioning.535 Applying active compres­
sion to the defibrillation pads is associated with lower defibrillation 
thresholds, lower total energy delivery, fewer shocks for successful 
ECV, and higher success rates.536 A randomized trial showed that max­
imum fixed-energy shocks were more effective than low-escalating en­
ergy for ECV.537
Immediate administration of vernakalant,538 or pre-treatment 
for 3–4 days with flecainide,539,540 ibutilide,541,542 propafenone,543 or 
amiodarone544–546 improves the rate of successful ECV and can 
facilitate long-term maintenance of sinus rhythm by preventing 
early recurrent AF.547 A meta-analysis demonstrated that pre- 
treatment with amiodarone (200–800 mg/day for 1–6 weeks pre- 
cardioversion) and post-treatment (200 mg/day) significantly improved 
the restoration and maintenance of sinus rhythm after ECV of AF.546
In some cases of persistent AF there is no clear relationship between 
the arrhythmia and symptoms. In these cases, restoring sinus rhythm by 
ECV might serve to confirm the impact of arrhythmia on symptoms 
and/or on heart failure symptoms and signs. Such an approach might 
be useful to identify truly asymptomatic individuals, to assess the impact 
of AF on LV function in patients with HFrEF, and to distinguish 
AF-related symptoms from heart failure symptoms.
7.2.3. Pharmacological cardioversion
Pharmacological cardioversion to sinus rhythm is an elective procedure 
in haemodynamically stable patients. It is less effective than electrical car­
dioversion for restoration of sinus rhythm,549 with timing of cardiover­
sion being a significant determinant of success.550 There are limited 
contemporary data on the true efficacy of pharmacological cardiover­
sion, which are likely biased by the spontaneous restoration of sinus 
rhythm in 76%–83% of patients with recent-onset AF (10%–18% within 
the first 3 h, 55%–66% within 24 h, and 69% within 48 h).10,119,445,551–555
The choice of a specific drug is based on the type and severity of con­
comitant heart disease (Table 13). A meta-analysis demonstrated that 
intravenous vernakalant and flecainide have the highest conversion rate 
within 4 h, possibly allowing discharge from the emergency department 
and reducing hospital admissions. Intravenous and oral formulations of 
Class IC antiarrhythmics (flecainide more so than propafenone) 
are superior regarding conversion rates within 12 h, while amiodarone 
efficacy is exhibited in a delayed fashion (within 24 h).556
Pharmacological cardioversion does not require fasting, sedation, or an­
aesthesia. Anticoagulation should be started or continued according to a 
formal (re-)assessment of thromboembolic risk.554,557–559
A single self-administered oral dose of flecainide or propafenone 
(pill-in-the-pocket) is effective in symptomatic patients with infre­
quent and recent-onset paroxysmal AF. Safe implementation of this 
strategy requires patient screening to exclude sinus node dysfunction, 
atrioventricular conduction defects, or Brugada syndrome, as well as 
prior in-hospital validation of its efficacy and safety.560 An atrioven­
tricular node-blocking drug should be instituted in patients treated 
with Class IC AADs to avoid 1:1 conduction if the rhythm transforms 
to AFL.561
Recommendation Table 17 — Recommendations for 
pharmacological cardioversion of AF (see also Evidence 
Table 17)
Recommendations
Classa
Levelb
Intravenous flecainide or propafenone is 
recommended when pharmacological cardioversion 
of recent-onset AF is desired, excluding patients with 
severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease.562–566
I
A
Intravenous vernakalant is recommended when 
pharmacological cardioversion of recent-onset AF is 
desired, excluding patients with recent ACS, HFrEF, 
or severe aortic stenosis.562–568
I
A
Intravenous amiodarone is recommended when 
cardioversion of AF in patients with severe left 
ventricular hypertrophy, HFrEF, or coronary artery 
disease is desired, accepting there may be a delay in 
cardioversion.473,569,570
I
A
A single self-administered oral dose of flecainide or 
propafenone (pill-in-the-pocket) should be 
considered for patient-led cardioversion in selected 
patients with infrequent paroxysmal AF, after efficacy 
and safety assessment and excluding those with 
severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease.560,571–573
IIa
B
Pharmacological cardioversion is not recommended 
for patients with sinus node dysfunction, 
atrioventricular conduction disturbances, or 
prolonged QTc (>500 ms), unless risks for 
proarrhythmia and bradycardia have been considered.
III
C
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; HFrEF, heart failure with reduced 
ejection fraction. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 16 — Recommendations for 
electrical cardioversion of AF (see also Evidence 
Table 16)
Recommendations
Classa
Levelb
Electrical cardioversion as a diagnostic tool should be 
considered in patients with persistent AF where 
there is uncertainty about the value of sinus rhythm 
restoration on symptoms, or to assess improvement 
in left ventricular function.548
IIa
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 44 -->

### Page 44

7.2.4. Antiarrhythmic drugs
The aims of long-term rhythm control are to maintain sinus rhythm, im­
prove quality of life, slow the progression of AF, and potentially reduce 
morbidity related to AF episodes (see Supplementary data online, 
Additional Evidence Table S19).17,445,574,575 Antiarrhythmic drugs do 
not eliminate recurrences of AF, but in patients with paroxysmal 
or persistent AF, a recurrence is not equivalent to treatment 
failure if episodes are less frequent, briefer, or less symptomatic. 
Antiarrhythmic drugs also have a role for long-term rhythm control in 
AF patients that are considered ineligible or unwilling to undergo cath­
eter or surgical ablation.
Before starting AAD treatment, reversible triggers should be identified 
and underlying comorbidities treated to reduce the arrhythmogenic sub­
strate, prevent progression of AF, and facilitate maintenance of sinus 
Table 13 Antiarrhythmic drugs for sinus rhythm restoration
Drug
Administration 
route
Initial dosing
Subsequent 
dosing [long- 
term approach]
Acute success 
rate and time 
to sinus 
rhythm
Contraindications and precautions
Flecainide
Oral
200–300 mg
[long-term  
50−150 mg twice 
daily]
50%–60% at 3 h 
and 75%–85% at 
6–8 h (3–8 h)
• Should not be used in patients with severe 
structural or coronary artery disease, Brugada 
syndrome, or severe renal failure (CrCl 
<35 mL/min/1.73 m2).
• Prior documentation of safety and efficacy in 
an inpatient setting is recommended prior to 
pill-in-the-pocket use.
• An AVN-blocking agent should be 
administered to avoid 1:1 conduction if 
transformation to AFL.
• Drug infusion should be discontinued in case 
of QRS widening >25% or bundle branch 
block occurrence.
• Caution is needed in patients with sinus node 
disease and AVN dysfunction.
• Do NOT use for conversion of atrial flutter.
Intravenous
1–2 mg/kg over 
10 min
52%–95%  
(Up to 6 h)
Propafenone
Oral
450–600 mg
[long-term  
150-300 mg three 
times daily]
45%–55% at 3 h, 
69%–78% at 8 h 
(3–8 h)
Intravenous
1.5–2 mg/kg over 
10 min
43%–89%  
(Up to 6 h)
Amiodarone
Intravenous (/oral)
300 mg intravenous 
over 30–60 min
900-1200 mg 
intravenous over 24 
hours (or 200 mg 
oral three times 
daily for 4 weeks). 
[long-term 200 mg 
oral daily]
44% (8–12 h to 
several days)
• May cause phlebitis (use a large peripheral 
vein, avoid i.v. administration >24 h and use 
preferably volumetric pump).
• May cause hypotension, bradycardia/ 
atrioventricular block, QT prolongation.
• Only if no other option in patients with 
hyperthyroidism (risk of thyrotoxicosis).
• Consider the broad range of drug 
interactions.
Ibutilide
Intravenous
1 mg over 10 min 
(0.01 mg/kg if body 
weight <60 kg)
1 mg over 10 min 
(10–20 min after 
the initial dose)
31%–51%  
(30–90 min)  
in AF 
60–75% in AFL 
(60 min)
• Should be used in the setting of a cardiac care 
unit as it may cause QT prolongation and 
torsades de pointes.
• ECG monitoring for at least 4 h after 
administration to detect any proarrhythmic 
effects.
• Should not be used in patients with prolonged 
QT, severe LVH, or low LVEF.
Vernakalant
Intravenous
3 mg/kg over 10 min 
(maximum 339 mg)
2 mg/kg over 10 min 
(10–15 min after 
the initial dose) 
(maximum 226 mg)
50% within 
10 min
• Should not be used in patients with arterial 
hypotension (SBP <100 mmHg), recent ACS 
(within 1 month), NYHA III or IV HF, QT 
prolongation or severe aortic stenosis.
• May cause arterial hypotension, QT 
prolongation, QRS widening, or 
non-sustained ventricular tachycardia.
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; AFL, atrial flutter; AVN, atrioventricular node; CrCl, creatinine clearance; ECG, electrocardiogram; HF, heart failure; LVEF, left 
ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; QT, QT interval; SBP, systolic blood pressure. Long-term dosage for maintenance 
of sinus rhythm  is indicated in [square brackets]. Long-term oral dosing for dronedarone is 400 mg twice daily, and for sotalol 80-160 mg twice daily.
ESC Guidelines                                                                                                                                                                                          3357


<!-- PAGE 45 -->

### Page 45

rhythm.39,128 The RACE 3 trial, including patients with early persistent AF 
and mild-to-moderate heart failure (predominantly HFpEF and HFmrEF), 
showed that targeted therapy of underlying conditions improved sinus 
rhythm maintenance at 1 year (75% vs. 63% as compared with standard 
care).39 The selection of an AAD for long-term rhythm control requires 
careful evaluation that takes into account AF type, patient parameters, 
and safety profile.445 It also includes shared decision-making, balancing 
the benefit/risk ratio of AADs in comparison with other strategies. 
Notably, recent evidence has shown that careful institution of AADs 
can be performed safely.17
The long-term effectiveness of AADs is limited. In a meta-analysis of 
59 RCTs, AADs reduced AF recurrences by 20%–50% compared with 
no treatment, placebo, or drugs for rate control.576,577 When one AAD 
fails to reduce AF recurrences, a clinically acceptable response may be 
achieved with another drug, particularly if from a different class.578
Combinations of AADs are not recommended. The data available sug­
gest that AADs do not produce an appreciable effect on mortality or 
other cardiovascular complications with the exception of increased 
mortality signals for sotalol574,579,580 and amiodarone.581 In contrast, 
use of AADs within a rhythm control strategy can be associated with 
reduction of morbidity and mortality in selected patients.582
All AADs may produce serious cardiac (proarrhythmia, negative in­
otropism, hypotension) and extracardiac adverse effects (organ tox­
icity, predominantly amiodarone). Drug safety, rather than efficacy, 
should determine the choice of drug. The risk of proarrhythmia in­
creases in patients with structural heart disease. Suggested doses for 
long-term oral AAD are presented in Table 13.577,583,584
7.2.5. Catheter ablation
Catheter ablation prevents AF recurrences, reduces AF burden, and 
improves quality of life in symptomatic paroxysmal or persistent AF 
where the patient is intolerant or does not respond to AAD.503–509
Multiple RCTs have provided evidence in favour of catheter ablation 
as a first-line approach for rhythm control in patients with paroxysmal 
AF, with a similar risk of adverse events as compared with initial AAD 
treatment (see Supplementary data online, Additional Evidence Table 
S20).15,16,591–594 In contrast, it is not clear whether first-line ablation 
is superior to drug therapy in persistent AF. Catheter ablation may 
also have a role in patients with symptoms due to prolonged pauses 
upon AF termination, where non-randomized data have shown im­
proved symptoms, and avoidance of pacemaker implantation.595–598
Pulmonary vein isolation (PVI) remains the cornerstone of AF cath­
eter ablation,503,508,593,599 but the optimal ablation strategy has not 
been clarified in the non-paroxysmal AF population.600 New technolo­
gies are emerging, such as pulsed field ablation, in which high-amplitude 
electrical pulses are used to ablate the myocardium by electroporation 
with high tissue specificity. In a single-blind RCT of 607 patients, pulsed 
field ablation was non-inferior for efficacy and safety endpoints com­
pared with conventional radiofrequency or cryoballoon ablation.601
Regarding timing of ablation, a small RCT found that delaying catheter 
ablation in patients with paroxysmal or persistent AF by 12 months 
(while on optimized medical therapy) did not impact on arrhythmia- 
free survival compared with ablation within 1 month.602
As with any type of rhythm control, many patients in clinical practice 
will not be suitable for catheter ablation due to factors that reduce the 
likelihood of a positive response, such as left atrial dilatation. Definitive 
evidence that supports the prognostic benefit of catheter ablation is 
needed before this invasive treatment can be considered for truly 
asymptomatic patients. As previously noted, the CABANA trial did 
not confirm a benefit of catheter ablation compared with medical ther­
apy, although high crossover rates and low event rates may have diluted 
the treatment effect.3 Therefore, only highly selected asymptomatic pa­
tients could be candidates for catheter ablation, and only after detailed 
discussion of associated risks and potential benefit of delaying AF pro­
gression.4,603 Randomized trials have shown that AF catheter ablation 
in patients with HFrEF significantly reduces arrhythmia recurrence 
and increases ejection fraction, with improvement in clinical outcomes 
and mortality also observed in selected patients.4,513,514,604–612 Several 
Recommendation Table 18 — Recommendations for 
antiarrhythmic drugs for long-term maintenance of si­
nus rhythm (see also Evidence Table 18)
Recommendations
Classa
Levelb
Amiodarone is recommended in patients with AF 
and HFrEF requiring long-term antiarrhythmic drug 
therapy to prevent recurrence and progression of 
AF, with careful consideration and monitoring for 
extracardiac toxicity.577,585–587
I
A
Dronedarone is recommended in patients with AF 
requiring long-term rhythm control, including those 
with HFmrEF, HFpEF, ischaemic heart disease, or 
valvular disease to prevent recurrence and 
progression of AF.512,577,588,589
I
A
Flecainide or propafenone is recommended in 
patients with AF requiring long-term rhythm control 
to prevent recurrence and progression of AF, 
excluding those with impaired left ventricular systolic 
function, severe left ventricular hypertrophy, or 
coronary artery disease.526,577,585,590
I
A
Concomitant use of a beta-blocker, diltiazem, or 
verapamil should be considered in AF patients 
treated with flecainide or propafenone, to prevent 
1:1 conduction if their rhythm is transformed to atrial 
flutter.
IIa
C
Continued 
Sotalol may be considered in patients with AF 
requiring long-term rhythm control with normal 
LVEF or coronary artery disease to prevent 
recurrence and progression of AF, but requires close 
monitoring of QT interval, serum potassium levels, 
renal function, and other proarrhythmia risk 
factors.585,587
IIb
A
Antiarrhythmic drug therapy is not recommended in 
patients with advanced conduction disturbances 
unless antibradycardia pacing is provided.
III
C
© ESC 2024
AF, atrial fibrillation; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, 
heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LVEF, left ventricular ejection fraction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 46 -->

### Page 46

characteristics, including but not limited to AF type, left atrial dilatation, 
and the presence of atrial and/or ventricular fibrosis, could refine pa­
tient selection to maximize outcome benefit from AF catheter ablation 
in patients with HFrEF.604,608,613–617 The prognostic value of catheter 
ablation in patients with HFpEF is less well established than for 
HFrEF.617–626
Recent registries and trials report varying rates of peri-procedural 
serious adverse events associated with catheter ablation (2.9%–7.2%) 
with a very low 30 day mortality rate (<0.1%). Operator experience 
and procedural volume at the ablation centre are critical, since they 
are associated with complication rates and 30 day mortality.627–631
Intermittent rhythm monitoring has typically been used to detect AF 
relapses following catheter ablation. Recent technology developments 
such as smartwatch or smartphone photoplethysmography and wear­
able patches may have an emerging role in post-ablation monitor­
ing.632,633 In addition, implantable loop recorders have been used to 
quantify AF burden before and after ablation as an additional endpoint 
beyond binary AF elimination.634 Management of arrhythmia recur­
rence post-ablation is an informed, shared decision-making process dri­
ven by available options for symptom control. In the post-AF ablation 
context, there is data supporting a role for AAD continuation or re- 
initiation, even for previously ineffective drugs.635 A short-term AAD 
treatment (2–3 months) following ablation reduces early recurrences 
of AF,554,635–639 but does not affect late recurrences636,637,640–642 or 
1 year clinical outcomes.642 Repeat PVI should be offered in patients 
with AF recurrence if symptom improvement was demonstrated after 
the first ablation, with shared decision-making and clear goals of treat­
ment.643–645
7.2.6. Anticoagulation in patients undergoing 
catheter ablation
The presence of left atrial thrombus is a contraindication to catheter- 
based AF ablation due to the risk of thrombus dislodgement leading 
to ischaemic stroke. Patients planned for catheter ablation of AF with 
an increased risk of thromboembolism should be on OAC for at least 
3 full weeks prior to the procedure.554,647
There is a wide range in practice for visualization of intra-atrial 
thrombi prior to catheter ablation, including TOE, intracardiac echo­
cardiography, or delayed phase cardiac computed tomography 
(CT).554,648 The prevalence of left atrial thrombus was 1.3% and 
2.7% in two meta-analyses of observational studies in patients planned 
for catheter ablation of AF on adequate OAC.649,650 The prevalence of 
left atrial thrombus was higher in patients with elevated stroke risk 
scores, and in patients with non-paroxysmal compared with paroxys­
mal AF.650 In addition, several patient subgroups with AF have increased 
risk of ischaemic stroke and intracardiac thrombus even if treated with 
adequate anticoagulation, including those with cardiac amyloidosis, 
rheumatic heart disease, and hypertrophic cardiomyopathy (HCM). 
Cardiac imaging before catheter ablation should be considered in these 
high-risk patient groups regardless of preceding effective OAC. 
Observational studies suggest that patients with a low thromboembolic 
risk profile may be managed without visualization of the LAA,651–653
but no RCTs have been performed (see Supplementary data online, 
Additional Evidence Table S21).
For patients who have been anticoagulated prior to the ablation pro­
cedure it is recommended to avoid interruption of OAC (see 
Supplementary data online, Additional Evidence Table S22).654–656
Patients with interrupted OAC showed an increase in silent stroke de­
tected by brain magnetic resonance imaging (MRI) as compared with 
those with uninterrupted OAC.657–659 In a true uninterrupted 
Recommendation Table 19 — Recommendations for 
catheter ablation of AF (see also Evidence Table 19)
Recommendations
Classa
Levelb
Shared decision-making
Shared decision-making is recommended when 
considering catheter ablation for AF, taking into 
account procedural risks, likely benefits, and risk 
factors for AF recurrence.128,210,503,646
I
C
AF patients resistant or intolerant to antiarrhythmic drug 
therapy
Catheter ablation is recommended in patients with 
paroxysmal or persistent AF resistant or intolerant 
to antiarrhythmic drug therapy to reduce symptoms, 
recurrence, and progression of AF.3,15,503,505,506,508
I
A
First-line rhythm control therapy
Catheter ablation is recommended as a first-line 
option within a shared decision-making rhythm 
control strategy in patients with paroxysmal AF, to 
reduce symptoms, recurrence, and progression of 
AF.16,591–594
I
A
Catheter ablation may be considered as a first-line 
option within a shared decision-making rhythm 
control strategy in selected patients with persistent 
AF to reduce symptoms, recurrence, and 
progression of AF.
IIb
C
Continued 
Patients with heart failure
AF catheter ablation is recommended in patients 
with AF and HFrEF with high probability of 
tachycardia-induced cardiomyopathy to reverse left 
ventricular dysfunction.604,611
I
B
AF catheter ablation should be considered in 
selected AF patients with HFrEF to reduce HF 
hospitalization and prolong survival.4,513,514,604,610,612
IIa
B
Sinus node disease/tachycardia–bradycardia syndrome
AF catheter ablation should be considered in patients 
with AF-related bradycardia or sinus pauses on AF 
termination to improve symptoms and avoid 
pacemaker implantation.595–598
IIa
C
Recurrence after catheter ablation
Repeat AF catheter ablation should be considered in 
patients with AF recurrence after initial catheter 
ablation, provided the patient’s symptoms were 
improved after the initial PVI or after failed initial PVI, 
to reduce symptoms, recurrence, and progression of 
AF.643–645
IIa
B
© ESC 2024
AF, atrial fibrillation; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; 
PVI, pulmonary vein isolation. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3359


<!-- PAGE 47 -->

### Page 47

DOAC strategy for once-daily dosing, a pre-procedural shift to evening 
intake might be considered to mitigate bleeding risk. Randomized trials 
show comparable safety and efficacy with minimally interrupted OAC 
(withholding the morning DOAC dose on the day of the procedure) 
and a totally uninterrupted peri-ablation OAC strategy.655
Anticoagulation with heparin during AF ablation is common 
practice.554 Post-ablation DOACs should be continued as per the 
dosing regimen when haemostasis has been achieved.335,554,647 All 
patients should be kept on an OAC for at least 2 months after an 
AF ablation procedure irrespective of estimated thromboembolic 
risk 
(see 
Supplementary 
data 
online, 
Additional 
Evidence 
Table S23).647 Meta-analyses of observational studies have tried to as­
sess the safety of stopping OAC treatment after catheter ablation for 
AF, but the results have been heterogenous.660–663 Until the comple­
tion of relevant RCTs (e.g. NCT02168829), it is recommended to 
continue OAC therapy post-AF ablation according to the patient’s 
CHA2DS2-VA score and not the perceived success of the ablation 
procedure.554
7.2.7. Endoscopic and hybrid AF ablation
Minimally invasive surgical AF ablation can be performed via a thoraco­
scopic approach or a subxiphoid approach. The term endoscopic cov­
ers both strategies. Hybrid ablation approaches have been developed 
where endoscopic epicardial ablation on the beating heart is performed 
in combination with endocardial catheter ablation, either in a simultan­
eous or sequential procedure. The rationale for combining an endocar­
dial with an epicardial approach is that a more effective transmural 
ablation strategy can be pursued.666,667
For paroxysmal AF, an endoscopic or hybrid ablation approach may 
be considered after a failed percutaneous catheter ablation strat­
egy.668–670 Long-term follow-up of the FAST RCT (mean of 7.0 years), 
which included patients with paroxysmal and persistent AF, found ar­
rhythmia recurrence was common but substantially lower with thor­
acoscopic ablation than catheter ablation: 34/61 patients (56%) 
compared with 55/63 patients (87%), with P < .001 for the compari­
son.669 For persistent AF, endoscopic or hybrid ablation approaches 
are suitable as a first procedure to maintain long-term sinus rhythm 
in selected patients.667–672 A meta-analysis of three RCTs confirmed 
a lower rate of atrial arrhythmia recurrence after thoracoscopic vs. 
catheter ablation (incidence rate ratio, 0.55; 95% CI, 0.38–0.78; 
with no heterogeneity between trials).669 An RCT with 12 month 
follow-up published after the meta-analysis in patients with long- 
standing persistent AF found no difference in arrhythmia freedom 
comparing thoracoscopic with catheter ablation.673 Although overall 
morbidity and mortality of both techniques is low, endoscopic and hy­
brid ablation have higher complication rates than catheter ablation, 
but similar long-term rates of the composite of mortality, MI, or 
stroke.667,669
More recent trials have assessed the efficacy and safety of the hybrid 
epicardial-plus-endocardial approach in persistent AF refractory to 
AAD therapy, including a single-centre RCT670 and two multicentre 
RCTs.671,674 Across these trials, hybrid ablation was consistently super­
ior to catheter ablation alone for maintaining long-term sinus rhythm, 
without significant differences in major adverse events. Notably, these 
studies were typically performed in highly experienced centres (see 
Supplementary data online, Additional Evidence Table S24).
Similar to other rhythm control approaches, this task force recom­
mends that OAC are continued in all patients who have a risk of 
thromboembolism, irrespective of rhythm outcome, and regardless 
of LAA exclusion performed as part of the surgical procedure.
Recommendation Table 21 — Recommendations for 
endoscopic and hybrid AF ablation (see also Evidence 
Table 21)
Recommendations
Classa
Levelb
Continuation of oral anticoagulation is 
recommended in patients with AF at elevated 
thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm 
outcome or LAA exclusion, to prevent ischaemic 
stroke and thromboembolism.
I
C
Continued 
Recommendation Table 20 — Recommendations for 
anticoagulation in patients undergoing catheter ablation 
(see also Evidence Table 20)
Recommendations
Classa
Levelb
Initiation of oral anticoagulation is recommended at 
least 3 weeks prior to catheter-based ablation in AF 
patients at elevated thromboembolic risk, to prevent 
peri-procedural ischaemic stroke and 
thromboembolism.554,647
I
C
Uninterrupted oral anticoagulation is recommended 
in patients undergoing AF catheter ablation to 
prevent peri-procedural ischaemic stroke and 
thromboembolism.664,665
I
A
Continuation of oral anticoagulation is 
recommended for at least 2 months after AF ablation 
in all patients, irrespective of rhythm outcome or 
CHA2DS2-VA score, to reduce the risk of 
peri-procedural ischaemic stroke and 
thromboembolism.554,663
I
C
Continuation of oral anticoagulation is 
recommended after AF ablation according to the 
patient’s CHA2DS2-VA score, and not the perceived 
success of the ablation procedure, to prevent 
ischaemic stroke and thromboembolism.554
I
C
Cardiac imaging should be considered prior to 
catheter ablation of AF in patients at high risk of 
ischaemic stroke and thromboembolism despite 
taking oral anticoagulation to exclude 
thrombus.649,650
IIa
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 48 -->

### Page 48

7.2.8. AF ablation during cardiac surgery
Atrial fibrillation is a significant risk factor for early mortality, late mor­
tality, and stroke in patients referred for cardiac surgery.675–677 The 
best validated method of surgical ablation is the Maze procedure, 
consisting of a pattern of transmural lesions including PVI, with 
subsequent modifications using bipolar radiofrequency and/or 
cryothermy ablation with LAA amputation (see Supplementary data 
online, Additional Evidence Table S25).678–681 Education and training, 
close co-operation within a multidisciplinary team, and shared 
decision-making can improve the quality and outcomes of surgical 
ablation.682
A number of RCTs have shown that surgical AF ablation during 
cardiac surgery increases freedom from arrhythmia recur­
rence.683–688 Performing surgical AF ablation, mainly targeting 
those patients needing mitral valve surgery, is not associated with 
increased morbidity or mortality.678,683–685 Observational data, 
including large registries, have supported the potential value of 
surgical AF ablation,689–700 but further RCTs are needed to evaluate 
which patients should be selected, and whether this approach 
contributes to the prevention of stroke, thromboembolism, and 
death.
Data on pacemaker implantation rates after surgical AF ablation 
are variable and are likely influenced by centre experience and the 
patients treated (e.g. underlying sinus node disease). In a systematic 
review of 22 RCTs (1726 patients), permanent pacemaker implant­
ation rates were higher with surgical AF ablation than without con­
comitant AF surgery (6.0% vs. 4.1%; RR, 1.69; 95% CI, 1.12–2.54).701
Observational registry data from contemporary cohorts (2011– 
2020) suggest an overall pacemaker rate post-operatively of 2.1% 
in patients selected for surgical AF ablation, with no discernible 
impact of surgical ablation on the need for a pacemaker, but 
higher rates in those needing multivalve surgery.702 With a safety- 
first approach in mind, imaging is advised during surgical AF ablation 
to exclude thrombus and help to plan the surgical approach 
(e.g. with TOE), regardless of effective pre-procedural anticoagulant 
use.
7.2.9. Atrial tachycardia after pulmonary vein 
isolation
After any ablation for AF, recurrent arrhythmias may manifest as AF, 
but also as atrial tachycardia (AT). Although AT may be perceived as 
a step in the right direction by the treating physician, this view is often 
not shared by the patient because AT can be equally or more symptom­
atic than the original AF. Conventionally, an early arrhythmia recur­
rence post-PVI (whether AT, AF, or flutter) is considered potentially 
transitory.708 Recent trials using continuous implantable loop recorders 
for peri-procedural monitoring have provided insight into the incidence 
and significance of early arrhythmia recurrences, and have confirmed a 
link between early and later recurrence.709 Discussion of management 
options for AT post-ablation should ideally involve a multidisciplinary 
team with experience in interventional management of complex ar­
rhythmias, considering technical challenges, procedural efficacy, and 
safety, in the context of patient preferences.
8. [E] Evaluation and dynamic 
reassessment
The development and progression of AF results from continuous 
interactions between underlying mechanisms (electrical, cellular, 
neurohormonal, and haemodynamic), coupled with a broad range of 
clinical factors and associated comorbidities. Each individual factor 
Endoscopic and hybrid ablation procedures should 
be considered in patients with symptomatic 
persistent AF refractory to AAD therapy to 
prevent symptoms, recurrence, and progression of 
AF, within a shared decision-making rhythm 
control team of electrophysiologists and 
surgeons.667–671,674
IIa
A
Endoscopic and hybrid ablation procedures may 
be considered in patients with symptomatic 
paroxysmal AF refractory to AAD therapy and 
failed percutaneous catheter ablation strategy to 
prevent symptoms, recurrence, and progression of 
AF, within a shared decision-making rhythm 
control team of electrophysiologists and 
surgeons.668,669
IIb
B
© ESC 2024
AAD, antiarrhythmic drugs; AF, atrial fibrillation; LAA, left atrial appendage. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 22 — Recommendations for 
AF ablation during cardiac surgery (see also Evidence 
Table 22)
Recommendations
Classa
Levelb
Concomitant surgical ablation is recommended in 
patients undergoing mitral valve surgery and AF 
suitable for a rhythm control strategy to prevent 
symptoms and recurrence of AF, with shared 
decision-making supported by an experienced team 
of electrophysiologists and arrhythmia surgeons.683– 
685,701
I
A
Intraprocedural imaging for detection of left atrial 
thrombus in patients undergoing surgical ablation is 
recommended to guide surgical strategy, 
independent of oral anticoagulant use, to prevent 
peri-procedural ischaemic stroke and 
thromboembolism.
I
C
Concomitant surgical ablation should be considered 
in patients undergoing non-mitral valve cardiac 
surgery and AF suitable for a rhythm control strategy 
to prevent symptoms and recurrence of AF, with 
shared decision-making supported by an 
experienced team of electrophysiologists and 
arrhythmia surgeons.701,703–707
IIa
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3361


<!-- PAGE 49 -->

### Page 49

has considerable variability over time, affecting its contribution to the 
AF-promoting substrate. The risk profile of each patient is also far 
from static, and requires a dynamic mode of care to ensure optimal 
AF management.710,711 Patients with AF require periodic reassessment 
of therapy based on this changing risk status if we are to improve the 
overall quality of care. Timely attention to modifiable factors and 
underpinning comorbidities has the potential to slow or reverse the 
progression of AF, increase quality of life, and prevent adverse out­
comes such as heart failure, thromboembolism, and major bleeding.
The [E] in AF-CARE encompasses the range of activity needed by 
healthcare professionals and patients to: (i) thoroughly evaluate asso­
ciated comorbidities and risk factors that can guide treatment; and 
(ii) provide the dynamic assessment needed to ensure that treatment 
plans remain suited to that particular patient. This task force recom­
mends an adaptive strategy that not only reacts to changes notified 
by a patient, but also proactively seeks out issues where altering man­
agement could impact on patient wellbeing. Avoidance of unnecessary 
and costly follow-up is also inherent in this framework, with educated 
and empowered patients contributing to identifying the need for access 
to specialist care or an escalation of management. The patient-centred, 
shared decision philosophy is embedded to improve efficiency in mod­
els of care and to address the needs of patients with AF.
Medical history and the results of any tests should be regularly re- 
evaluated to address the dynamic nature of comorbidities and risk fac­
tors.712 This may have impact on therapeutic decisions; e.g. resumption 
of full-dose DOAC therapy after improvement in the patient’s renal 
function. The timing of review of the AF-CARE pathway is patient spe­
cific and should respond to changes in clinical status. In most cases, this 
task force advises re-evaluation 6 months after initial presentation, and 
then at least annually by a healthcare professional in primary or second­
ary care (see Figure 3).
8.1. Implementation of dynamic care
A multidisciplinary-based approach is advocated to improve implemen­
tation of dynamic AF-CARE (see Figure 2); although potentially re­
source intensive, this is preferred to more simplistic or opportunistic 
methods. For example, in a pragmatic trial of 47 333 AF patients iden­
tified through health insurance claims, there was no difference in OAC 
initiation at 1 year in those randomized to a single mailout of patient and 
clinician education, compared with those in the usual care group.713 For 
co-ordination of care there is a core role for cardiologists, general prac­
titioners, specialized nurses, and pharmacists.714 If needed, and depend­
ing on local resources, others may also be involved (cardiac surgeons, 
physiotherapists, neurologists, psychologists, and other allied health 
professionals). It is strongly advocated that one core team member co- 
ordinates care, and that additional team members become involved ac­
cording to the needs of the individual patient throughout their AF 
trajectory.
Several organizational models of integrated care for AF have been 
evaluated, but which components are most useful remains unclear. 
Some models include a multidisciplinary team,715,716 while others are 
nurse-led79,122,124,717 or cardiologist-led.79,122,124,717 Several published 
models used computerized decision support systems or electronic 
health applications.79,122,715,718 Evaluation within RCTs has demon­
strated mixed results due to the variety of methods tested and differ­
ences in regional care. Several studies report significant improvements 
with respect to adherence to anticoagulation, cardiovascular mortality, 
and hospitalization relative to standard of care.121–123 However, the 
RACE 4 (IntegRAted Chronic Care Program at Specialized AF Clinic 
Versus Usual CarE in Patients with Atrial Fibrillation) trial, which in­
cluded 1375 patients, failed to demonstrate superiority of nurse-led 
over usual care.79 New studies of the components and optimal models 
for delivery for integrated care approaches in routine practice are on­
going (ACTRN12616001109493, NCT03924739).
8.2. Improving treatment adherence
Advances in the care of patients with AF can only be effective if appro­
priate tools are available to support the implementation of the treat­
ment regimen.719 A number of factors are related to the optimal 
implementation of care at the level of: (i) the individual patient (culture, 
cognitive impairment, and psychological status); (ii) the treatment 
(complexity, side effects, polypharmacy, impact on daily life, and 
cost); (iii) the healthcare system (access to treatment and multidiscip­
linary approach); and (iv) the healthcare professional (knowledge, 
awareness of guidelines, expertise, and communication skills). A collab­
orative approach to patient care, based upon shared decision-making 
and goals tailored to individual patient needs, is crucial in promoting on­
going patient adherence to the agreed treatment regimen.720 Even 
when treatment seems feasible for the individual, patients often lack ac­
cess to reliable and up-to-date information about risks and benefits of 
various treatment options, and consequently are not empowered to 
engage in their own management. A sense of ownership that promotes 
the achievement of joint goals can be encouraged through the use of 
educational programmes, websites (such as https://afibmatters.org), 
app-based tools, and individually tailored treatment protocols which 
take into account gender, ethnic, socioeconomic, environmental, and 
work factors. In addition, practical tools (e.g. schedules, apps, bro­
chures, reminders, pillboxes) can help to implement treatment in daily 
life.721,722 Regular review by members of the multidisciplinary team en­
ables the evolution of a flexible and responsive management regimen 
that the patient will find easier to follow.
8.3. Cardiac imaging
A TTE is a valuable asset across all four AF-CARE domains when 
there are changes in the clinical status of an individual patient 
(Figure 13).723–725 The key findings to consider from an echocardiogram 
are any structural heart disease (e.g. valvular disease or left ventricular 
hypertrophy), impairment of left ventricular function (systolic and/or 
diastolic to classify heart failure subtype), left atrial dilatation, and right 
heart dysfunction.59,67,726 To counter irregularity when in AF, obtaining 
measurements in cardiac cycles that follow two similar RR intervals can 
improve the value of parameters compared with sequential averaging of 
cardiac cycles.723,727 Contrast TTE or alternative imaging modalities 
may be required where image quality is poor, and quantification of 
left ventricular systolic function is needed for decisions on rate or 
rhythm control. Other cardiac imaging techniques, such as cardiac mag­
netic resonance (CMR), CT, TOE, and nuclear imaging can be valuable 
when: (i) TTE quality is suboptimal for diagnostic purposes; (ii) addition­
al information is needed on structure, substrate, or function; and (iii) to 
support decisions on interventional procedures (see Supplementary 
data online, Figure S1).59,724,725,728 As with TTE, other types of cardiac 
imaging can be challenging in the context of AF irregularity or with rapid 
heart rate, requiring technique-specific modifications when acquiring 
ECG-gated sequences.729–731


<!-- PAGE 50 -->

### Page 50

8.4. Patient-reported outcome measures
Patients with AF have a lower quality of life compared with the general 
population.732 Improvement in quality of life and functional status should 
play a key role in assessing and reassessing treatment decisions (see 
Supplementary data online, Additional Evidence Table S26).36
Patient-reported outcome measures are valuable to measure quality of 
life, functional status, symptoms, and treatment burden for patients 
with AF over time.55,733–735 Patient-reported outcome measures are 
playing an increasing role in clinical trials to assess the success of treat­
ment; however, they remain under-utilized.736,737 They can be divided 
into generic or disease-specific tools, with the latter helping to provide 
insight into AF-related impacts.738 However, multimorbidity can still con­
found the sensitivity of all PROMs, impacting on association with other 
established metrics of treatment performance such as mEHRA symptom 
AF-CARE
pathway
Objective for imaging
To identify comorbidities which are associated with recurrence and progression of AF
To determine stroke risk, choice of anticoagulant drug and ensure safety for cardioversion
To determine optimal choice of rate and rhythm control strategy and likely success of ablation
To detect changes in the patient's heart structure and function which would affect their management plan
C
Comorbidity and risk factor management
R
Reduce symptoms by rate and rhythm control
Avoid stroke and thromboembolism
A
Evaluation and dynamic reassessment
E
Assessment
Left ventricular ejection fraction, 
wall motion abnormalities, diastolic indices, right ventricular function and 
left ventricular hypertrophy to determine subtype and aetiology of heart failure
Detection of valvular disease
Detection of pericardial fluid or pericardial disease
Detection of heart failure for
CHA2DS2-VA score
Transoesophageal echocardiogram for left atrial appendage assessment to exclude thrombus prior to cardioversion
Detection of moderate-severe mitral stenosis to determine choice of anticoagulation
Reassess known valve disease for increase in severity
Reassess left ventricular size and function if there is a change in the patient’s clinical status or symptoms
Left ventricular ejection fraction to determine choice of rate control
Left ventricular size and function to determine choice of rhythm control
Severity of valvular disease to determine choice of rhythm control
Left atrial size and function to determine risk of arrhythmia recurrence following ablation
Example of pathology
Cardiac amyloid
Clot in LAA
Severe LV
impairment
Mixed mitral valve disease
Figure 13 Relevance of echocardiography in the AF-CARE pathway. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk fac­
tor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; 
CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; LAA, left atrial appendage; LV, left ventricle.
ESC Guidelines                                                                                                                                                                                          3363


<!-- PAGE 51 -->

### Page 51

class and natriuretic peptides.48 Intervention studies have demonstrated 
an association between improvement in PROM scores and reduction in 
AF burden and symptoms.48,738
Atrial fibrillation-specific questionnaires include the AF 6 (AF6),739
Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT),740 the Atrial 
Fibrillation Quality of Life Questionnaire (AFQLQ),741 the Atrial 
Fibrillation Quality of Life (AF-QoL),742 and the Quality of Life in 
Atrial Fibrillation (QLAF).743 The measurement properties of most of 
these tools lack sufficient validation.49 The International Consortium 
for Health Outcomes Measurement (ICHOM) working group recom­
mends the use of the AFEQT PROM or a symptom questionnaire called 
the Atrial Fibrillation Severity Scale (AFSS) for measuring exercise tol­
erance and the impact of symptoms in AF.744 Through wider use of pa­
tient experience measures, there is an opportunity at the institutional 
level to improve the quality of care delivered to patients with AF.49–55
9. The AF-CARE pathway in specific 
clinical settings
The following sections detail specific clinical settings where approaches 
to AF-CARE may vary. Unless specially discussed, measures for [C] co­
morbidity and risk factor management, [A] avoidance of stroke and 
thromboembolism, [R] rate and rhythm control, and [E] evaluation 
and dynamic reassessment should follow the standard pathways intro­
duced in Section 4.
9.1. AF-CARE in unstable patients
Unstable patients with AF include those with haemodynamic instability 
caused by the arrhythmia or acute cardiac conditions, and severely ill 
patients who develop AF (sepsis, trauma, surgery, and particularly 
cancer-related surgery). Conditions such as sepsis, adrenergic over­
stimulation, and electrolyte disturbances contribute to onset and recur­
rence of AF in these patients. Spontaneous restoration of sinus rhythm 
has been reported in up to 83% during the first 48 h after appropriate 
treatment of the underlying cause.551,745
Emergency electrical cardioversion is still considered the first-choice 
treatment if sinus rhythm is thought to be beneficial, despite the limita­
tion of having a high rate of immediate relapse.746 Amiodarone is a 
second-line option because of its delayed activity; however, it may be 
an appropriate alternative in the acute setting.747,748 In a multicentre co­
hort study carried out in the United Kingdom and the United States of 
America, amiodarone and beta-blockers were similarly effective for 
rate control in intensive care patients, and superior to digoxin and cal­
cium channel blockers.749 The ultra-short acting and highly selective beta- 
blocker landiolol can safely control rapid AF in patients with low ejection 
fraction and acutely decompensated heart failure, with a limited impact 
on myocardial contractility or blood pressure.477,750,751
9.2. AF-CARE in acute and chronic 
coronary syndromes
The incidence of AF in acute coronary syndromes (ACS) ranges from 
2% to 23%.752 The risk of new-onset AF is increased by 60%–77% in 
patients suffering an MI,753 and AF may be associated with an increased 
risk of ST-segment elevation myocardial infarction (STEMI) or 
non-STEMI ACS.754 Overall, 10%–15% of AF patients undergo percu­
taneous intervention (PCI) for CAD.755 In addition, AF is a common 
precipitant for type 2 MI.756 Observational studies show that patients 
with both ACS and AF are less likely to receive appropriate antithrom­
botic therapy757 and more likely to experience adverse outcomes.758
Peri-procedural management of patients with ACS or chronic coronary 
syndromes (CCS) are detailed in the 2023 ESC Guidelines for the man­
agement of acute coronary syndromes and 2024 ESC Guidelines for the 
management of chronic coronary syndromes.759,760
The combination of AF with ACS is the area where use of multiple 
antithrombotic drugs is most frequently indicated, consisting of antiplate­
let agents plus OAC (Figure 14) (see Supplementary data online, 
Additional Evidence Table S27). There is a general trend to decrease the 
duration of DAPT to reduce bleeding; however, this may increase ischae­
mic events and stent thrombosis.761,762 In ACS there is a high risk of pre­
dominantly platelet-driven atherothrombosis and thus of coronary 
ischaemic events. Acute coronary syndromes treated by PCI require 
DAPT for improved short- and long-term prognosis. Therefore, a peri- 
procedural triple antithrombotic regimen including an OAC, aspirin, and 
a P2Y12 inhibitor should be the default strategy for most patients. Major 
thrombotic events vs. major bleeding risk need to be balanced when pre­
scribing antiplatelet therapy and OAC after the acute phase and/or after 
PCI. The combination of OAC (preferably a DOAC) and a P2Y12 inhibi­
tor results in less major bleeding than triple therapy that includes aspirin. 
Clopidogrel is the preferred P2Y12 inhibitor, as the evidence for ticagre­
lor and prasugrel is less clear with higher bleeding risk.763–769 Ongoing 
trials will add to our knowledge about safely combining DOACs with 
antiplatelet agents (NCT04981041, NCT04436978). When using 
VKAs with antiplatelet agents, there is consensus opinion to use an 
INR range of 2.0–2.5 to mitigate excess bleeding risk.
Short–term triple therapy (≤1 week) is recommended for all pa­
tients without diabetes after ACS or PCI. In pooled analyses of 
RCTs, omitting aspirin in patients with ACS undergoing PCI has 
the potential for higher rates of ischaemic/stent thrombosis, without 
impact on incident stroke.761,762,770–772 None of the trials were 
powered for ischaemic events. All patients in AUGUSTUS (an open– 
label, 2 × 2 factorial, randomized controlled clinical trial to evaluate 
the safety of apixaban vs. vitamin k antagonist and aspirin vs. aspirin pla­
cebo in patients with AF and ACS or PCI) received aspirin plus a P2Y12 
inhibitor for a median time of 6 days.773 At the end of the trial, apixaban 
and a P2Y12 inhibitor without aspirin was the optimal treatment regi­
men for most patients with AF and ACS and/or PCI, irrespective of 
the patient’s baseline bleeding and stroke risk.774,775
Recommendation Table 23 — Recommendations to 
improve patient experience (see also Evidence Table 23)
Recommendations
Classa
Levelb
Evaluating quality of care and identifying 
opportunities for improved treatment of AF should 
be considered by practitioners and institutions to 
improve patient experiences.49–55
IIa
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 52 -->

### Page 52

Prolonged triple therapy up to 1 month after ACS/PCI should 
be considered in patients at high ischaemic risk, e.g. STEMI, 
prior stent thrombosis, complex coronary procedures, and pro­
longed cardiac instability, even though these patients were not 
adequately represented in the RCTs so far available.776 In AF 
patients with ACS or CCS and diabetes mellitus undergoing 
coronary stent implantation, prolonging triple therapy with low- 
dose aspirin, clopidogrel, and an OAC up to 3 months may be 
of benefit if thrombotic risk outweighs bleeding risk in the individ­
ual patient.207
When using VKA in combination with antiplatelet therapy, keep INR 2.0–2.5 and TTR >70%
(Class IIa)
VKA: INR 2.0–3.0
(Class I)
Clopidogrel is the preferred P2Y12i when combining with any OAC
Use the appropriate DOAC dosea.  A reduced dose is not recommended unless the patient meets DOAC-specific criteriaa
(Class III)
DOACs rather than VKA are recommended in eligible patients when combining with antiplatelet therapy
(Class I)
ACS, PCI or CCS
Up to 1 week
1 month
6 months
12 months
CCS
uncomplicated
PCI
CCS high ischaemic riskb
OAC + P2Y12i
+ aspirin
(Class I)
OAC only (Class I)
ACS
undergoing
PCI
OAC + P2Y12i (Class I)
OAC + P2Y12i
+ aspirin 
(Class I)
OAC only (Class I)
OAC + P2Y12i (Class I)
Stable CCS
OAC + P2Y12i
+ aspirin
(Class IIa)
OAC only (Class I)
OAC + P2Y12i (Class I)
ACS high ischaemic riskb
OAC + P2Y12i
+ aspirin
(Class IIa)
OAC only (Class I)
OAC + P2Y12i (Class I)
ACS
medically managed
OAC only
OAC only
OAC + P2Y12i
Figure 14 Antithrombotic therapy in patients with AF and acute or chronic coronary syndromes. ACS, acute coronary syndromes; CCS, chronic 
coronary syndrome; DOAC, direct oral anticoagulant; INR, international normalized ratio of prothrombin time; OAC, oral anticoagulant; P2Y12i, 
P2Y12-receptor inhibitor antiplatelet agents (clopidogrel, prasugrel, ticagrelor); PCI, percutaneous intervention; TTR, time in therapeutic range; 
VKA, vitamin K antagonist. The flowchart applies to those patients with an indication for oral anticoagulant therapy. aThe full standard dose of 
DOACs should be used unless the patient fulfils dose-reduction criteria (Table 11). When rivaroxaban or dabigatran are used as the DOAC and con­
cerns about bleeding risk prevail over stent thrombosis or ischaemic stroke, the reduced dose should be considered (15 mg and 110 mg respectively; 
Class IIa). bIn patients with diabetes mellitus undergoing coronary stent implantation, prolonging triple antithrombotic therapy for up to 3 months may 
be of value if thrombotic risk outweighs the bleeding risk.
ESC Guidelines                                                                                                                                                                                          3365


<!-- PAGE 53 -->

### Page 53

The evidence for ACS treated without revascularization is 
limited. Six to 12 months of a single antiplatelet agent in addition to a 
long-term DOAC is usually sufficient and can minimize bleeding 
risk.760,764,774 Although there are no head-to-head comparisons be­
tween aspirin and clopidogrel, studies have typically used clopidogrel. 
In patients with stable CCS for more than 12 months, sole 
therapy with a DOAC is sufficient and no additional antiplatelet therapy 
is required.353 In patients at potential risk of gastrointestinal bleeding, 
use of proton pump inhibitors is reasonable during combined 
antithrombotic therapy, although evidence in AF patients is 
limited.437,777–779 Multimorbid patients with ACS or CCS need careful 
assessment of ischaemic risk and management of modifiable bleeding 
risk factors, with a comprehensive work-up to individually adapt 
antithrombotic therapy.
9.3. AF-CARE in vascular disease
Peripheral arterial disease (PAD) is common in patients with AF, ran­
ging from 6.7% to 14% of patients.783,784 Manifest PAD is associated 
with incident AF.785 PAD predicts a higher mortality in patients with 
AF and is an independent predictor of stroke in those not on 
OAC.783,786 Patients with lower extremity artery disease and AF 
also have a higher overall mortality and risk of major cardiac 
events.784,787,788 A public health database of >40 000 patients 
hospitalized for PAD or critical limb ischaemia showed AF to be an 
independent predictor for mortality (HR, 1.46; 95% CI, 1.39–1.52) 
and ischaemic stroke (HR, 1.63; 95% CI, 1.44–1.85) as compared 
with propensity-matched controls.784 Similarly, in patients undergoing 
carotid endarterectomy or stenting, the presence of AF is associated 
with higher mortality (OR, 1.59; 95% CI, 1.11–2.26).789
Anticoagulation alone is usually sufficient in the chronic disease 
phase, with DOACs being the preferred agents despite one RCT sub­
analysis showing a higher risk of bleeding as compared with warfarin.790
In the case of recent endovascular revascularization, a period of com­
bination with single antiplatelet therapy should be considered, weighing 
bleeding and thrombotic risks and keeping the period of combination 
antithrombotic therapy as brief as possible (ranging between 1 month 
for peripheral791 and 90 days for neuro-interventional procedures).792
9.4. AF-CARE in acute stroke or 
intracranial haemorrhage
9.4.1. Management of acute ischaemic stroke
Management of acute stroke in patients with AF is beyond the scope of 
these guidelines. In AF patients presenting with acute ischaemic stroke 
while taking OAC, acute therapy depends on the treatment regimen 
and intensity of OAC. Management should be co-ordinated by a spe­
cialist neurologist team according to relevant guidelines.793
Recommendation Table 24 — Recommendations for 
patients with acute coronary syndromes or undergoing 
percutaneous intervention (see also Evidence Table 24)
Recommendations
Classa
Levelb
General recommendations for patients with AF and an 
indication for concomitant antiplatelet therapy
For combinations with antiplatelet therapy, a DOAC 
is recommended in eligible patients in preference to a 
VKA to mitigate bleeding risk and prevent 
thromboembolism.764,766
I
A
Rivaroxaban 15 mg once daily should be considered 
in preference to rivaroxaban 20 mg once daily when 
combined with antiplatelet therapy in patients where 
concerns about bleeding risk prevail over concerns 
about stent thrombosis or ischaemic stroke.765
IIa
B
Dabigatran 110 mg twice daily should be considered 
in preference to dabigatran 150 mg twice daily when 
combined with antiplatelet therapy in patients where 
concerns about bleeding risk prevail over concerns 
about stent thrombosis or ischaemic stroke.766
IIa
B
Carefully regulated VKA dosing with a target INR of 
2.0–2.5 and TTR >70% should be considered when 
combined with antiplatelet therapy in AF patients to 
mitigate bleeding risk.
IIa
C
Recommendations for AF patients with ACS
Early cessation (≤1 week) of aspirin and continuation 
of an oral anticoagulant (preferably DOAC) with a 
P2Y12 inhibitor (preferably clopidogrel) for up to 12 
months is recommended in AF patients with ACS 
undergoing an uncomplicated PCI to avoid major 
bleeding, if the risk of thrombosis is low or bleeding 
risk is high.764–767
I
A
Triple therapy with aspirin, clopidogrel, and oral 
anticoagulation for longer than 1 week after an ACS 
should be considered in patients with AF when 
ischaemic risk outweighs the bleeding risk, with the 
total duration (≤1 month) decided according to 
assessment of these risks and clear documentation of 
the discharge treatment plan.776
IIa
C
Continued 
Recommendations for AF patients undergoing PCI
After uncomplicated PCI, early cessation (≤1 week) 
of aspirin and continuation of an oral anticoagulant 
and a P2Y12 inhibitor (preferably clopidogrel) for up 
to 6 months is recommended to avoid major 
bleeding, if ischaemic risk is low.763–766,776,780
I
A
Triple therapy with aspirin, clopidogrel, and an oral 
anticoagulant for longer than 1 week should be 
considered after PCI when the risk of stent 
thrombosis outweighs the bleeding risk, with the total 
duration (≤1 month) decided according to 
assessment of these risks and clear documentation.776
IIa
B
Recommendations for AF patients with chronic coronary or 
vascular disease
Antiplatelet therapy beyond 12 months is not 
recommended in stable patients with chronic 
coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid 
major bleeding.353,781,782
III
B
© ESC 2024
ACS, acute coronary syndromes; AF, atrial fibrillation; DOAC, direct oral anticoagulant; 
INR, international normalized ratio of prothrombin time; PCI, percutaneous 
intervention; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 54 -->

### Page 54

9.4.2. Introduction or re-introduction of 
anticoagulation after ischaemic stroke
The optimal time for administering OAC in patients with acute cardio­
embolic stroke and AF remains unclear. Randomized control trials have 
been unable to provide any evidence to support the administration of 
anticoagulants or heparin in patients with acute ischaemic stroke within 
48 h from stroke onset. This suggests that low-dose aspirin should be 
administered to all patients during this timeframe.794
Two trials have examined the use of DOAC therapy early after 
stroke, with no difference in clinical outcomes compared with delayed 
DOAC prescription. The ELAN (Early versus Late initiation of direct 
oral Anticoagulants in post-ischaemic stroke patients with atrial 
fibrillatioN) trial randomized 2013 patients with acute ischaemic stroke 
and AF to open-label early use of DOACs (<48 h after minor/moderate 
stroke; day 6–7 after major stroke) vs. later DOAC prescription (day 
3–4 after minor stroke; day 6–7 after moderate stroke; day 12–14 after 
major stroke). There was no significant difference in the composite 
thromboembolic, bleeding, and vascular death outcome at 30 days 
(risk difference early vs. late, −1.18%; 95% CI, −2.84 to 0.47).795 The 
TIMING (Timing of Oral Anticoagulant Therapy in Acute Ischemic 
Stroke With Atrial Fibrillation) trial, a registry-based, non-inferiority, 
open-label, blinded endpoint trial randomized 888 patients within 
72 h of ischaemic stroke onset to early (≤4 days) or delayed (5–10 days) 
DOAC initiation. Early DOAC use was non-inferior to the delayed 
strategy for the composite of thromboembolism, bleeding and all-cause 
mortality at 90 days (risk difference, −1.79%; 95% CI, −5.31% to 
1.74%).796 Two ongoing trials will provide further guidance on the 
most appropriate timing of DOAC therapy after ischaemic stroke 
(NCT03759938, NCT03021928).
9.4.3. Introduction or re-introduction of 
anticoagulation after haemorrhagic stroke
There is insufficient evidence currently to recommend whether OAC 
should be started or re-started after ICH to protect against the high 
risk of ischaemic stroke in these patients (see Supplementary data 
online, Additional Evidence Table S28). Data from two pilot trials are avail­
able. The APACHE-AF (Apixaban After Anticoagulation-associated 
Intracerebral Haemorrhage in Patients With Atrial Fibrillation) trial 
was a prospective, randomized, open-label trial with masked endpoint as­
sessment; 101 patients who survived 7–90 days after anticoagulation- 
associated ICH were randomized to apixaban or no OAC. During a 
median of 1.9 years follow-up (222 person-years), there was no differ­
ence in non-fatal stroke or vascular death, with an annual event rate of 
12.6% with apixaban and 11.9% with no OAC (adjusted HR, 1.05; 95% 
CI, 0.48–2.31; P = .90).797 SoSTART (Start or STop Anticoagulants 
Randomised Trial) was an open-label RCT in 203 patients with AF after 
symptomatic spontaneous ICH. Starting OAC was not non-inferior to 
avoiding long-term (≥1 year) OAC, with ICH recurrence in 8/101 
(8%) vs. 4/102 (4%) patients (adjusted HR, 2.42; 95% CI, 0.72–8.09). 
Mortality occurred in 22/101 (22%) patients in the OAC group vs. 
11/102 (11%) patients where OAC were avoided.798
Until additional trials report on the clinical challenge of post-ICH an­
ticoagulation (NCT03950076, NCT03996772), an individualized multi­
disciplinary approach is advised led by an expert neurology team.
9.5. AF-CARE for trigger-induced AF
Trigger-induced AF is defined as new AF in the immediate association of a 
precipitating and potentially reversible factor. Also known as ‘secondary’ 
AF, this task force prefer the term trigger-induced as there are almost 
always underlying factors in individual patients that can benefit from full 
consideration of the AF-CARE pathway. The most common precipitant 
unmasking a tendency to AF is acute sepsis, where AF prevalence is 
between 9% and 20% and has been associated with a worse 
prognosis.11–14 The degree of inflammation correlates with the incidence 
of AF,799 which may partly explain the wide variability across studies in 
prevalence, as well as recurrence of AF. Longer-term data suggest that 
AF triggered by sepsis recurs after discharge in between a third to a half 
of patients.12,800–807In addition to other acute triggers which may be causal 
(such as alcohol808,809 and illicit drug use810), numerous conditions are also 
associated with chronic inflammation leading to subacute stimuli for AF 
(Table 14). The specific trigger of an operative procedure is discussed in 
Section 9.6.
After meeting the diagnostic criteria for AF (see Section 3.2), the 
management of trigger-induced AF is recommended to follow the 
AF-CARE principles, with critical consideration of underlying risk factors 
and comorbidities. Based on retrospective and observational data, patients 
with AF and trigger-induced AF seem to carry the same thromboembolic 
risk as patients with primary AF.811,812 In the acute phase of sepsis, patients 
show an unclear risk–benefit profile with anticoagulation therapy.813,814
Prospective studies on anticoagulation in patients with triggered AF epi­
sodes are lacking.802,812,815 Acknowledging that there are no RCTs specif­
ically available in this population to assess trigger-induced AF, long-term 
OAC therapy should be considered in suitable patients with trigger- 
induced AF who are at elevated risk of thromboembolism, starting 
OAC after the acute trigger has been corrected and considering the antici­
pated net clinical benefit and informed patient preferences. As with any de­
cision on OAC, not all patients will be suitable for OAC, depending on 
relative and absolute contraindications and the risk of major bleeding. 
The approach to rate and rhythm control will depend on subsequent re­
currence of AF or any associated symptoms, and re-evaluation should be 
individualized to take account of the often high AF recurrence rate.
Table 14 Non-cardiac conditions associated with 
trigger-induced AF
Acute conditions
Infections (bacterial and viral)
Pericarditis, myocarditis
Emergency conditions (burn injury, severe trauma, shock)
Binge alcohol consumption
Drug use, including methamphetamines, cocaine, opiates, and cannabis
Acute interventions, procedures, and surgery
Endocrine disorders (thyroid, adrenal, pituitary, others)
Chronic conditions with inflammation and enhanced AF 
substrate
Immune-mediated diseases (rheumatoid arthritis, systemic lupus 
erythematosus, inflammatory bowel disease, coeliac disease, psoriasis, 
others)
Obesity
Chronic obstructive airways disease
Obstructive sleep apnoea
Cancer
Fatty liver disease
Stress
Endocrine disorders (see Section 9.10)
© ESC 2024
ESC Guidelines                                                                                                                                                                                          3367


<!-- PAGE 55 -->

### Page 55

9.6. AF-CARE in post-operative patients
Peri-operative AF describes the onset of the arrhythmia during an 
ongoing intervention. Post-operative AF (POAF), defined as new- 
onset AF in the immediate post-operative period, is a common com­
plication with clinical impact that occurs in 30%–50% of patients 
undergoing cardiac surgery,816–818 and in 5%–30% of patients under­
going non-cardiac surgery. Intra- and post-operative changes and 
specific AF triggers (including peri-operative complications) and 
pre-existing AF-related risk factors and comorbidities increase the 
susceptibility to POAF.819 Although POAF episodes may be self- 
terminating, POAF is associated with 4–5 times increase in recurrent 
AF during the next 5 years,820,821 and is a risk factor for stroke, MI, 
heart failure, and death.822–827 Other adverse events associated 
with POAF include haemodynamic instability, prolonged hospital 
stay, infections, renal complications, bleeding, increased in-hospital 
death, and greater healthcare cost.828–830
While multiple strategies to prevent POAF with pre-treatment or acute 
drug treatment have been described, there is a lack of evidence from large 
RCTs. Pre-operative use of propranolol or carvedilol plus N-acetyl 
cysteine in cardiac and non-cardiac surgery is associated with a reduced 
incidence of POAF,831–834 but not major adverse events.835 An umbrella 
review of 89 RCTs from 23 meta-analyses (19 211 patients, but not neces­
sarily in AF) showed no benefit from beta-blockers in cardiac surgery for 
mortality, MI, or stroke. In non-cardiac surgery, beta-blockers were asso­
ciated with reduced rates of MI after surgery (RR range, 0.08–0.92), but 
higher mortality (RR range, 1.03–1.31), and increased risk of stroke (RR 
range, 1.33–7.72).836 Prevention of peri-operative AF can also be achieved 
with amiodarone. In a meta-analyses, amiodarone (oral or intravenous 
[i.v.]) and beta-blockers were equally effective in reducing post-operative 
AF,837 but their combination was better than beta-blockers alone.838
Lower cumulative doses of amiodarone (<3000 mg during the 
loading phase) could be effective, with fewer adverse events.837,839,840
Withdrawal of beta-blockers should be avoided due to increased risk 
of POAF.841 Other treatment strategies (steroids, magnesium, sotalol, 
(bi)atrial pacing, and botulium injection into the epicardial fat pad) lack 
scientific evidence for the prevention of peri-operative AF.842,843
Peri-operative posterior pericardiotomy, due to the reduction of post- 
operative pericardial effusion, showed a significant decrease in POAF 
in patients undergoing cardiac surgery (OR, 0.44; 95% CI, 0.27–0.70; 
P = .0005).844–846 In 3209 patients undergoing non-cardiac thoracic sur­
gery, colchicine did not lead to any significant reduction in AF compared 
with placebo (HR, 0.85; 95% CI, 0.65–1.10; P = .22).847
The evidence for prevention of ischaemic stroke in POAF by OAC 
is limited.822,827 Oral anticoagulant therapy is associated with a high 
bleeding risk soon after cardiac surgery or major non-cardiac inter­
ventions.827 Conversely, meta-analyses of observational cohort stud­
ies suggest a possible protective impact of OAC in POAF for all-cause 
mortality848 and a lower risk of thromboembolic events following car­
diac surgery, accompanied by higher rates of bleeding.849 This task 
force recommends to treat post-operative AF according to the 
AF-CARE pathway as discussed for trigger-induced AF (with the [R] 
pathway the same as for first-diagnosed AF). Ongoing RCTs in cardiac 
surgery (NCT04045665) and non-cardiac surgery (NCT03968393) 
will inform optimal long-term OAC use among patients with POAF. 
While awaiting the results of these trials, this task force recommends 
that after acute bleeding risk has settled, long-term OAC should be 
considered in patients with POAF according to their thromboembolic 
risk factors.
9.7. AF-CARE in embolic stroke of 
unknown source
The term ‘embolic stroke of undetermined source’ (ESUS) was introduced 
to identify non-lacunar strokes whose mechanism is likely to be embolic, 
but the source remains unidentified.856 Of note, these patients have a re­
current risk of stroke of 4%–5% per year.856 The main embolic sources as­
sociated with ESUS are concealed AF, atrial cardiomyopathy, left 
ventricular disease, atherosclerotic plaques, patent foramen ovale (PFO), 
valvular diseases, and cancer. Atrial cardiomyopathy and left ventricular dis­
ease are the most prevalent causes.856 AF is reported to be the underlying 
mechanism in 30% of ESUS patients.857–859 The detection of AF among 
ESUS patients increases the longer cardiac monitoring is provided (see 
Supplementary data online, Additional Evidence Table S29).857,860–864 This 
also holds for the duration of implantable cardiac monitoring, with prob­
ability of AF detection ranging from 2% with 1 week to over 20% by 3 
years.865 In patients with ESUS, factors associated with an increased detec­
tion of AF are increasing age,866,867 left atrial enlargement,866 cortical loca­
tion of stroke,868 large or small vessel disease,863 an increased number of 
Recommendation Table 26 — Recommendations for 
management of post-operative AF (see also Evidence 
Table 26)
Recommendations
Classa
Levelb
Peri-operative amiodarone therapy is recommended 
where drug therapy is desired to prevent 
post-operative AF after cardiac surgery.838,839,850,851
I
A
Concomitant posterior peri-cardiotomy should be 
considered in patients undergoing cardiac surgery to 
prevent post-operative AF.845,846
IIa
B
Long-term oral anticoagulation should be considered 
in patients with post-operative AF after cardiac and 
non-cardiac surgery at elevated thromboembolic 
risk, to prevent ischaemic stroke and 
thromboembolism.811,852–854
IIa
B
Routine use of beta-blockers is not recommended in 
patients undergoing non-cardiac surgery for the 
prevention of post-operative AF.836,855
III
B
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 25 — Recommendations for 
trigger-induced AF (see also Evidence Table 25)
Recommendation
Classa
Levelb
Long-term oral anticoagulation should be considered 
in suitable patients with trigger-induced AF at 
elevated thromboembolic risk to prevent ischaemic 
stroke and systemic thromboembolism.13,800,806,807,815
IIa
C
© ESC 2024
AF, atrial fibrillation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 56 -->

### Page 56

atrial premature beats per 24 h,868 rhythm irregularity,859 and risk stratifi­
cation scores (such as CHA2DS2-VASc,869
Brown ESUS-AF,870
HAVOC,871 and C2HEST872). This task force recommends prolonged 
monitoring depending on the presence of the above-mentioned risk 
markers.865,873,874
Currently available evidence, including two completed RCTs and one 
stopped for futility, do not support the use of DOACs compared with 
aspirin in patients with acute ESUS without documented AF.875–877
Ongoing trials will provide further guidance (NCT05134454, 
NCT05293080, NCT04371055).
9.8. AF-CARE during pregnancy
Atrial fibrillation is one of the most common arrhythmias during preg­
nancy, with prevalence increasing due to higher maternal age and 
changes in lifestyle, and because more women with congenital heart dis­
ease survive to childbearing age.878–881 Rapid atrioventricular conduc­
tion of AF may have serious haemodynamic consequences for 
mother and foetus. AF during pregnancy is associated with an increased 
risk of death.882 A multidisciplinary approach is essential to prevent ma­
ternal and foetal complications, bringing together gynaecologists, neo­
natologists, anaesthesiologists, and cardiologists experienced in 
maternal medicine.883
Pregnancy is associated with a hypercoagulable state and increased 
thromboembolic risk.884 The same rules for risk assessment of 
thromboembolism should be used as in non-pregnant women, as de­
tailed in the 2018 ESC Guidelines for the management of cardiovascular 
diseases during pregnancy.885 The preferred agents for anticoagulation 
of AF during pregnancy are unfractionated or low molecular weight he­
parins (LMWHs), which do not cross the placenta. Vitamin K antago­
nists should be avoided in the first trimester (risk of miscarriage, 
teratogenicity) and from week 36 onwards (risk of foetal intracranial 
bleeding if early unexpected delivery). Direct oral anticoagulants are 
not recommended during pregnancy due to concerns about safety.886
However, an accidental exposure during pregnancy should not lead to a 
recommendation for termination of the pregnancy.887 Vaginal delivery 
should be advised for most women, but is contraindicated during VKA 
treatment because of the risk of foetal intracranial bleeding.885
Intravenous selective beta-1 receptor blockers are recommended as 
first choice for acute heart rate control of AF.888 This does not include 
atenolol, which can lead to intrauterine growth retardation.889 If beta- 
blockers fail, digoxin and verapamil can be considered for rate control 
(verapamil should be avoided in the first trimester). Rhythm control is 
the preferred strategy during pregnancy. Electrical cardioversion is re­
commended if there is haemodynamic instability, considerable risk to 
mother or foetus, or with concomitant HCM. Electrical cardioversion 
can be performed safely without compromising foetal blood flow, 
and the consequent risk for foetal arrhythmias or pre-term labour is 
low. The foetal heart rate should be closely monitored throughout 
and after cardioversion, which should generally be preceded by anticoa­
gulation.885 In haemodynamically stable women without structural 
heart disease, intravenous ibutilide or flecainide may be considered 
for termination of AF, but experience is limited.890 Catheter ablation 
is normally avoided during pregnancy,883 but is technically feasible with­
out radiation in refractory symptomatic cases with a minimal/zero 
fluoroscopy approach.883
Counselling is important in women of childbearing potential prior to 
pregnancy, highlighting the potential risks of anticoagulation and rate or 
rhythm control drugs (including teratogenic risk, where relevant). 
Contraception and timely switch to safe drugs should be proactively 
discussed.
Recommendation Table 27 — Recommendations for 
patients with embolic stroke of unknown source (see 
also Evidence Table 27)
Recommendations
Classa
Levelb
Prolonged monitoring for AF is recommended in 
patients with ESUS to inform on AF treatment 
decisions.861–863
I
B
Initiation of oral anticoagulation in ESUS patients 
without documented AF is not recommended due to 
lack of efficacy in preventing ischaemic stroke and 
thromboembolism.875,876
III
A
© ESC 2024
AF, atrial fibrillation; ESUS, embolic stroke of undetermined source. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 28 — Recommendations for 
patients with AF during pregnancy (see also Evidence 
Table 28)
Recommendations
Classa
Levelb
Immediate electrical cardioversion is recommended 
in patients with AF during pregnancy and 
haemodynamic instability or pre-excited AF to 
improve maternal and foetal outcomes.885,891–893
I
C
Therapeutic anticoagulation with LMWHs or VKAs 
(except VKAs for the first trimester or beyond 
Week 36) is recommended for pregnant patients 
with AF at elevated thromboembolic risk to prevent 
ischaemic stroke and thromboembolism.885
I
C
Beta-1 selective blockers are recommended for 
heart rate control of AF in pregnancy to reduce 
symptoms and improve maternal and foetal 
outcomes, excluding atenolol.888
I
C
Electrical cardioversion should be considered for 
persistent AF in pregnant women with HCM to 
improve maternal and foetal outcomes.885,894
IIa
C
Digoxin should be considered for heart rate control 
of AF in pregnancy, if beta-blockers are ineffective or 
not tolerated, to reduce symptoms and improve 
maternal and foetal outcomes.885
IIa
C
Intravenous ibutilide or flecainide may be considered 
for termination of AF in stable pregnant patients with 
a structurally normal heart to improve maternal and 
foetal outcomes.895,896
IIb
C
Flecainide or propafenone may be considered for 
longer-term rhythm control in pregnancy, if rate 
controlling drugs are ineffective or not tolerated, to 
reduce symptoms and improve maternal and foetal 
outcomes.885
IIb
C
© ESC 2024
AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; LMWH, low molecular weight 
heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3369


<!-- PAGE 57 -->

### Page 57

9.9. AF-CARE in congenital heart disease
Survival of patients with congenital heart disease has increased over 
time, but robust data on the management of AF are missing and avail­
able evidence is derived mainly from observational studies. Oral anti­
coagulants are recommended for all patients with AF and intracardiac 
repair, cyanotic congenital heart disease, Fontan palliation, or systemic 
right ventricle irrespective of the individuals’ thromboembolic risk 
factors.897 Patients with AF and other congenital heart diseases should 
follow the general risk stratification for OAC use in AF (i.e. depending 
on the thromboembolic risk or CHA2DS2-VA score). Direct oral 
anticoagulants are contraindicated in patients with mechanical heart 
valves,331 but appear safe in patients with congenital heart dis­
ease,898,899 or those with a valvular bioprosthesis.900,901
Rate control drugs such as selective beta-1 receptor blockers, 
verapamil, diltiazem, and digoxin can be used with caution, with moni­
toring for bradycardia and hypotension. Rhythm control strategies such 
as amiodarone may be effective, but warrant monitoring for bradycar­
dia. When cardioversion is planned, both 3 weeks of OAC and TOE 
should be considered because thrombi are common in patients with 
congenital heart disease and atrial arrhythmias.902,903 Ablation ap­
proaches can be successful in patients with congenital heart disease, 
but AF recurrence rates may be high (see Supplementary data online, 
Additional Evidence Table S30).
In patients with atrial septal defect, closure may be performed be­
fore the fourth decade of life to decrease the risk of AF or AFL.904
Patients with stroke who underwent closure of their PFO may have 
an increased risk of AF,905 but in patients with PFO and AF, PFO clos­
ure is not recommended for stroke prevention. AF surgery or cath­
eter ablation can be considered at the time of closure of the atrial 
septal defect within a multidisciplinary team.906–908 AF catheter 
ablation of late atrial arrhythmias is likely to be effective after surgical 
atrial septal closure.909
9.10. AF-CARE in endocrine disorders
Endocrine dysfunction is closely related to AF, both as the direct action 
of endocrine hormones and as a consequence of treatments for endo­
crine disease. Optimal management of endocrine disorders is therefore 
part of the AF-CARE pathway.910,911
Clinical and subclinical hyperthyroidism, as well as subclinical hypo­
thyroidism, are associated with an increased risk of AF.912,913 Patients 
presenting with new-onset or recurrent AF should be tested for 
thyroid-stimulating hormone (TSH) levels. The risk of AF is enhanced 
in vulnerable patients, including the elderly and those with structural 
atrial diseases,914,915 as well as cancer patients on immune checkpoint 
inhibitors.916,917 In hyperthyroidism, and even in the euthyroid range, 
the risk of AF increases according to the reduction in TSH and elevated 
levels of thyroxine.918,919 Moreover, the risk of stroke is higher in 
patients with hyperthyroidism, which can be mitigated by treating the 
thyroid disorder.920,921 Amiodarone induces thyroid dysfunction in 
15%–20% of treated patients, leading to both hypo- and hyperthyroid­
ism,922,923 which warrants referral to an endocrinologist (see 
Supplementary data online for further details).
Hypercalcaemia may also induce arrhythmias, but the role of primary 
hyperparathyroidism in incident AF is poorly studied. Surgical para­
thyroidectomy has been found to reduce both supraventricular and ven­
tricular premature beats.924–926 Primary aldosteronism is related to an 
increased risk of AF through direct actions and vascular effects,927,928
with a three-fold higher rate of incident AF compared with patients 
with essential hypertension.929 Increases in genetically predicted plasma 
cortisol are associated with greater risk of AF, and patients with adrenal 
incidentalomas with subclinical cortisol secretion have a higher preva­
lence of AF.930,931 Acromegaly may predispose to an increased sub­
strate for AF, with incident AF rates significantly higher than controls 
in long-term follow-up, even after adjusting for AF risk factors.932
The association between type 2 diabetes and AF is discussed in 
Sections 5.3 (AF recurrence) and Section 10.5 (incident AF). In addition 
to insulin-resistance mechanisms typical of type 2 diabetes, the loss of 
insulin signalling has recently been associated with electrical changes 
that can lead to AF. Type 1 diabetes is associated with an increased 
risk of several cardiovascular diseases including AF.933–937
9.11. AF-CARE in inherited 
cardiomyopathies and primary 
arrhythmia syndromes
A higher incidence and prevalence of AF have been described in pa­
tients with inherited cardiomyopathies and primary arrhythmia syn­
dromes.271,938–970 AF can be the presenting or only clinically overt 
feature.969,971–975 AF in these patients is associated with adverse clinical 
outcomes,947,954,959,963,965,976–978 and has important implications on 
management (see Supplementary data online, Additional Evidence 
Table S31). When AF presents at a young age, there should be a careful 
interrogation about family history and a search for underlying 
disease.979
Rhythm control approaches may be challenging in patients with inher­
ited cardiomyopathies and primary arrhythmia syndromes. For example, 
many drugs have a higher risk of adverse events or may be contraindicated 
(e.g. amiodarone and sotalol in congenital long QT syndrome, and Class IC 
AADs in Brugada syndrome) (see Supplementary Data online, Table S6). 
Owing to long-term adverse effects, chronic use of amiodarone is prob­
lematic in these typically young individuals. In patients with an implantable 
cardioverter defibrillator, AF is a common cause of inappropriate 
shocks.959,966,980,981 Programming a single high-rate ventricular fibrillation 
zone ≥210–220 b.p.m. with long detection time is safe,950,953,982 and is 
suggested in patients without documented slow monomorphic ventricu­
lar tachycardia. Implantation of an atrial lead may be considered in the case 
of significant bradycardia with beta-blocker treatment.
Patients with Wolff–Parkinson–White syndrome and AF are at risk 
of fast ventricular rates from rapid conduction of atrial electrical activity 
to the ventricles via the accessory pathway, potentially leading to ven­
tricular fibrillation and sudden death.983,984 Immediate electrical cardi­
oversion is needed for haemodynamically compromised patients with 
Recommendation Table 29 — Recommendations for 
patients with AF and congenital heart disease (see also 
Evidence Table 29)
Recommendation
Classa
Levelb
Oral anticoagulation should be considered in all adult 
congenital heart disease patients with AF/AFL and 
intracardiac repair, cyanosis, Fontan palliation, or 
systemic right ventricle to prevent ischaemic stroke 
and thromboembolism, regardless of other 
thromboembolic risk factors.897
IIa
C
© ESC 2024
AF, atrial fibrillation; AFL, atrial flutter. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 58 -->

### Page 58

pre-excited AF, and atrioventricular node-modulating drugs should be 
avoided.985,986 Pharmacological cardioversion can be attempted using 
ibutilide987 or flecainide, while propafenone should be used with cau­
tion due to effects on the atrioventricular node.988,989 Amiodarone 
should be avoided in pre-excited AF due to its delayed action. 
Further details on inherited cardiomyopathies can be found in the 
9.12. AF-CARE in cancer
All types of cancer show an increased risk of AF, with prevalence vary­
ing from 2% to 28%.991–995 The occurrence of AF may often be related 
to a pre-existing atrial substrate with vulnerability to AF. AF may be an 
indicator of an occult cancer, but also can appear in the context of con­
comitant surgery, chemotherapy, or radiotherapy.916,994,996 Risk of AF 
is dependent on, among other factors, the cancer type and stage,997 and 
is greater in older patients with pre-existing cardiovascular dis­
ease.991,993,994 Some procedures are associated with higher incidence 
of AF, including lung surgery (from 6% to 32%) and non-thoracic sur­
gery such as a colectomy (4%–5%).994
Atrial fibrillation in the context of cancer is associated with a two- 
fold higher risk of systemic thromboembolism and stroke, and six-fold 
increased risk of heart failure.991,994 On the other hand, the coexistence 
of cancer increases the risk of all-cause mortality and major bleeding in 
patients with AF.998 Bleeding in those receiving OAC can also unmask 
the presence of cancer.999
Stroke risk scores may underestimate thromboembolic risk in cancer 
patients.1000 The association between cancer, AF, and ischaemic stroke 
also differs between cancer types. In some types of cancer, the risk of 
bleeding seems to exceed the risk of thromboembolism.998 Risk strati­
fication is therefore complex in this population, and should be per­
formed on an individual basis considering cancer type, stage, 
prognosis, bleeding risk, and other risk factors. These aspects can 
change within a short period of time, requiring dynamic assessment 
and management.
As with non-cancer patients, DOACs in those with cancer have simi­
lar efficacy and better safety compared with VKAs.1001–1010 Low 
molecular weight heparin is a short-term anticoagulation option, mostly 
during some cancer treatments, recent active bleeding, or thrombo­
cytopaenia.1011 Decision-making on AF management, including on 
rhythm control, is best performed within a cardio-oncology multi­
disciplinary team.916,1012 Attention is required on interactions with can­
cer treatments, in particular QT-interval prolongation with AADs.
9.13. AF-CARE in older, multimorbid, or 
frail patients
Atrial fibrillation increases with age, and older patients more frequently 
have multimorbidity and frailty which are associated with worse clinical 
outcomes.1013–1016 Multimorbidity is the coexistence of two or more 
medically diagnosed diseases in the same individual. Frailty is defined 
as a person more vulnerable and less able to respond to a stressor 
or acute event, increasing the risk of adverse outcomes.1016,1017 The 
prevalence of frailty in AF varies due to different methods of assess­
ment from 4.4% to 75.4%, and AF prevalence in the frail population 
ranges from 48.2% to 75.4%.1018 Frailty status is a strong independent 
risk factor for new-onset AF among older adults with hypertension.1019
Atrial fibrillation in frail patients is associated with less use of 
OAC and lower rates of management with a rhythm control 
strategy.1015,1018,1020 Oral anticoagulation initiation in older, frail 
multimorbid AF patients has improved since the introduction of 
DOACs, but is still lower in AF patients at older age (OR, 0.98 per 
year; 95% CI, 0.98–0.98), with dementia (OR, 0.57; 95% CI, 
0.55–0.58), or frailty (OR, 0.74; 95% CI, 0.72–0.76).1021 The value of 
observational data which show potential benefit from OAC (in particu­
lar, DOACs) is limited due to prescription biases.1022–1027 Frail patients 
aged ≥75 years with polypharmacy and stable on a VKA may remain on 
the VKA rather than switching to a DOAC (Section 6.2).309
9.14. AF-CARE in atrial flutter
Due to the association between AFL and thromboembolic outcomes, 
and the frequent development of AF in patients with AFL, the manage­
ment of comorbidities and risk factors in AFL should mirror that for AF 
(see Section 5). Similarly, the approach to prevent thromboembolism in 
AFL includes peri-procedural and long-term OAC (see Section 6). Rate 
control can be difficult to achieve in AFL, despite combination therapy. 
Rhythm control is often the first-line approach,983 with small rando­
mized trials showing that cavo-tricuspid isthmus (CTI) ablation is super­
ior to AADs.1028,1029 Recurrence of AFL is uncommon after achieving 
and confirming bidirectional block in typical CTI-dependent AFL. 
However, the majority of patients (50%–70%) have manifested AF 
during long-term follow-up in observational studies after AFL 
ablation.1030,1031 Hence the necessity for long-term dynamic re- 
evaluation in all patients with AFL in keeping with the AF-CARE 
approach. More detail on the management of AFL and other atrial ar­
rhythmias is described in the 2019 ESC Guidelines for the management of 
patients with supraventricular tachycardia.983
10. Screening and prevention of AF
10.1. Epidemiology of AF
Atrial fibrillation is the most common sustained arrhythmia worldwide, 
with an estimated global prevalence in 2019 of 59.7 million persons 
with AF.1033 Incident cases of AF are doubling every few decades.1034
Future increases are anticipated, in particular in middle-income coun­
tries.1034 In community-based individuals, the prevalence of AF in a 
United States of America cohort was up to 5.9%.1035
The 
age-standardized prevalence and incidence rates have remained con­
stant over time.1033,1036 The increase in overall prevalence is largely at­
tributable to population growth, ageing, and survival from other cardiac 
conditions. In parallel, increases in risk factor burden, better awareness, 
and improved detection of AF have been observed.1037 The lifetime risk 
Recommendation Table 30 — Recommendations for 
prevention of thromboembolism in atrial flutter (see 
also Evidence Table 30)
Recommendation
Classa
Levelb
Oral anticoagulation is recommended in patients 
with atrial flutter at elevated thromboembolic risk to 
prevent ischaemic stroke and 
thromboembolism.86,1032
I
B
© ESC 2024
AF, atrial fibrillation; AFL, atrial flutter. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          3371


<!-- PAGE 59 -->

### Page 59

of AF has been estimated to be as high as 1 in 3 for older individuals,1038
with age-standardized incidence rates higher for men than women. 
Populations of European ancestry are typically found to have higher 
AF prevalence, individuals of African ancestry have worse outcomes, 
and other groups may have less access to interventions.1039–1041
Socioeconomic and other factors likely play a role in racial and ethnic 
differences in AF, but studies are also limited due to differences in 
how groups access healthcare. Greater deprivation in socioeconomic 
and living status is associated with higher AF incidence.1042
10.2. Screening tools for AF
In recent years, an abundance of novel devices that can monitor heart 
rhythm have come to the market, including fitness bands and smart­
watches. Although the evidence for clinical effectiveness of digital de­
vices is limited, they may be useful in detecting AF, and their clinical, 
economic, legal, and policy implications merit further investiga­
tion.1043,1044 Devices for AF detection can broadly be divided into those 
that provide an ECG, and those with non-ECG approaches such as 
photoplethysmography (Figure 15 and Table 15).
Diagnostic for AF if diagnosis is confirmed by a physician
(Class I)
Not diagnostic (may be indicative for AF)
No of leads
Tracing
1 or 2
ECG-based methods
Non ECG-based methods
6
>6
Method
Tracing
Pulse palpation
Oscillometry
Contact
Contactless
Contactless
PPG
Smart speaker
Mechanocardiography
Figure 15 Non-invasive diagnostic methods for AF screening. AF, atrial fibrillation; BP, blood pressure; ECG, electrocardiogram; PPG, 
photoplethysmography.


<!-- PAGE 60 -->

### Page 60

Most consumer-based devices use photoplethysmography, and 
several large studies have been performed typically in low-risk indi­
viduals.633,1076,1117,1118 In an RCT of 5551 participants invited by 
their health insurer, smartphone-based photoplethysmography in­
creased the odds of OAC-treated new AF by 2.12 (95% CI, 
1.19–3.76; P = .01) compared with usual care.605 RCTs powered 
for assessment of clinical outcomes are still lacking for consumer- 
based AF screening. Further head-to-head comparisons between 
novel digital devices and those commonly used in healthcare set­
tings are needed to establish their comparative effectiveness in 
the clinical setting and account for different populations and set­
tings.1119 In a systematic review of smartphone-based photo­
plethysmography compared with a reference ECG, unrealistically 
high sensitivity and specificity were noted, likely due to small, low- 
quality studies with a high degree of patient selection bias.1120
Hence, when AF is suggested by a photoplethysmography device 
or any other screening tool, a single-lead or continuous ECG tra­
cing of >30 s or 12-lead ECG showing AF analysed by a physician 
with expertise in ECG rhythm interpretation is recommended to 
establish a definitive diagnosis of AF.1091,1121–1125
The combination of big data and artificial intelligence (AI) is hav­
ing an increasing impact on the field of electrophysiology. 
Algorithms have been created to improve automated AF diagnosis 
and several algorithms to aid diagnostics are being investigated.1046
However, the clinical performance and broad applicability of these 
solutions are not yet known. The use of AI may enable future 
treatment changes to be assessed with dynamic and continuous 
patient-directed monitoring using wearable devices.1126 There are 
still challenges in the field that need clarification, such as data acqui­
sition, model performance, external validity, clinical implementation, 
algorithm interpretation, and confidence, as well as the ethical 
aspects.1127
10.3. Screening strategies for AF
Screening can be performed systematically, with an invitation issued to 
a patient, or opportunistically, at the time of an ad hoc meeting with a 
healthcare professional. Regardless of the mode of invitation, screening 
should be part of a structured programme1128 and is not the same as 
identification of AF during a routine healthcare visit or secondary to ar­
rhythmia symptoms.
Screening can be done at a single timepoint (snapshot of the heart 
rhythm), e.g. using pulse palpation or a 12-lead ECG. Screening can 
also be of an extended duration, i.e. prolonged, using either intermittent 
or continuous monitoring of heart rhythm. Most studies using an oppor­
tunistic strategy have screened for AF at a single timepoint with short 
duration (such as a single timepoint ECG), compared with systematic 
screening studies that have mainly used prolonged (repeated or continu­
ous) rhythm assessment.1129 The optimal screening method will vary de­
pending on the population being studied (Figure 16) (see Supplementary 
data online, Additional Evidence Table S32). More sensitive methods will 
detect more AF but may lead to an increased risk of false positives and 
an increased detection of low burden AF, whereas more specific meth­
ods result in less false positives, at the risk of missing AF.
Invasive monitoring of heart rhythm in high-risk populations ex­
tended for several years has been shown to result in device-detected 
AF prevalence of around 30%, albeit most of whom have a low burden 
of AF.5,857,1130,1131 Pacemaker studies have shown that patients with a 
low burden of device-detected subclinical AF have a lower risk of is­
chaemic stroke.5,24,1131,1132 This has been confirmed in RCTs assessing 
DOAC use in patients with device-detected subclinical AF (see Section 
6.1.1).5,281,282 The burden needed for device-detected subclinical AF to 
translate into stroke risk is not known, and further studies are clearly 
needed.1133,1134 Benefit and cost-effectiveness of screening are dis­
cussed in the Supplementary data online.
Table 15 Tools for AF screening
Tools for AF screening
(i) Pulse palpation1045
(ii) Use of artificial intelligence algorithms to identify patients at risk1046
(iii) ECG-based devices 
(a) Conventional ECG devices 
(1) Classic 12-lead ECG 1047
(2) Holter monitoring (from 24 h to a week or more)1048
(3) Mobile cardiac telemetry (during hospitalization)1049
(4) Handheld devices1050–1052
(5) Wearable patches (up to 14 days)1053–1067
(6) Biotextiles (up to 30 days)1068–1072
(7) Smart devices (30 s)1073–1091
(b) Implantable loop recorders (3–5 years)1092–1099
(iv) Non-ECG-based devices 
(a) Photoplethysmography and automatic algorithms: contact (fingertip, smart device, band) and contactless (video)1100–1106
(b) Oscillometry (blood pressure monitors that derive heart rhythm regularity algorithmically)1107–1110
(c) Mechanocardiography (accelerometers and gyroscopes to sense the mechanical activity of the heart)1111
(d) Contactless video plethysmography (through video monitoring)1112–1115
(e) Smart speakers (through the identification of abnormal heart rate patterns)1116
© ESC 2024
ECG, electrocardiogram.
ESC Guidelines                                                                                                                                                                                          3373


<!-- PAGE 61 -->

### Page 61

10.3.1. Single timepoint screening ‘snapshot’
Several cluster RCTs in primary care settings have explored whether 
screening performed as a snapshot of the heart rhythm at one time­
point can detect more AF compared with usual care in individuals 
aged ≥65 years.1138–1140 No increased detection of AF was seen in 
groups randomized to single timepoint screening.1138–1140 These find­
ings were confirmed in a meta-analysis of RCTs showing that screening 
as a one-time event did not increase detection of AF compared with 
usual care.1135 Notably, these studies were performed in healthcare 
settings where the detection of AF in the population might be high, 
hence the results might not be generalizable to healthcare settings 
with a lower spontaneous AF detection. There are no RCTs addressing 
clinical outcomes in patients with AF detected by single timepoint 
screening.1123,1135
10.3.2. Prolonged screening
Studies using prolonged screening have shown an increased detection 
of AF leading to initiation of OAC.1129,1135,1141 Two RCTs have inves­
tigated the effect on clinical outcomes in prolonged screening for AF.5,6
In the STROKESTOP trial (Systematic ECG Screening for Atrial 
Fibrillation Among 75 Year Old Subjects in the Region of Stockholm 
Recommendation Table 31 — Recommendations for 
screening for AF (see also Evidence Table 31)
Recommendations
Classa
Levelb
Review of an ECG (12-lead, single, or multiple leads) 
by a physician is recommended to provide a definite 
diagnosis of AF and commence appropriate 
management.1091,1121–1123,1125
I
B
Routine heart rhythm assessment during healthcare 
contact is recommended in all individuals aged ≥65 
years for earlier detection of AF.
I
C
Population-based screening for AF using a prolonged 
non-invasive ECG-based approach should be 
considered in individuals aged ≥75 years, or ≥65 
years with additional CHA2DS2-VA risk factors to 
ensure earlier detection of AF.6,1135–1137
IIa
B
© ESC 2024
AF, atrial fibrillation; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years 
(2 
points), 
diabetes 
mellitus, 
prior 
stroke/transient 
ischaemic 
attack/arterial 
thromboembolism (2 points), vascular disease, age 65–74 years; ECG, electrocardiogram. 
aClass of recommendation. 
bLevel of evidence.
Screening approach
Population example
Setting for 
AF detection
Type of screening
Follow
AF-CARE
After thromboembolic event
Patients with embolic stroke of unknown source
Age ≥65 years,
or risk of thromboembolism
Age ≥75 years,
or ≥65 years plus other
CHA2DS2-VA
factors
Initiated after index event
At the time of routine healthcare contact
Structured national or regional screening programmes
Ad-hoc to catch AF
In patients with risk factors
Patient informed about implications of AF
detection
C
Comorbidity and risk factor management
A
Avoid stroke and thromboembolism
R
Reduce symptoms by rate and rhythm control
E
Evaluation and 
dynamic reassessment
Any rhythm check,
confirmed by ECG
Routine heart rhythm assessment
(Class I)
Invasive or non-invasive ECG
Prolonged monitoring
(Class I)
Population-based 
Non-invasive ECG
(Class IIa)
Figure 16 Approaches to screening for AF. AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk factor management, [A] Avoid 
stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; CHA2DS2-VA, congestive 
heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/TIA/arterial thromboembolism (2 points), vascular disease, age 65– 
74 years; ECG, electrocardiogram. See Figure 15 for non-invasive ECG methods.


<!-- PAGE 62 -->

### Page 62

and Halland, Sweden), 75- and 76-year-olds were randomized to be in­
vited to prolonged screening for AF using single-lead ECGs twice daily 
for 2 weeks, or to standard of care. After a median of 6.9 years there 
was a small reduction in the primary combined endpoint of all-cause 
mortality, stroke, systematic embolism, and severe bleeding in favour 
of prolonged screening (HR, 0.96; 95% CI, 0.92–1.00; P = .045).6 In 
the LOOP (Atrial Fibrillation Detected by Continuous ECG 
Monitoring) trial, individuals at increased risk of stroke were rando­
mized to receive an implantable loop recorder that monitored heart 
rhythm for an average of 3.3 years, or to a control group receiving 
standard of care. Although there was a higher detection of AF 
(31.8%) and subsequent initiation of OAC in the loop recorder 
group compared with standard of care (12.2%), this was not accom­
panied by a difference in the primary outcome of stroke or systemic 
embolism.5 In a meta-analysis of recent RCTs on the outcome of 
stroke, a small but significant benefit was seen in favour of prolonged 
screening (RR, 0.91; 95% CI, 0.84–0.99).1136 This was not repeated 
in a second meta-analysis including older RCTs, where no risk reduc­
tion was seen with regard to mortality or stroke.1135 Notably, both 
these meta-analyses are likely underpowered to assess clinical 
outcomes.
10.4. Factors associated with incident AF
The most common risk predictors for incident (new-onset) AF are 
shown in Table 16. While the factors listed are robustly associated 
with incident AF in observational studies, it is not known whether 
the relationships are causal. Studies using Mendelian randomization 
(genetic proxies for risk factors to estimate causal effects) robustly im­
plicate systolic BP and higher BMI as causal risk factors for incident 
AF.1142
A high degree of interaction occurs between all factors related to AF 
development (see Supplementary data online, Additional Evidence 
Table S33).1038,1039,1143–1145 For ease of clinical application, risk predic­
tion tools have combined various factors, and have recently employed 
machine learning algorithms for prediction.1146,1147 Classical risk scores 
are also available with variable predictive ability and model performance 
(see Supplementary data online, Table S7).1148 Improved outcomes 
when using these risk scores have yet to be demonstrated. Although 
knowledge is rapidly increasing about the genetic basis for AF in 
some patients, the value of genetic screening is limited at the present 
time (see Supplementary data online).
10.5. Primary prevention of AF
Preventing the onset of AF before clinical manifestation has clear 
potential to improve the lives of the general population and reduce 
the considerable health and social care costs associated with 
development of AF. Whereas the [C] in AF-CARE is focused on the 
effective management of risk factors and comorbidities to limit AF 
recurrence and progression, there is also evidence they can be targeted 
to prevent AF. Available data are presented below for hypertension, 
heart failure, type 2 diabetes mellitus, obesity, sleep apnoea syndrome, 
Table 16 Factors associated with incident AF
Demographic factors
Age1149–1151
Male sex1149–1152
European ancestry1149,1150
Lower socioeconomic status1150
Lifestyle behaviours
Smoking/tobacco use1149–1151
Alcohol intake1149,1150
Physical inactivity1149,1150
Vigorous exercise1153–1156
Competitive or athlete-level endurance 
sports1151,1157
Caffeine1158–1160
Continued 
Comorbidities and risk 
factors
Hypertension1149–1151
Heart failure178,1149–1151,1161
Valvular disease1149,1151,1162–1164
Coronary artery disease1149,1151,1161,1165
Peripheral arterial disease785
Congenital heart disease1149,1166
Heart rate, heart rate variability1167,1168
Total cholesterol1149,1150
Low-density lipoprotein cholesterol1150
High-density lipoprotein cholesterol1150
Triglycerides1150
Impaired glucose tolerance,1169–1172diabetes 
mellitus1149–1151,1169
Renal dysfunction/CKD1149–1151,1173,1174
Obesity1149–1151,1175,1176
Body mass index, weight1149–1151
Height1150
Sleep apnoea1149,1151,1177,1178
Chronic obstructive pulmonary disease1179
Subclinical 
atherosclerosis
Coronary artery calcification1149,1151,1180
Carotid IMT and carotid plaque1149,1151,1181,1182
ECG abnormalities
PR interval prolongation1149,1151,1183
Sick sinus syndrome1149,1184,1185
Wolff–Parkinson–White1149,1186
Genetic factors
Family history of AF1149,1151,1187–1190
AF-susceptible loci identified by 
GWAS1149,1151,1191,1192
Short QT syndrome1149
Genetic cardiomyopathies990,1193
Biomarkers
C-reactive protein1150,1151
Fibrinogen1150
Growth differentiation factor-151194
Natriuretic peptides (atrial and B-type)1195–1200
Cardiac troponins1199
Inflammatory biomarkers 1149,1151
Others
Thyroid dysfunction912,1149–1151
Autoimmune diseases1150
Air pollution1149,1201
Sepsis1149,1202
Psychological factors 1203,1204
© ESC 2024
AF, atrial fibrillation; CKD, chronic kidney disease; GWAS, genome-wide association 
studies; HF, heart failure; IMT, intima-media thickness.
ESC Guidelines                                                                                                                                                                                          3375


<!-- PAGE 63 -->

### Page 63

physical activity, and alcohol, although many other risk markers can 
also be targeted. Further information on each factor’s attributable 
risk for AF is provided in the Supplementary data online (see 
Supplementary data online, Evidence Table 32 and additional Evidence 
Tables S34–S39).
10.5.1. Hypertension
Management of hypertension has been associated with a reduction in 
incident AF.1205–1207,1232 In the LIFE (Losartan Intervention for End 
point reduction in hypertension) trial, a 10 mmHg reduction in systolic 
BP was associated with a 17% reduction in incident AF.1207 Secondary 
analysis of RCTs and observational studies suggest that ACE inhibitors 
or ARBs may be superior to beta-blockers, calcium channel blockers, or 
diuretics for the prevention of incident AF.1233–1236
10.5.2. Heart failure
Long-standing established pharmacological treatments for HFrEF have 
been associated with a reduction in incident AF. The use of ACE inhi­
bitors or ARBs in patients with known HFrEF was associated with a 
44% reduction in incidence of AF.1208 Similarly, beta-blockers in 
HFrEF led to a 33% reduction in the odds of incident AF.133
Mineralocorticoid receptor antagonists have also been shown to re­
duce the risk of new-onset AF by 42% in patients with HFrEF.1209
Although there have been variable effects of SGLT2 inhibitors on 
incident AF, several meta-analyses have demonstrated that there is 
an 18%–37% reduction in incident AF.136,1210,1211,1237 However, treat­
ment of HFrEF with sacubitril/valsartan has not yet been shown to con­
fer any adjunctive benefit in reducing new-onset AF when compared 
with ACE inhibitors/ARBs alone.1238 There is some evidence to suggest 
that effective CRT in eligible patients with HFrEF reduces the risk of in­
cident AF.1239 To date, no treatments in HFpEF have been shown to 
reduce incident AF.
10.5.3. Type 2 diabetes mellitus
The integrated care of type 2 diabetes, based on lifestyle and pharma­
cological treatments for comorbidities such as obesity, hypertension, 
and dyslipidaemia, are useful steps in preventing atrial remodelling 
and subsequent AF. Intensive glucose-lowering therapy targeting an 
HbA1c level of <6.0% (<42 mmol/mol) failed to show a protective ef­
fect on incident AF.1240 More than glycaemic control per se, the class of 
glucose-lowering agent may influence the risk of AF.1240 Insulin pro­
motes adipogenesis and cardiac fibrosis, and sulfonylureas have been 
consistently associated with an increased risk of AF.193 Observational 
studies have associated metformin with lower rates of incident 
AF.1224,1225,1241–1243 Various recent studies and meta-analyses point 
to the positive role of SGLT2 inhibitors to reduce the risk of incident 
AF in diabetic and non-diabetic patients.136,1226,1244–1246 Pooled 
data from 22 trials including 52 951 patients with type 2 diabetes and 
heart failure showed that SGLT2 inhibitors compared with placebo 
can significantly reduce the incidence of AF by 18% in studies on dia­
betes, and up to 37% in heart failure with or without type 2 
diabetes.1210,1211
10.5.4. Obesity
Management of weight is important in the prevention of AF. In a large 
population-based cohort study, normal weight was associated with a 
reduced risk of incident AF compared with those who were obese 
(4.7% increase in the risk of incident AF for each 1 kg/m2 increase of 
BMI).208 In the Women’s Health Study, participants who became obese 
had a 41% increased risk of incident AF compared with those who 
maintained their BMI <30 kg/m2.1212 Similarly, observational studies 
in populations using bariatric surgery for weight loss in morbidly obese 
individuals (BMI ≥40 kg/m2) have observed a lower risk of incident 
AF.1227–1231
10.5.5. Sleep apnoea syndrome
Although it would seem rational to optimize sleep habits, to date there 
is no conclusive evidence to support this for the primary prevention of 
AF. The SAVE (Sleep Apnea cardioVascular Endpoints) trial failed to 
demonstrate a difference in clinical outcomes in those randomized to 
CPAP therapy or placebo.230 There was no difference in incident AF, 
albeit the analysis of AF was not based on systematic screening but ra­
ther on clinically documented AF.
10.5.6. Physical activity
Several studies have demonstrated beneficial effects of moderate phys­
ical activity on cardiovascular health.1247 Moderate aerobic exercise 
may also reduce the risk of new-onset AF.1214–1219 It should be noted 
that the incidence of AF appears to be increased among athletes, with a 
meta-analysis of observational studies showing a 2.5-fold increased risk 
of AF compared with non-athlete controls.1248
Recommendation Table 32 — Recommendations for 
primary prevention of AF (see also Evidence Table 32)
Recommendation
Classa
Levelb
Maintaining optimal blood pressure is recommended 
in the general population to prevent AF, with ACE 
inhibitors or ARBs as first-line therapy.1205–1207
I
B
Appropriate medical HF therapy is recommended in 
individuals with HFrEF to prevent AF.133,136,1208–1211
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is 
recommended for the general population to prevent 
AF.208,1212,1213
I
B
Maintaining an active lifestyle is recommended to 
prevent AF, with the equivalent of 150–300 min 
per week of moderate intensity or 75–150 min per 
week of vigorous intensity aerobic physical 
activity.1214–1219
I
B
Avoidance of binge drinking and alcohol excess is 
recommended in the general population to prevent 
AF.1220–1223
I
B
Metformin or SGLT2 inhibitors should be considered 
for individuals needing pharmacological management 
of diabetes mellitus to prevent AF.1210,1211,1224–1226
IIa
B
Weight reduction should be considered in obese 
individuals to prevent AF.1212,1227–1231
IIa
B
© ESC 2024
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; ARB, angiotensin receptor 
blocker; BMI, body mass index; HF, heart failure; HFrEF, heart failure with reduced 
ejection fraction; SGLT2, sodium-glucose cotransporter-2. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 64 -->

### Page 64

10.5.7. Alcohol intake
The premise that reducing alcohol intake can prevent AF is based on 
observational studies linking alcohol to an excess risk of incident AF 
in a dose-dependent manner (see Supplementary data online).1220–1222
In addition, a population cohort study of those with high alcohol con­
sumption (>60 g/day for men and >40 g/day for women) found that ab­
stinence from alcohol was associated with a lower incidence of AF 
compared with patients who continued heavy drinking.1223
11. Key messages
(1) General management: optimal treatment according to the 
AF-CARE pathway, which includes: [C] Comorbidity and risk fac­
tor management; [A] Avoid stroke and thromboembolism; [R] 
Reduce symptoms by rate and rhythm control; and [E] 
Evaluation and dynamic reassessment.
(2) Shared care: patient-centred AF management with joint decision- 
making and a multidisciplinary team.
(3) Equal care: avoid health inequalities based on gender, ethnicity, 
disability, and socioeconomic factors.
(4) Education: for patients, family members, caregivers, and health­
care professionals to aid shared decision-making.
(5) Diagnosis: clinical AF requires confirmation on an ECG device to 
initiate risk stratification and AF management.
(6) Initial evaluation: medical history, assessment of symptoms and 
their impact, blood tests, echocardiography/other imaging, 
patient-reported outcome measures, and risk factors for 
thromboembolism and bleeding.
(7) Comorbidities and risk factors: thorough evaluation and manage­
ment critical to all aspects of care for patients with AF to avoid 
recurrence and progression of AF, improve success of AF treat­
ments, and prevent AF-related adverse outcomes.
(8) Focus on conditions associated with AF: including hypertension, 
heart failure, diabetes mellitus, obesity, obstructive sleep apnoea, 
physical inactivity, and high alcohol intake.
(9) Assessing the risk of thromboembolism: use locally validated risk 
tools or the CHA2DS2-VA score and assessment of other risk fac­
tors, with reassessment at periodic intervals to assist in decisions 
on anticoagulant prescription.
(10) Oral anticoagulants: recommended for all eligible patients, except 
those at low risk of incident stroke or thromboembolism 
(CHA2DS2-VA = 1 anticoagulation should be considered; 
CHA2DS2-VA ≥2 anticoagulation recommended).
(11) Choice of anticoagulant: DOACs (apixaban, dabigatran, edoxa­
ban, and rivaroxaban) are preferred over VKAs (warfarin and 
others), except in patients with mechanical heart valves and mitral 
stenosis.
(12) Dose/range of anticoagulant: use full standard doses for DOACs 
unless the patient meets specific dose-reduction criteria; for 
VKAs, keep INR generally 2.0–3.0, and in range for >70% of the 
time.
(13) Switching anticoagulants: switch from a VKA to DOAC if risk of 
intracranial haemorrhage or poor control of INR levels.
(14) Bleeding risk: modifiable bleeding risk factors should be managed 
to improve safety; bleeding risk scores should not be used to de­
cide on starting or withdrawing anticoagulants.
(15) Antiplatelet therapy: avoid combining anticoagulants and antipla­
telet agents, unless the patient has an acute vascular event or 
needs interim treatment for procedures.
(16) Rate control therapy: use beta-blockers (any ejection fraction), di­
goxin (any ejection fraction), or diltiazem/verapamil (LVEF >40%) 
as initial therapy in the acute setting, an adjunct to rhythm control 
therapies, or as a sole treatment strategy to control heart rate and 
symptoms.
(17) Rhythm control: consider in all suitable AF patients, explicitly dis­
cussing with patients all potential benefits and risks of cardiover­
sion, antiarrhythmic drugs, and catheter or surgical ablation to 
reduce symptoms and morbidity.
(18) Safety first: keep safety and anticoagulation in mind when consid­
ering rhythm control; e.g. delay cardioversion and provide at least 
3 weeks of anticoagulation beforehand if AF duration >24 h, and 
consider toxicity and drug interactions for antiarrhythmic 
therapy.
(19) Cardioversion: use electrical cardioversion in cases of haemo­
dynamic instability; otherwise choose electrical or pharmacologic­
al cardioversion based on patient characteristics and preferences.
(20) Indication for long-term rhythm control: the primary indication 
should be reduction in AF-related symptoms and improvement 
in quality of life; for selected patient groups, sinus rhythm main­
tenance can be pursued to reduce morbidity and mortality.
(21) Success or failure of rhythm control: continue anticoagulation ac­
cording to the patient’s individual risk of thromboembolism, irre­
spective of whether they are in AF or sinus rhythm.
(22) Catheter ablation: consider as second-line option if antiarrhyth­
mic drugs fail to control AF, or first-line option in patients with 
paroxysmal AF.
(23) Endoscopic or hybrid ablation: consider if catheter ablation fails, 
or an alternative to catheter ablation in persistent AF despite anti­
arrhythmic drugs.
(24) Atrial fibrillation ablation during cardiac surgery: perform in cen­
tres with experienced teams, especially for patients undergoing 
mitral valve surgery.
(25) Dynamic evaluation: periodically reassess therapy and give atten­
tion to new modifiable risk factors that could slow/reverse the 
progression of AF, increase quality of life, and prevent adverse 
outcomes.
12. Gaps in evidence
The following bullet list gives the most important gaps in evidence 
where new clinical trials could substantially aid the patient pathway:
Definition and clinical impact of AF 
• Paroxysmal AF is not one entity, and patterns of AF progression and 
regression are highly variable. It is uncertain what the relevance is for 
treatment strategies and management decisions.
• Thirty seconds as definition for clinical AF needs validation and evalu­
ation whether it is related to AF-related outcomes.
• Definition, clinical features, diagnosis, and implementation for treat­
ment choices of atrial cardiomyopathy in patients with AF is 
unsettled.
• Diversity in AF presentation, underlying pathophysiological mechan­
isms, and associated comorbidities is incompletely understood with 
regard to differences in sex, gender, race/ethnicity, socioeconomic 
state, education, and differences between low-, moderate-, and high- 
income countries.
• Personalized risk prediction for AF incidence, AF progression, and as­
sociated outcomes remains challenging.
ESC Guidelines                                                                                                                                                                                          3377


<!-- PAGE 65 -->

### Page 65

• Insights into psychosocial and environmental factors and risk of AF 
and adverse outcomes in AF are understudied.
Patient-centred, multidisciplinary AF management 
• The benefit of additional education directed to patients, to family 
members, and to healthcare professionals in order to optimize 
shared decision-making still needs to be proved.
• Access to patient-centred management according to the AF-CARE 
principles to ensure equality in healthcare provision and improve out­
comes warrants evidence.
• The place of remote monitoring and telemedicine for identification 
and follow-up of patients with AF, or its subgroups is non-established, 
though widely applied.
[C] Comorbidity and risk factor management 
• Methods to achieve consistent and reproducible weight loss in pa­
tients with AF requires substantial improvement. Despite some evi­
dence demonstrating the benefits of weight loss, widespread 
adoption has been limited by the need for reproducible strategies.
• The importance of sleep apnoea syndrome and its treatment on 
AF-related outcomes remains to be elucidated.
[A] Avoid stroke and thromboembolism 
• Data are lacking on how to treat patients with low risk of stroke (with 
a CHA2DS2-VA score of 0 or 1), as these patients were excluded 
from large RCTs.
• Not enough evidence is available for OAC in elderly patients, frail 
polypharmacy patients, those with cognitive impairment/dementia, 
recent bleeding, previous ICH, severe end-stage renal failure, liver im­
pairment, cancer, or severe obesity.
• In elderly patients, routinely switching VKAs to DOACs is associated 
with increased bleeding risk; however, the reasons why this happens 
are unclear.
• The selection of which patients with asymptomatic device-detected 
subclinical AF benefit from OAC therapy needs to be defined.
• There is a lack of evidence whether and when to (re)start anticoagu­
lation after intracranial haemorrhage.
• There is lack of evidence about optimal anticoagulation in patients 
with ischaemic stroke or left atrial thrombus while being treated 
with OAC.
• There is uncertainty about the place of LAA closure and how to man­
age antithrombotic post-procedural management when LAAO is 
performed.
• Balance of thromboembolism and bleeding is unclear in patients with 
AF and incidental cerebral artery aneurysms identified on brain MRI.
[R] Reduce symptoms by rate and rhythm control 
• In some patients, AF can be benign in terms of symptoms and out­
comes. In which patients rhythm control is not needed warrants 
investigation.
• Application of antiarrhythmic drugs has been hampered by poor ef­
fectiveness and side effects; however, new antiarrhythmic drugs are 
needed to increase the therapeutic arsenal for AF patients.
• The amount of AF reduction obtained by rhythm control to improve 
outcomes is unknown.
• Large catheter ablation studies showed no improved outcome of 
patients with AF. Some small studies in specific subpopulations 
have observed an improved outcome. This warrants further inves­
tigation to provide each patient with AF with personalized treat­
ment goals.
• Uncertainty exists on the time of duration of AF and risk of stroke 
when performing a cardioversion.
• The value of diagnostic cardioversion for persistent AF in steering 
management of AF is unknown.
• Decisions on continuation of OAC are completely based on stroke 
risk scores and irrespective of having (episodes) of AF; whether 
this holds for patients undergoing successful catheter ablation is 
uncertain.
• Large variability in ablation strategies and techniques exist for pa­
tients with persistent AF, or after first failed catheter ablation for par­
oxysmal AF. The optimal catheter ablation strategy and techniques, 
however, are unknown.
• Sham-controlled intervention studies are lacking to determine the ef­
fects on AF symptoms, quality of life, and PROMS, accounting for the 
placebo effect that is associated with interventions.
The AF-CARE pathway in specific clinical settings 
• The optimal duration of triple therapy in patients with AF at high risk 
of recurrent coronary events after acute coronary syndrome is 
unclear.
• The role of the coronary vessel involved and whether this should im­
pact on the duration of combined OAC and antiplatelet treatment 
needs further study.
• The role of antiplatelet therapy in patients with AF and peripheral ar­
tery disease on OAC is uncertain.
• The use of DOACs in patients with congenital heart disease, particu­
larly in patients with complex corrected congenital defects, is poorly 
studied.
• Improved risk stratification for stroke in patients with AF and cancer, 
or with post-operative or trigger-induced AF is needed to inform on 
OAC treatment decisions.
Screening and prevention of AF 
• There are a lack of adequately powered randomized controlled stud­
ies on ischaemic stroke rate in patients screened for AF, both in the 
primary prevention setting and in secondary prevention (post- 
stroke), and its cost-effectiveness.
• Population selection that might benefit the most from screening, the 
optimal duration of screening, and the burden of AF that might in­
crease the risk for patients with screening-detected AF are uncertain.
• Evaluation of strategies to support longer-term use of technologies 
for AF detection are awaited.
• The role of photoplethysmography technology for AF screening in an 
effort to assess AF burden and reduce stroke is still unclear.
• How new consumer devices and wearable technology can be used 
for diagnostic and monitoring purposes in routine clinical practice 
needs to be clarified.


<!-- PAGE 66 -->

### Page 66

13. ‘What to do’ and ‘What not to do’ messages from the guidelines
Table 17 lists all Class I and Class III recommendations from the text alongside their level of evidence.
Table 17 ‘What to do’ and ‘what not to do’
Recommendations
Classa
Levelb
Recommendations for the diagnosis of AF
Confirmation by an electrocardiogram (12-lead, multiple, or single leads) is recommended to establish the diagnosis of clinical AF and 
commence risk stratification and treatment.
I
A
Recommendations for symptom evaluation in patients with AF
Evaluating the impact of AF-related symptoms is recommended before and after major changes in treatment to inform shared 
decision-making and guide treatment choices.
I
B
Recommendations for diagnostic evaluation in patients with new AF
A transthoracic echocardiogram is recommended in patients with an AF diagnosis where this will guide treatment decisions.
I
C
Recommendations for patient-centred care and education
Education directed to patients, family members, caregivers, and healthcare professionals is recommended to optimize shared 
decision-making, facilitating open discussion of both the benefit and risk associated with each treatment option.
I
C
Access to patient-centred management according to the AF-CARE principles is recommended in all patients with AF, regardless of gender, 
ethnicity, and socioeconomic status, to ensure equality in healthcare provision and improve outcomes.
I
C
Recommendations for comorbidity and risk factor management in AF
Identification and management of risk factors and comorbidities is recommended as an integral part of AF care.
I
B
Blood pressure lowering treatment is recommended in patients with AF and hypertension to reduce recurrence and progression of AF and 
prevent adverse cardiovascular events.
I
B
Diuretics are recommended in patients with AF, HF, and congestion to alleviate symptoms and facilitate better AF management.
I
C
Appropriate medical therapy for HF is recommended in AF patients with HF and impaired LVEF to reduce symptoms and/or HF 
hospitalization and prevent AF recurrence.
I
B
Sodium-glucose cotransporter-2 inhibitors are recommended for patients with HF and AF regardless of left ventricular ejection fraction to 
reduce the risk of HF hospitalization and cardiovascular death.
I
A
Effective glycaemic control is recommended as part of comprehensive risk factor management in individuals with diabetes mellitus and AF, 
to reduce burden, recurrence, and progression of AF.
I
C
Weight loss is recommended as part of comprehensive risk factor management in overweight and obese individuals with AF to reduce 
symptoms and AF burden, with a target of 10% or more reduction in body weight.
I
B
A tailored exercise programme is recommended in individuals with paroxysmal or persistent AF to improve cardiorespiratory fitness and 
reduce AF recurrence.
I
B
Reducing alcohol consumption to ≤3 standard drinks (≤30 grams of alcohol) per week is recommended as part of comprehensive risk 
factor management to reduce AF recurrence.
I
B
When screening for obstructive sleep apnoea in individuals with AF, using only symptom-based questionnaires is not recommended.
III
B
Recommendations to assess and manage thromboembolic risk in AF
Oral anticoagulation is recommended in patients with clinical AF at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
A
A CHA2DS2-VA score of 2 or more is recommended as an indicator of elevated thromboembolic risk for decisions on initiating oral 
anticoagulation.
I
C
Oral anticoagulation is recommended in all patients with AF and hypertrophic cardiomyopathy or cardiac amyloidosis, regardless of 
CHA2DS2-VA score, to prevent ischaemic stroke and thromboembolism.
I
B
Individualized reassessment of thromboembolic risk is recommended at periodic intervals in patients with AF to ensure anticoagulation is 
started in appropriate patients.
I
B
Antiplatelet therapy is not recommended as an alternative to anticoagulation in patients with AF to prevent ischaemic stroke and 
thromboembolism.
III
A
Using the temporal pattern of clinical AF (paroxysmal, persistent, or permanent) is not recommended to determine the need for oral 
anticoagulation.
III
B
Continued 
ESC Guidelines                                                                                                                                                                                          3379


<!-- PAGE 67 -->

### Page 67

Recommendations for oral anticoagulation in AF
Direct oral anticoagulants are recommended in preference to VKAs to prevent ischaemic stroke and thromboembolism, except in patients 
with mechanical heart valves or moderate-to-severe mitral stenosis.
I
A
A target INR of 2.0–3.0 is recommended for patients with AF prescribed a VKA for stroke prevention to ensure safety and effectiveness.
I
B
Switching to a DOAC is recommended for eligible patients that have failed to maintain an adequate time in therapeutic range on a VKA 
(TTR <70%) to prevent thromboembolism and intracranial haemorrhage.
I
B
A reduced dose of DOAC therapy is not recommended, unless patients meet DOAC-specific criteria, to prevent underdosing and 
avoidable thromboembolic events.
III
B
Recommendations for combining antiplatelet drugs with anticoagulants for stroke prevention
Adding antiplatelet treatment to oral anticoagulation is not recommended in AF patients for the goal of preventing ischaemic stroke or 
thromboembolism.
III
B
Recommendations for thromboembolism despite anticoagulation
Adding antiplatelet treatment to anticoagulation is not recommended in patients with AF to prevent recurrent embolic stroke.
III
B
Switching from one DOAC to another, or from a DOAC to a VKA, without a clear indication is not recommended in patients with AF to 
prevent recurrent embolic stroke.
III
B
Recommendations for surgical left atrial appendage occlusion
Surgical closure of the left atrial appendage is recommended as an adjunct to oral anticoagulation in patients with AF undergoing cardiac 
surgery to prevent ischaemic stroke and thromboembolism.
I
B
Recommendations for assessment of bleeding risk
Assessment and management of modifiable bleeding risk factors is recommended in all patients eligible for oral anticoagulation, as part of 
shared decision-making to ensure safety and prevent bleeding.
I
B
Use of bleeding risk scores to decide on starting or withdrawing oral anticoagulation is not recommended in patients with AF to avoid 
under-use of anticoagulation.
III
B
Recommendations for management of bleeding in anticoagulated patients
Interrupting anticoagulation and performing diagnostic or treatment interventions is recommended in AF patients with active bleeding until 
the cause of bleeding is identified and resolved.
I
C
Recommendations for heart rate control in patients with AF
Rate control therapy is recommended in patients with AF, as initial therapy in the acute setting, an adjunct to rhythm control therapies, or as 
a sole treatment strategy to control heart rate and reduce symptoms.
I
B
Beta-blockers, diltiazem, verapamil, or digoxin are recommended as first-choice drugs in patients with AF and LVEF >40% to control heart 
rate and reduce symptoms.
I
B
Beta-blockers and/or digoxin are recommended in patients with AF and LVEF ≤40% to control heart rate and reduce symptoms.
I
B
Recommendations for general concepts in rhythm control
Electrical cardioversion is recommended in AF patients with acute or worsening haemodynamic instability to improve immediate patient 
outcomes.
I
C
Direct oral anticoagulants are recommended in preference to VKAs in eligible patients with AF undergoing cardioversion for 
thromboembolic risk reduction.
I
A
Therapeutic oral anticoagulation for at least 3 weeks (adherence to DOACs or INR ≥2.0 for VKAs) is recommended before scheduled 
cardioversion of AF and atrial flutter to prevent procedure-related thromboembolism.
I
B
Transoesophageal echocardiography is recommended if 3 weeks of therapeutic oral anticoagulation has not been provided, for exclusion of 
cardiac thrombus to enable early cardioversion.
I
B
Oral anticoagulation is recommended to continue for at least 4 weeks in all patients after cardioversion and long-term in patients with 
thromboembolic risk factor(s) irrespective of whether sinus rhythm is achieved, to prevent thromboembolism.
I
B
Early cardioversion is not recommended without appropriate anticoagulation or transoesophageal echocardiography if AF duration is 
longer than 24 h, or there is scope to wait for spontaneous cardioversion.
III
C
Recommendations for pharmacological cardioversion of AF
Intravenous flecainide or propafenone is recommended when pharmacological cardioversion of recent-onset AF is desired, excluding 
patients with severe left ventricular hypertrophy, HFrEF, or coronary artery disease.
I
A
Intravenous vernakalant is recommended when pharmacological cardioversion of recent-onset AF is desired, excluding patients with recent 
ACS, HFrEF, or severe aortic stenosis.
I
A
Intravenous amiodarone is recommended when cardioversion of AF in patients with severe left ventricular hypertrophy, HFrEF, or 
coronary artery disease is desired, accepting there may be a delay in cardioversion.
I
A
Pharmacological cardioversion is not recommended for patients with sinus node dysfunction, atrioventricular conduction disturbances, or 
prolonged QTc (>500 ms), unless risks for proarrhythmia and bradycardia have been considered.
III
C
Continued


<!-- PAGE 68 -->

### Page 68

Recommendations for antiarrhythmic drugs for long-term maintenance of sinus rhythm
Amiodarone is recommended in patients with AF and HFrEF requiring long-term antiarrhythmic drug therapy to prevent recurrence and 
progression of AF, with careful consideration and monitoring for extracardiac toxicity.
I
A
Dronedarone is recommended in patients with AF requiring long-term rhythm control, including those with HFmrEF, HFpEF, ischaemic 
heart disease, or valvular disease to prevent recurrence and progression of AF.
I
A
Flecainide or propafenone is recommended in patients with AF requiring long-term rhythm control to prevent recurrence and progression 
of AF, excluding those with impaired left ventricular systolic function, severe left ventricular hypertrophy, or coronary artery disease.
I
A
Antiarrhythmic drug therapy is not recommended in patients with advanced conduction disturbances unless antibradycardia pacing is 
provided.
III
C
Recommendations for catheter ablation of AF
Shared decision-making
Shared decision-making is recommended when considering catheter ablation for AF, taking into account procedural risks, likely benefits, and 
risk factors for AF recurrence.
I
C
Atrial fibrillation patients resistant or intolerant to antiarrhythmic drug therapy
Catheter ablation is recommended in patients with paroxysmal or persistent AF resistant or intolerant to antiarrhythmic drug therapy to 
reduce symptoms, recurrence, and progression of AF.
I
A
First-line rhythm control therapy
Catheter ablation is recommended as a first-line option within a shared decision-making rhythm control strategy in patients with 
paroxysmal AF, to reduce symptoms, recurrence, and progression of AF.
I
A
Patients with heart failure
Atrial fibrillation catheter ablation is recommended in patients with AF and HFrEF with high probability of tachycardia-induced 
cardiomyopathy to reverse left ventricular dysfunction.
I
B
Recommendations for anticoagulation in patients undergoing catheter ablation
Initiation of oral anticoagulation is recommended at least 3 weeks prior to catheter-based ablation in AF patients at elevated 
thromboembolic risk, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic 
stroke and thromboembolism.
I
A
Continuation of oral anticoagulation is recommended for at least 2 months after AF ablation in all patients, irrespective of rhythm outcome 
or CHA2DS2-VA score, to reduce the risk of peri-procedural ischaemic stroke and thromboembolism.
I
C
Continuation of oral anticoagulation is recommended after AF ablation according to the patient’s CHA2DS2-VA score, and not the 
perceived success of the ablation procedure, to prevent ischaemic stroke and thromboembolism.
I
C
Recommendations for endoscopic and hybrid AF ablation
Continuation of oral anticoagulation is recommended in patients with AF at elevated thromboembolic risk after concomitant, endoscopic, 
or hybrid AF ablation, independent of rhythm outcome or LAA exclusion, to prevent ischaemic stroke and thromboembolism.
I
C
Recommendations for AF ablation during cardiac surgery
Concomitant surgical ablation is recommended in patients undergoing mitral valve surgery and AF suitable for a rhythm control strategy to 
prevent symptoms and recurrence of AF, with shared decision-making supported by an experienced team of electrophysiologists and 
arrhythmia surgeons.
I
A
Intraprocedural imaging for detection of left atrial thrombus in patients undergoing surgical ablation is recommended to guide surgical 
strategy, independent of oral anticoagulant use, to prevent peri-procedural ischaemic stroke and thromboembolism.
I
C
Recommendations for patients with acute coronary syndromes or undergoing percutaneous intervention
General recommendations for patients with AF and an indication for concomitant antiplatelet therapy
For combinations with antiplatelet therapy, a DOAC is recommended in eligible patients in preference to a VKA to mitigate bleeding risk 
and prevent thromboembolism.
I
A
Recommendations for AF patients with ACS
Early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant (preferably DOAC) with a P2Y12 inhibitor (preferably 
clopidogrel) for up to 12 months is recommended in AF patients with ACS undergoing an uncomplicated PCI to avoid major bleeding, if the 
risk of thrombosis is low or bleeding risk is high.
I
A
Recommendations for AF patients undergoing PCI
After uncomplicated PCI, early cessation (≤1 week) of aspirin and continuation of an oral anticoagulant and a P2Y12 inhibitor (preferably 
clopidogrel) for up to 6 months is recommended to avoid major bleeding, if ischaemic risk is low.
I
A
Continued 
ESC Guidelines                                                                                                                                                                                          3381


<!-- PAGE 69 -->

### Page 69

### 14 Evidence tables

Evidence tables are available at European Heart Journal online.
15. Data availability statement
No new data were generated or analysed in support of this research.
16. Author information
Author/Task Force Member Affiliations: Michiel Rienstra, 
Department of Cardiology, University of Groningen, University 
Medical Center Groningen, Groningen, Netherlands; Karina 
V. Bunting, Institute of Cardiovascular Sciences, University of 
Birmingham, Birmingham, United Kingdom, Cardiology Department, 
Queen Elizabeth Hospital, University Hospitals Birmingham NHS 
Foundation 
Trust, 
Birmingham, 
United 
Kingdom; 
Ruben 
Casado-Arroyo, Department of Cardiology, H.U.B.-Hôpital 
Erasme, Université Libre de Bruxelles, Brussels, Belgium; Valeria 
Caso, Stroke Unit, Santa della Misericordia Hospital, Perugia, Italy; 
Harry J.G.M. Crijns, Cardiology Maastricht University Medical 
Centre, Maastricht, Netherlands, Cardiology Cardiovascular Research 
Institute Maastricht, Maastricht University, Maastricht, Netherlands; 
Tom J. R. De Potter, Department of Cardiology, OLV Hospital, 
Recommendations for AF patients with chronic coronary or vascular disease
Antiplatelet therapy beyond 12 months is not recommended in stable patients with chronic coronary or vascular disease treated with oral 
anticoagulation, due to lack of efficacy and to avoid major bleeding.
III
B
Recommendations for management of post-operative AF
Peri-operative amiodarone therapy is recommended where drug therapy is desired to prevent post-operative AF after cardiac surgery.
I
A
Routine use of beta-blockers is not recommended in patients undergoing non-cardiac surgery for the prevention of post-operative AF.
III
B
Recommendations for patients with embolic stroke of unknown source
Prolonged monitoring for AF is recommended in patients with ESUS to inform on AF treatment decisions.
I
B
Initiation of oral anticoagulation in ESUS patients without documented AF is not recommended due to lack of efficacy in preventing 
ischaemic stroke and thromboembolism.
III
A
Recommendations for patients with AF during pregnancy
Immediate electrical cardioversion is recommended in patients with AF during pregnancy and haemodynamic instability or pre-excited AF 
to improve maternal and foetal outcomes.
I
C
Therapeutic anticoagulation with LMWHs or VKAs (except VKAs for the first trimester or beyond Week 36) is recommended for pregnant 
patients with AF at elevated thromboembolic risk to prevent ischaemic stroke and thromboembolism.
I
C
Beta-1 selective blockers are recommended for heart rate control of AF in pregnancy to reduce symptoms and improve maternal and foetal 
outcomes, excluding atenolol.
I
C
Recommendations for prevention of thromboembolism in atrial flutter
Oral anticoagulation is recommended in patients with atrial flutter at elevated thromboembolic risk to prevent ischaemic stroke and 
thromboembolism.
I
B
Recommendations for screening for AF
Review of an ECG (12-lead, single, or multiple leads) by a physician is recommended to provide a definite diagnosis of AF and commence 
appropriate management.
I
B
Routine heart rhythm assessment during healthcare contact is recommended in all individuals aged ≥65 years for earlier detection of AF.
I
C
Recommendations for primary prevention of AF
Maintaining optimal blood pressure is recommended in the general population to prevent AF, with ACE inhibitors or ARBs as first-line 
therapy.
I
B
Appropriate medical HF therapy is recommended in individuals with HFrEF to prevent AF.
I
B
Maintaining normal weight (BMI 20–25 kg/m2) is recommended for the general population to prevent AF.
I
B
Maintaining an active lifestyle is recommended to prevent AF, with the equivalent of 150–300 min per week of moderate intensity or 75– 
150 min per week of vigorous intensity aerobic physical activity.
I
B
Avoidance of binge drinking and alcohol excess is recommended in the general population to prevent AF.
I
B
© ESC 2024
AAD, antiarrhythmic drugs; ACEi, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndromes; AF, atrial fibrillation; AF-CARE, atrial fibrillation—[C] Comorbidity and risk 
factor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment; AFL, atrial flutter; ARB, 
angiotensin receptor blocker; BMI, body mass index; CHA2DS2-VA, congestive heart failure, hypertension, age ≥75 years (2 points), diabetes mellitus, prior stroke/transient ischaemic 
attack/arterial thromboembolism (2 points), vascular disease, age 65–74 years; DOAC, direct oral anticoagulant; ECG, electrocardiogram; ESUS, embolic stroke of undetermined source; 
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
INR, international normalized ratio of prothrombin time; LAA, left atrial appendage; LMWH, low molecular weight heparin; LVEF, left ventricular ejection fraction; PCI, percutaneous 
intervention; SGLT2, sodium-glucose cotransporter-2; TTR, time in therapeutic range; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 70 -->

### Page 70

Aalst, Belgium; Jeremy Dwight (United Kingdom), ESC Patient 
Forum, Sophia Antipolis, France; Luigina Guasti, Department of 
Medicine and Surgery, University of Insubria, Varese, Italy, Division of 
Geriatrics and Clinical Gerontology, ASST-Settelaghi, Varese, Italy; 
Thorsten Hanke, Clinic For Cardiac Surgery, Asklepios Klinikum, 
Harburg, Hamburg, Germany; Tiny Jaarsma, Department of 
Cardiology, Linkoping University, Linkoping, Sweden, Julius Center 
for Health Sciences and Primary Care, University Medical Center 
Utrecht, Utrecht, Netherlands; Maddalena Lettino, Department 
for Cardiac, Thoracic and Vascular Diseases, Fondazione IRCCS San 
Gerardo dei Tintori, Monza, Italy; Maja-Lisa Løchen, Deparment 
of Clincal Medicine UiT, The Arctic University of Norway, Tromsø, 
Norway, Department of Cardiology, University Hospital of North 
Norway, Tromsø, Norway; R. Thomas Lumbers, Institute of 
Health Informatics, University College London, London, United 
Kingdom, Saint Bartholomew’s Hospital, Barts Health NHS Trust, 
London, United Kingdom, University College Hospital, University 
College London Hospitals NHS Trust, London, United Kingdom; 
Bart Maesen, Department of Cardiothoracic Surgery, Maastricht 
University Medical Centre+, Maastricht, Netherlands, Cardiovascular 
Research Institute Maastricht, Maastricht University, Maastricht, 
Netherlands; Inge Mølgaard (Denmark), ESC Patient Forum, 
Sophia Antipolis, France; Giuseppe M.C. Rosano, Department of 
Human Sciences and Promotion of Quality of Life, Chair of 
Pharmacology, San Raffaele University of Rome, Rome, Italy, 
Cardiology, 
San 
Raffaele 
Cassino 
Hospital, 
Cassino, 
Italy, 
Cardiovascular Academic Group, St George’s University Medical 
School, London, United Kingdom; Prashanthan Sanders, Centre 
for Heart Rhythm Disorders, University of Adelaide, Adelaide, 
Australia, Department of Cardiology, Royal Adelaide Hospital, 
Adelaide, Australia; Renate B. Schnabel, Cardiology University 
Heart & Vascular Center Hamburg, University Medical Center 
Hamburg-Eppendorf, Hamburg, Germany, German Center for 
Cardiovascular Research (DZHK) Partner site Hamburg/Kiel/Lübeck, 
Germany; Piotr Suwalski, Department of Cardiac Surgery and 
Transplantology, National Medical Institute of the Ministry of Interior 
and Administration, Centre of Postgraduate Medical Education, 
Warsaw, Poland; Emma Svennberg, Department of Medicine, 
Karolinska University Hospital Huddinge, Karolinska Institutet, 
Stockholm, Sweden, Department of Cardiology, Karolinska University 
Hospital, Stockholm, Sweden; Juan Tamargo, Pharmacology and 
Toxicology School of Medicine, Universidad Complutense, Madrid, 
Spain; Otilia Tica, Department of Cardiology, Emergency County 
Clinical 
Hospital of 
Bihor, 
Oradea, Romania, 
Institute 
of 
Cardiovascular Sciences, University of Birmingham, Birmingham, 
United Kingdom; Vassil Traykov, Department of Invasive 
Electrophysiology, Acibadem City Clinic Tokuda University Hospital, 
Sofia, Bulgaria; and Stylianos Tzeis, Cardiology Department, Mitera 
Hospital, Athens, Greece.
17. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Nikolaos Dagres (CPG Review 
Co-ordinator) (Germany), Bianca Rocca (CPG Review Co-ordinator) 
(Italy), Syed Ahsan (United Kingdom), Pietro Ameri (Italy), Elena 
Arbelo (Spain), Axel Bauer (Austria), Michael A. Borger (Germany), 
Sergio Buccheri (Sweden), Barbara Casadei (United Kingdom), Ovidiu 
Chioncel (Romania), Dobromir Dobrev (Germany), Laurent Fauchier 
(France), Bruna Gigante (Sweden), Michael Glikson (Israel), Ziad 
Hijazi (Sweden), Gerhard Hindricks (Germany), Daniela Husser 
(Germany), Borja Ibanez (Spain), Stefan James (Sweden), Stefan Kaab 
(Germany), Paulus Kirchhof (Germany), Lars Køber (Denmark), 
Konstantinos C. Koskinas (Switzerland), Thomas Kumler (Denmark), 
Gregory Y.H. Lip (United Kingdom), John Mandrola (United States of 
America), Nikolaus Marx (Germany), John William Mcevoy (Ireland), 
Borislava Mihaylova (United Kingdom), Richard Mindham (United 
Kingdom), Denisa Muraru (Italy), Lis Neubeck (United Kingdom), Jens 
Cosedis Nielsen (Denmark), Jonas Oldgren (Sweden), Maurizio 
Paciaroni (Italy), Agnes A. Pasquet (Belgium), Eva Prescott 
(Denmark), Filip Rega (Belgium), Francisco Javier Rossello (Spain), 
Marcin Rucinski (Poland), Sacha P. Salzberg (Switzerland), Sam 
Schulman (Canada), Philipp Sommer (Germany), Jesper Hastrup 
Svendsen (Denmark), Jurrien M. ten Berg (Netherlands), Hugo Ten 
Cate (Netherlands), Ilonca Vaartjes (Netherlands), Christiaan Jm. 
Vrints (Belgium), Adam Witkowski (Poland), and Katja Zeppenfeld 
(Netherlands).
ESC National Cardiac Societies actively involved in the review 
process of the 2024 ESC Guidelines for the management of atrial 
fibrillation:
Albania: Albanian Society of Cardiology, Leonard Simoni; Algeria: 
Algerian Society of Cardiology, Brahim Kichou; Armenia: Armenian 
Cardiologists Association, Hamayak S. Sisakian; Austria: Austrian 
Society of Cardiology, Daniel Scherr; Belgium: Belgian Society of 
Cardiology, Frank Cools; Bosnia and Herzegovina: Association of 
Cardiologists of Bosnia and Herzegovina, Elnur Smajić; Bulgaria: 
Bulgarian Society of Cardiology, Tchavdar Shalganov; Croatia: 
Croatian Cardiac Society, Sime Manola; Cyprus: Cyprus Society 
of Cardiology, Panayiotis Avraamides; Czechia: Czech Society of 
Cardiology, Milos Taborsky; Denmark: Danish Society of 
Cardiology, Axel Brandes; Egypt: Egyptian Society of Cardiology, 
Ahmed M. El-Damaty; Estonia: Estonian Society of Cardiology, Priit 
Kampus; Finland: Finnish Cardiac Society, Pekka Raatikainen; 
France: French Society of Cardiology, Rodrigue Garcia; Georgia: 
Georgian Society of Cardiology, Kakhaber Etsadashvili; Germany: 
German Cardiac Society, Lars Eckardt; Greece: Hellenic Society of 
Cardiology, Eleftherios Kallergis; Hungary: Hungarian Society of 
Cardiology, László Gellér; Iceland: Icelandic Society of Cardiology, 
Kristján Guðmundsson; Ireland: Irish Cardiac Society, Jonathan 
Lyne; Israel: Israel Heart Society, Ibrahim Marai; Italy: Italian 
Federation of Cardiology, Furio Colivicchi; Kazakhstan: Association 
of Cardiologists of Kazakhstan, Ayan Suleimenovich Abdrakhmanov; 
Kosovo (Republic of): Kosovo Society of Cardiology, Ibadete 
Bytyci; 
Kyrgyzstan: 
Kyrgyz 
Society 
of 
Cardiology, 
Alina 
Kerimkulova; Latvia: Latvian Society of Cardiology, Kaspars Kupics; 
Lebanon: Lebanese Society of Cardiology, Marwan Refaat; Libya: 
Libyan Cardiac Society, Osama Abdulmajed Bheleel; Lithuania: 
Lithuanian Society of Cardiology, Jūratė Barysienė; Luxembourg: 
Luxembourg Society of Cardiology, Patrick Leitz; Malta: Maltese 
Cardiac Society, Mark A. Sammut; Moldova (Republic of): 
Moldavian Society of Cardiology, Aurel Grosu; Montenegro: 
Montenegro Society of Cardiology, Nikola Pavlovic; Morocco: 
Moroccan 
Society 
of 
Cardiology, 
Abdelhamid 
Moustaghfir; 
Netherlands: Netherlands Society of Cardiology, Sing-Chien Yap; 
North Macedonia: National Society of Cardiology of North 
Macedonia, Jane Taleski; Norway: Norwegian Society of Cardiology, 
Trine Fink; Poland: Polish Cardiac Society, Jaroslaw Kazmierczak; 
Portugal: Portuguese Society of Cardiology, Victor M. Sanfins; 
Romania: Romanian Society of Cardiology, Dragos Cozma; San 
ESC Guidelines                                                                                                                                                                                          3383


<!-- PAGE 71 -->

### Page 71

Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia: 
Cardiology Society of Serbia, Dragan V. Kovačević; Slovakia: Slovak 
Society of Cardiology, Peter Hlivak; Slovenia: Slovenian Society of 
Cardiology, Igor Zupan; Spain: Spanish Society of Cardiology, David 
Calvo; Sweden: Swedish Society of Cardiology, Anna Björkenheim; 
Switzerland: Swiss Society of Cardiology, Michael Kühne; Tunisia: 
Tunisian Society of Cardiology and Cardiovascular Surgery, Sana 
Ouali; Turkey: Turkish Society of Cardiology, Sabri Demircan; 
Ukraine: Ukrainian Association of Cardiology, Oleg S. Sychov; 
United Kingdom of Great Britain and Northern Ireland: 
British Cardiovascular Society, Andre Ng; and Uzbekistan: 
Association of Cardiologists of Uzbekistan, Husniddin Kuchkarov.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rossello (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands). Andrea Sarkozy* (Belgium) *Contributor ei­
ther stepped down or was engaged in only a part of the review process.
